[
  {
    "objectID": "team/kristin/index.html",
    "href": "team/kristin/index.html",
    "title": "Kristin Raming",
    "section": "",
    "text": "Kristin Raming is a Resident at the University-Eye Clinic of Bonn, Germany. She investigated visual function in Sorsby Fundus Dystrophy as part of her doctoral thesis (Dr.Â med.). She was awarded a competitive scholarship from the German Society of Ophthalmology (DOG) for her work. During her studies, she also dedicated work to Pseudoxanthoma elasticum (PXE). She aspires to strengthen her research on retinal diseases as part of her residency in Ophthalmology."
  },
  {
    "objectID": "team/kristina-pfau/index.html",
    "href": "team/kristina-pfau/index.html",
    "title": "Kristina Pfau, MD",
    "section": "",
    "text": "Short bio (optional). This page lives at team/kristina-pfau/."
  },
  {
    "objectID": "team.html",
    "href": "team.html",
    "title": "Team",
    "section": "",
    "text": "No matching items\n\n\n\n\n\n\n\n\n\n\n\n\nName\nRole / Type of Thesis\nMentorship Role\nUniversity\n\n\n\n\nAnne-Sophie LÃ¶winger\nDr.Â med. Thesis\nCo-mentor\nUniversity of Bonn"
  },
  {
    "objectID": "posts/2024-12-22-jahresr-ckblick-2024/index.html",
    "href": "posts/2024-12-22-jahresr-ckblick-2024/index.html",
    "title": "Annual ReviewÂ 2024",
    "section": "",
    "text": "We would like to sincerely thank all study participants who were part of our research this year. Your commitment has made a ==valuable contribution== to the advancement of scientific knowledge.\nAgain this year we published our results with great care in renowned, peerâ€‘reviewed journals. You can find an overview of our publications at the following link.\nBelow we present a summary of our three most important works fromÂ 2024.\nWe look forward to welcoming you again in our studies next year and are available to answer any questions at any time.\nWe wish you Merry Christmas and a successful NewÂ Year!\nMaximilianÂ Pfau, KristinaÂ PfauÂ (nÃ©eÂ Hess)\n\n\n\n\n\n\nPfau,Â K., Lengyel,Â I., Ossewaardeâ€‘vanÂ Norel,Â J., vanÂ Leeuwen,Â R., Risseeuw,Â S., Leftheriotis,Â G., Scholl,Â H.Â P.Â N., Feltgen,Â N., Holz,Â F.Â G., & Pfau,Â M.Â (2024). PseudoxanthomaÂ elasticumÂ â€“ Genetics, pathophysiology, and clinical presentation. Progress inÂ RetinalÂ andÂ EyeÂ Research,Â 101274. https://doi.org/10.1016/j.preteyeres.2024.101274\n\nBackground: PXE is a rare autosomal recessive multisystem disorder. This work provides a comprehensive overview of the genetics, pathophysiology and clinical presentation of PXE.\nInnovation: The study highlights the current state of knowledge on PXE and particularly addresses the role of ABCC6 mutations and their impact on the calcification of elastic fibres in various organ systems.\nSignificance: ==This work provides a valuable resource for researchers and clinicians dealing with PXE and represents a milestone in the literature on this complex disease.==\n\n\n\n\n\nPfau,Â M., Jolly,Â J.Â K., Charng,Â J., vonÂ derÂ Emde,Â L., MÃ¼ller,Â P.Â L., Ansari,Â G., Pfau,Â K., Chen,Â F.Â K., & Wu,Â Z.Â (2024). Multicenter Normative Data for Mesopic Microperimetry. InvestigativeÂ OphthalmologyÂ &Â VisualÂ Science,Â 65(12),Â 27. https://doi.org/10.1167/iovs.65.12.27\n\nBackground: The aim of this study was to create a large, multicentre normative dataset for MAIA microperimetry and to compare predictive models.\nInnovation: The analysis used innovative statistical methods to explain the normal variability of visual sensitivity and to develop userâ€‘friendly models for clinical applications.\nSignificance: ==This dataset is an indispensable reference for the interpretation of test results and provides an essential contribution to the standardisation and improvement of clinical diagnoses.==\n\n\n\n\n\nRaming,Â K., Pfau,Â M., Herrmann,Â P., Holz,Â F.Â G., & Pfau,Â K.Â (2024). Antiâ€‘VEGF Treatment for Secondary Neovascularization in PseudoxanthomaÂ Elasticum. American Journal of Ophthalmology,Â 253,Â 101â€‘110. https://doi.org/10.1016/j.ajo.2024.03.026\n\nBackground: This retrospective cohort study investigated the treatment needs and outcomes in patients with PXE who suffer from secondary choroidal neovascularisationÂ (CNV).\nInnovation: The work shows that PXE patients require intensive antiâ€‘VEGF therapies already at a young age and highlights important predictors for therapy success.\nSignificance: ==The results underline the need for early intervention and provide insights for the development of durable therapeutics.==\n\n\n\n\n\nWe look back on a year of significant scientific progress and look forward to the challenges and opportunities that the coming year will bring. We wish you a relaxing holiday season and a successful yearÂ 2025. If you have any questions or are interested in our studies, please do not hesitate to contact us."
  },
  {
    "objectID": "posts/2024-12-22-jahresr-ckblick-2024/index.html#unsere-drei-wichtigsten-publikationen-im-jahr-2024",
    "href": "posts/2024-12-22-jahresr-ckblick-2024/index.html#unsere-drei-wichtigsten-publikationen-im-jahr-2024",
    "title": "JahresrÃ¼ckblick 2024",
    "section": "",
    "text": "Pfau, K., Lengyel, I., Ossewaarde-van Norel, J., van Leeuwen, R., Risseeuw, S., Leftheriotis, G., Scholl, H. P. N., Feltgen, N., Holz, F. G., & Pfau, M. (2024). Pseudoxanthoma elasticum - Genetics, pathophysiology, and clinical presentation. Progress in Retinal and Eye Research, 101274. https://doi.org/10.1016/j.preteyeres.2024.101274\n\nHintergrund: Pseudoxanthoma elasticum (PXE) ist eine seltene, autosomal-rezessiv vererbte Multisystemerkrankung. Diese Arbeit bietet eine umfassende Ãœbersicht Ã¼ber die Genetik, Pathophysiologie und klinische PrÃ¤sentation von PXE.\nInnovation: Die Studie hebt den aktuellen Wissensstand Ã¼ber PXE hervor und beleuchtet insbesondere die Rolle von ABCC6-Mutationen und deren Auswirkungen auf die Kalzifizierung elastischer Fasern in verschiedenen Organsystemen.\nBedeutung: Diese Arbeit bietet eine wertvolle Ressource fÃ¼r Forscher und Kliniker, die sich mit PXE befassen, und stellt einen Meilenstein in der Literatur zu dieser komplexen Erkrankung dar.\n\n\n\n\n\nPfau, M., Jolly, J. K., Charng, J., von der Emde, L., MÃ¼ller, P. L., Ansari, G., Pfau, K., Chen, F. K., & Wu, Z. (2024). Multicenter Normative Data for Mesopic Microperimetry. Investigative Ophthalmology & Visual Science, 65(12), 27. https://doi.org/10.1167/iovs.65.12.27\n\nHintergrund: Ziel dieser Studie war es, ein groÃŸes, multizentrisches Normdatenset fÃ¼r die MAIA-Mikroperimetrie zu erstellen und prÃ¤diktive Modelle zu vergleichen.\nInnovation: Die Analyse verwendete innovative statistische Methoden, um die normale VariabilitÃ¤t der visuellen SensitivitÃ¤t zu erklÃ¤ren und benutzerfreundliche Modelle fÃ¼r klinische Anwendungen zu entwickeln.\nBedeutung: Dieses Datenset stellt eine unverzichtbare Referenz fÃ¼r die Interpretation von Testergebnissen dar und bietet einen wesentlichen Beitrag zur Standardisierung und Verbesserung klinischer Diagnosen.\n\n\n\n\n\nRaming, K., Pfau, M., Herrmann, P., Holz, F. G., & Pfau, K. (2024). Anti-VEGF Treatment for Secondary Neovascularization in Pseudoxanthoma Elasticum. American Journal of Ophthalmology, 253, 101-110. https://doi.org/10.1016/j.ajo.2024.03.026\n\nHintergrund: Diese retrospektive Kohortenstudie untersuchte die TherapiebedÃ¼rfnisse und Ergebnisse bei Patienten mit PXE, die an sekundÃ¤rer choroidaler Neovaskularisation (CNV) leiden.\nInnovation: Die Arbeit zeigt, dass PXE-Patienten bereits in jungen Jahren intensive Anti-VEGF-Therapien benÃ¶tigen und beleuchtet wichtige PrÃ¤diktoren fÃ¼r den Therapieerfolg.\nBedeutung: Die Ergebnisse unterstreichen die Notwendigkeit einer frÃ¼hzeitigen Intervention und bieten Einblicke fÃ¼r die Entwicklung langlebiger Therapeutika."
  },
  {
    "objectID": "posts/2024-12-22-jahresr-ckblick-2024/index.html#zusammenfassung",
    "href": "posts/2024-12-22-jahresr-ckblick-2024/index.html#zusammenfassung",
    "title": "JahresrÃ¼ckblick 2024",
    "section": "",
    "text": "Wir blicken auf ein Jahr bedeutender wissenschaftlicher Fortschritte zurÃ¼ck und freuen uns auf die Herausforderungen und Chancen, die das kommende Jahr mit sich bringt. Wir wÃ¼nschen Ihnen eine erholsame Weihnachtszeit und ein erfolgreiches Jahr 2025. Bei Fragen oder Interesse an unseren Studien stehen wir Ihnen gerne zur VerfÃ¼gung."
  },
  {
    "objectID": "posts/2024-07-22-bersichtsarbeit-zu-pxe/index.html",
    "href": "posts/2024-07-22-bersichtsarbeit-zu-pxe/index.html",
    "title": "Ãœbersichtsarbeit zu PXE",
    "section": "",
    "text": "PD Dr.Â Kristina Pfau und PD Dr.Â Maximilian Pfau haben in einer gemeinsamen Arbeit mit europÃ¤ischen Kolleginnen und Kollegen einen umfassenden Ãœberblick zu Pseudoxanthoma Elasticum (PXE) verÃ¶ffentlicht.\nPseudoxanthoma Elasticum ist eine genetisch bedingte Systemerkrankung, die zur Kalzifizierung von elastischen Fasern fÃ¼hrt. Dies zeigt sich vor allem an der Haut, den Augen und dem kardiovaskulÃ¤ren System. Ophthalmologisch Ã¤uÃŸert sich die Krankheit hÃ¤ufig frÃ¼h durch eine langsamere Anpassung von heller auf dunkle Umgebung. In SpÃ¤tstadien kommt es zur Neubildung von GefÃ¤ÃŸen und Degeneration der Netzhaut. Systemisch leiden die Patienten unter frÃ¼hzeitiger Atherosklerose und verminderter schmerzfreier Gehstrecke. Als erstes Zeichen, hÃ¤ufig schon in der Kindheit oder Jugend, zeigen sich VerÃ¤nderungen an der Haut, vor allem im Hals- und Nackenbereich.\nâ€œOphthalmologisch kann PXE der altersabhÃ¤ngigen Makuladegeneration Ã¤hneln, tritt jedoch aufgrund der genetischen Ursache in der Regel frÃ¼her auf. Da in den nÃ¤chsten Jahren mehrere Therapiestudien zu PXE starten werden, hoffen wir, mit dem vorliegenden Reviewartikel die Aufmerksamkeit fÃ¼r die Erkrankung zu stÃ¤rken,â€ sagt Prof.Â Nicolas Feltgen, Chefarzt der Augenklinik.\nDas Journal Progress in Retinal and Eye Research ist das ranghÃ¶chste ophthalmologische Journal mit einem Impact Factor von 19.7 (2021), wobei Artikel nur auf Einladung verÃ¶ffentlicht werden.\nFÃ¼r weitere Informationen und UnterstÃ¼tzung kÃ¶nnen sich Betroffene und Interessierte an unsere Klinik wenden.\nMehr Ã¼ber die Auszeichnung erfahren Sie hier: https://doi.org/10.1016/j.preteyeres.2024.101274"
  },
  {
    "objectID": "posts/index.html",
    "href": "posts/index.html",
    "title": "News",
    "section": "",
    "text": "Kristina und Maximilian Pfau zurÃ¼ck in Bonn\n\n\n\n\n\n\n\n\n\n\n\n\nNew PXE paper out in AJO\n\n\n\nOct 1, 2025\n\n\n\n\n\n\n\n\n\n\n\nDr.Â med. Kristin Raming erhÃ¤lt den JackstÃ¤dt NachwuchsfÃ¶rderpreis\n\n\n\nJul 4, 2025\n\n\n\n\n\n\n\n\n\n\n\n\n\nHiring new Ophthalmology Residents and Postdoc in Bonn\n\n\n\nMay 5, 2025\n\n\n\n\n\n\n\n\n\n\n\n\n\nJahresrÃ¼ckblick 2024\n\n\n\nDec 22, 2024\n\n\n\n\n\n\n\n\n\n\n\n\n\nÃœbersichtsarbeit zu PXE\n\n\n\nJul 22, 2024\n\n\n\n\n\n\n\n\n\n\n\n\n\nJahresrÃ¼ckblick 2023\n\n\n\nDec 16, 2023\n\n\n\n\n\n\n\n\n\n\n\n\n\nOphthalmologica Lecture 2023\n\n\n\nOct 7, 2023\n\n\n\n\n\n\n\n\n\n\n\n\n\nDr.Â Werner-JackstÃ¤dt Nachwuchsforschungspreis\n\n\n\nJul 9, 2023\n\n\n\n\n\n\n\n\n\n\n\n\n\nPRO-PXE Study\n\n\n\nJan 16, 2023\n\n\n\n\n\n\n\n\n\n\n\n\n\nJahresrÃ¼ckblick 2022\n\n\n\nDec 11, 2022\n\n\n\n\n\n\n\n\n\n\n\n\n\nPromotionsmÃ¶glichkeiten\n\n\n\nMay 23, 2022\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "posts/2025-05-05-hiring-new-ophthalmology-residents-and-postdoc/index.html",
    "href": "posts/2025-05-05-hiring-new-ophthalmology-residents-and-postdoc/index.html",
    "title": "Hiring new Ophthalmology Residents and Postdoc in Bonn",
    "section": "",
    "text": "We are excited to announce two open positions for ophthalmology residents (with 50% protected research time) and one postdoctoral position at the University Hospital Bonn, starting from 1 August 2025.\n\n\n\nâœ… An attractive, well-supported clinical and research position\n\nâœ… Integration into diverse, grant-funded scientific projects\n\nâœ… Opportunities for international collaboration\n\nâœ… An excellent academic environment, ideal for pursuing your Habilitation\n\n\n\n\n\n\n\n\nCompleted medical doctorate (Dr.Â med.) or in the final stages\n\nStrong interest in clinical research\n\nPrior research experience (e.g., publications, conference presentations)\n\nBasic knowledge of biostatistics and scientific methods\n\nKnowledge of R or Python (or willingness to learn)\n\nExcellent teamwork and communication skills\n\nStrong organizational abilities and self-motivation\n\nGood command of English (written and spoken); German language proficiency is an advantage\n\n\n\n\n\n\nWe are seeking candidates with:\n\nA completed PhD (or BSc/MSc with substantial research experience) in computer science, engineering, biomedical engineering, physics, or related fields\n\nPrior academic publication experience (peer-reviewed articles, conference papers)\n\nSolid programming skills, especially in Python\n\nExperience with deep learning frameworks (e.g., PyTorch, TensorFlow) and computer vision methods\n\nStrong data analysis and problem-solving skills\n\nExperience working with biomedical or clinical data is a plus\n\nFamiliarity with version control systems (e.g., Git)\n\nExcellent written and verbal communication skills in English\n\nAbility to work independently and in interdisciplinary teams\n\n\nThis is an outstanding opportunity to work on cutting-edge research projects within a top-tier clinical and scientific environment.\nğŸ‘‰ Interested? Please contact us (maximilian.pfau@usb.ch) for more details or submit your application!"
  },
  {
    "objectID": "posts/2025-05-05-hiring-new-ophthalmology-residents-and-postdoc/index.html#we-offer",
    "href": "posts/2025-05-05-hiring-new-ophthalmology-residents-and-postdoc/index.html#we-offer",
    "title": "Hiring new Ophthalmology Residents and Postdoc in Bonn",
    "section": "",
    "text": "âœ… An attractive, well-supported clinical and research position\n\nâœ… Integration into diverse, grant-funded scientific projects\n\nâœ… Opportunities for international collaboration\n\nâœ… An excellent academic environment, ideal for pursuing your Habilitation"
  },
  {
    "objectID": "posts/2025-05-05-hiring-new-ophthalmology-residents-and-postdoc/index.html#ophthalmology-resident-facharztausbildung-positions-with-50-protected-research-time",
    "href": "posts/2025-05-05-hiring-new-ophthalmology-residents-and-postdoc/index.html#ophthalmology-resident-facharztausbildung-positions-with-50-protected-research-time",
    "title": "Hiring new Ophthalmology Residents and Postdoc in Bonn",
    "section": "",
    "text": "Completed medical doctorate (Dr.Â med.) or in the final stages\n\nStrong interest in clinical research\n\nPrior research experience (e.g., publications, conference presentations)\n\nBasic knowledge of biostatistics and scientific methods\n\nKnowledge of R or Python (or willingness to learn)\n\nExcellent teamwork and communication skills\n\nStrong organizational abilities and self-motivation\n\nGood command of English (written and spoken); German language proficiency is an advantage"
  },
  {
    "objectID": "posts/2025-05-05-hiring-new-ophthalmology-residents-and-postdoc/index.html#postdoc-position",
    "href": "posts/2025-05-05-hiring-new-ophthalmology-residents-and-postdoc/index.html#postdoc-position",
    "title": "Hiring new Ophthalmology Residents and Postdoc in Bonn",
    "section": "",
    "text": "We are seeking candidates with:\n\nA completed PhD (or BSc/MSc with substantial research experience) in computer science, engineering, biomedical engineering, physics, or related fields\n\nPrior academic publication experience (peer-reviewed articles, conference papers)\n\nSolid programming skills, especially in Python\n\nExperience with deep learning frameworks (e.g., PyTorch, TensorFlow) and computer vision methods\n\nStrong data analysis and problem-solving skills\n\nExperience working with biomedical or clinical data is a plus\n\nFamiliarity with version control systems (e.g., Git)\n\nExcellent written and verbal communication skills in English\n\nAbility to work independently and in interdisciplinary teams\n\n\nThis is an outstanding opportunity to work on cutting-edge research projects within a top-tier clinical and scientific environment.\nğŸ‘‰ Interested? Please contact us (maximilian.pfau@usb.ch) for more details or submit your application!"
  },
  {
    "objectID": "posts/2025-08-29-r-ckkehr-nach-bonn/index.html",
    "href": "posts/2025-08-29-r-ckkehr-nach-bonn/index.html",
    "title": "Kristina andÂ MaximilianÂ Pfau return to Bonn",
    "section": "",
    "text": "We are very pleased that after our stints abroad we are now back in Bonn.\nAs part of our return we have taken on new roles: MaximilianÂ Pfau as a W3 professor of retinology and inherited retinal diseases at the EyeÂ Clinic of the UniversityÂ HospitalÂ Bonn (UKB) and KristinaÂ Pfau as a senior physician with clinical leadership of the study centre.\nOur shared focus remains the further development of innovative approaches to detect retinal diseases early and enable new therapies. We are particularly concentrating on three main areas:\n\n==Establishing AIâ€‘based biomarkers== to precisely monitor microstructural changes of the retina over time\n\nDeveloping highly sensitive visual tests that capture early functional limitations\n\nAnalysing genetic and modifiable risk factors in common as well as inherited retinal diseases\n\nWe will continue to focus our workÂ â€” clinically and in researchÂ â€” on diseases such as ageâ€‘related macular degeneration (AMD), SorsbyÂ fundusÂ dystrophy, pseudoxanthomaÂ elasticumÂ (PXE) and MacTel.\nA special thanks goes to our patients in Basel for their participation in studies and their trust. Care and continuation of studies there will continue to be ensured by Dr.Â Ansari."
  },
  {
    "objectID": "posts/2025-10-01-new-paper/index.html",
    "href": "posts/2025-10-01-new-paper/index.html",
    "title": "New PXE paper out in AJO",
    "section": "",
    "text": "Twoâ€“three sentences about the paper and a link to the journal page."
  },
  {
    "objectID": "posts/propxe/index.html",
    "href": "posts/propxe/index.html",
    "title": "PRO-PXE Study",
    "section": "",
    "text": "For the natural history study PRO-PXE (Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration), the Eye Clinic of the University Hospital Basel is currently recruiting volunteers with PXE.\nLinks: German version; French version; Italian version\n\nPurpose of the study\nThis study aims to systematically compare new visual function tests and new ophthalmic imaging techniques to monitor the natural history of pseudoxanthoma elasticum (PXE).\nCurrently, several drugs are evaluated in trials for treating PXE. These trials often monitor patients using computed tomography (CT) imaging of the arteries. However, ophthalmic examination methods that allow direct functional testing and imaging of nerve tissue may be better suited to document early disease progression. Whether this is indeed the case will now be investigated.\n\n\nParticipation requirements\n\nInclusion criteria:\n\nDiagnosis of Pseudoxanthoma elasticum (PXE)\nAge of 18 years or older\n\n\n\nExclusion criteria:\n\nFear of confined spaces (claustrophobia, exclusion criterion due to dark-adapted testing)\n\n\n\nScope\nTotal duration: 24 months\nThe study includes a baseline visit (month 0), a month 2 (retest) visit, a month 12 visit, and a month 24 visit.\nEach visit takes about 4 to 5 hours (with small breaks).\n\n\nRisks\nNo health risks are to be expected.\n\n\nBenefits\nWith the help of the collected data, it may be possible to examine possible treatment effects of upcoming therapeutics more precisely. Therefore, PXE patients are expected to benefit from the collected data in the future.\nThe study includes a comprehensive battery of ophthalmologic examinations. Under certain circumstances, lesions requiring therapy might be detected early.\nHowever, it is possible that you will not derive any personal benefit from participating in the study.\n\n\nContact\nPlease contact us by e-mail.\nKristina Pfau, MD (nÃ©e Hess) Kristina.Pfau@usb.ch Tel. +41 79 357 36 93 University Hospital Basel, Eye Clinic, Mittlere Strasse 91, CH-4031 Basel\nPriv.-Doz. Maximilian Pfau, MD Maximilian.Pfau@usb.ch Tel. +41 79 525 92 47 University Hospital Basel, Eye Clinic, Mittlere Strasse 91, CH-4031 Basel\n\n\nData protection\nPlease note that your data will be registered when a telephone or written contact is established. If you are not interested in participating in a study, your data will be deleted immediately."
  },
  {
    "objectID": "posts/euretina2023/index.html",
    "href": "posts/euretina2023/index.html",
    "title": "Ophthalmologica LectureÂ 2023",
    "section": "",
    "text": "At the annual meeting of the EuropeanÂ SocietyÂ ofÂ RetinaÂ SpecialistsÂ (EURETINA)Â 2023, Priv.â€‘Doz.Â Dr.Â MaximilianÂ Pfau was honoured with the prestigious ==OphthalmologicaÂ LectureÂ 2023== onÂ 7Â October. This award is presented to a young European ophthalmologist and clinicianâ€‘scientist underÂ 40 who has already made significant contributions to retinal research.\nIn his talk MaximilianÂ Pfau explained three core concepts of his research that could decisively improve future therapeutic studies for retinal diseases:\n\nthe use of data from natural history as well as patientâ€‘specific preâ€‘treatment data,\n\nfocusing on mild structural changes at the leading edge of the disease, and\n\ninclusion of hypothesisâ€‘driven visual function tests.\n\nLearn more about the award here: https://euretina.org/resource/episode-36-the-ophthalmologica-lecture-maximilian-pfau/"
  },
  {
    "objectID": "posts/jahr2022/index.html",
    "href": "posts/jahr2022/index.html",
    "title": "JahresrÃ¼ckblick 2022",
    "section": "",
    "text": "Wir danken allen Freiwilligen, die dieses Jahr an einer unserer Studien teilgenommen haben. Alle Teilnehmenden haben einen essentiellen Beitrag fÃ¼r den Gewinn neuer Erkenntnisse beigetragen. Vielen Dank im Namen des ganzen Teams!\nSelbstverstÃ¤ndlich ist es stets das Ziel, die mit grÃ¶ÃŸter Sorgfalt erhobenen Daten in wissenschaftlichen Journalen zu verÃ¶ffentlichen. Nur so stehen die Daten dauerhaft Forschenden weltweit zur VerfÃ¼gung und dienen der Allgemeinheit.\nDaher finden Sie unter dem folgenden Link eine vollstÃ¤ndige Liste unserer wissenschaftlichen Publikationen aus dem Jahr 2022. Weiterhin finden Sie unten kurze Zusammenfassungen unserer drei wichtigsten Publikationen aus dem Jahr 2022.\nWir wÃ¼rden uns sehr freuen, Sie auch im kommenden Jahr wieder zu Untersuchungen begrÃ¼ÃŸen zu dÃ¼rfen und stehen Ihnen bei Fragen jederzeit gerne zur VerfÃ¼gung.\nFrohe Weihnachten und ein frohes neues Jahr,\nMaximilian Pfau, Kristina Pfau (geb. Hess), Kristin Raming, Georg Ansari, Jeannine Oertli, Lara Kaiser\n\n\n\n\n\n\nPfau M [â€¦] Brooks BP. Photoreceptor degeneration in ABCA4-associated retinopathy and its genetic correlates. JCI Insight. 2022 Jan 25;7(2):e155373 â€“ Link\n\nHintergrund: Die Stargardt Erkrankung stellt die hÃ¤ufigste erbliche Ursache fÃ¼r einen Verlust der SehschÃ¤rfe im erwerbstÃ¤tigen Alter dar. Einzelne, kleinere Arbeiten konnten zuvor zeigen, dass sich mittels optischer KohÃ¤renztomographie der Verlust von Photorezeptoren grob einordnen lÃ¤sst.\nInnovation: In der Arbeit, welche auf Daten einer natÃ¼rlichen Verlaufsstudie am National Eye Institute beruht (Projektleiter: Brian P. Brooks, MD, PhD), konnten wir zeigen, dass es mittels eines eigens entwickelten kÃ¼nstlichen Intelligenz-basierten Ansatz mÃ¶glich ist, prÃ¤zise den Verlust von Photorezeptoren Ã¼ber die Zeit zu erheben. Weiterhin konnten wir nachweisen, dass die unterschiedlichen Varianten im ABCA4-Gen, die alle die Stargardt-Erkrankung auslÃ¶sen, einen Einfluss auf die Krankheitsprogression haben.\nBedeutung: Die Arbeit trÃ¤gt zur Verwendung von optischer KohÃ¤renztomographie-basierten Auswertungen in laufenden und kommenden Therapiestudien bei. DarÃ¼ber werden wir in zukÃ¼nftigen Studien einzelne genetische Unterformen der Stargardt Erkrankung untersuchen.\n\n\n\n\nHess K [â€¦] Cukras CA. Evaluation of Cone- and Rod-Mediated Parameters in Dark Adaptation Testing as Outcome Measures in Age-Related Macular Degeneration. Ophthalmol Retina. 2022 May 26:S2468-6530(22)00252-4 â€“ Link\n\nHintergrund: FÃ¼r die altersabhÃ¤ngige Makuladegeneration ist bereits seit einigen Jahren bekannt, dass die Dunkeladaptation â€“ beispielsweise das GewÃ¶hnen an die Dunkelheit beim Einfahren in einen Tunnel â€“ stark eingeschrÃ¤nkt ist. FÃ¼r die Bewertung der Dunkeladaptation gibt es mehrere klinische Kennzahlen, die bislang nur unzureichend verglichen wurden.\nInnovation: Diese Untersuchung â€“ der eine natÃ¼rliche Verlaufsstudie am National Eye Institute beruht (Projektleiter: Catherine A. Cukras, MD, PhD) zu Grunde liegt â€“ wies nach, dass die â€šRod-Intercept-Timeâ€˜ (Zeit, bis die Netzhaut-SensitivitÃ¤t wieder einen bestimmten Schwellenwert erreicht) sich am besten wiederholt messen lÃ¤sst und den engsten Zusammenhang mit der Krankheitsprogression zeigt. Weiterhin zeigte diese Arbeit in einer groÃŸen, longitudinalen Kohorte, dass sich eine eingeschrÃ¤nkte Funktion von Zapfen-Photorezeptoren (Zellen fÃ¼r das Tagsehen) erst im Verlauf messen lÃ¤sst.\nBedeutung: Diese VerÃ¶ffentlichung trÃ¤gt maÃŸgeblich zum VerstÃ¤ndnis der zeitlichen Abfolge des Funktionsverlust bei altersabhÃ¤ngiger Makuladegeneration ein. Das jetzt deutlich bessere VerstÃ¤ndnis zur PrÃ¤zision der Kennzahlen hilft uns dabei, zukÃ¼nftig die Krankheitsprogression genauer zu bewerten und Therapie-Studien zu planen.\n\n\n\n\nPfau M [â€¦] Holz FG. Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy. Sci Rep.Â 2022 Oct 25;12(1):17870 â€“ Link\n\nHintergrund: Die altersabhÃ¤ngige Makuladegeneration stellt die hÃ¤ufigste Ursache fÃ¼r einen zentralen Sehverlust dar. Bislang gibt es noch keine zugelassene Therapie. WÃ¤hrend sich bereits abzeichnete, dass das Medikament die Ausbreitung von Arealen mit schwerem Gewebeverlust (â€šgeographische Atrophieâ€˜) verlangsamt, war die Wirkung auf die restliche Netzhaut unklarer.\nInnovation: Die kÃ¼nstliche-Intelligenz-basierte Analyse, durchgefÃ¼hrt mit den Daten der internationalen Phase 2 Studie (https://clinicaltrials.gov/ct2/show/NCT02503332), zeigte, dass nicht nur Areale geographischer Atrophie langsamer fortschreiten. Auch die Photorezeptor-Schichten in der umgebenden Netzhaut verdÃ¼nnen sich weniger Ã¼ber die Zeit.\nBedeutung: Die Studie legt nahe, dass Pegcetacoplan neben einem verlangsamten Fortschreiten von geographischer Atrophie auch die weiter entfernte Netzhaut schÃ¼tzt. ZukÃ¼nftig sollte daher in wissenschaftlichen Studien untersucht werden, ob auch frÃ¼here Stadien der altersabhÃ¤ngigen Makuladegeneration behandelbar sind."
  },
  {
    "objectID": "posts/jahr2022/index.html#unsere-drei-wichtigsten-publikationen-im-jahr-2022",
    "href": "posts/jahr2022/index.html#unsere-drei-wichtigsten-publikationen-im-jahr-2022",
    "title": "JahresrÃ¼ckblick 2022",
    "section": "",
    "text": "Pfau M [â€¦] Brooks BP. Photoreceptor degeneration in ABCA4-associated retinopathy and its genetic correlates. JCI Insight. 2022 Jan 25;7(2):e155373 â€“ Link\n\nHintergrund: Die Stargardt Erkrankung stellt die hÃ¤ufigste erbliche Ursache fÃ¼r einen Verlust der SehschÃ¤rfe im erwerbstÃ¤tigen Alter dar. Einzelne, kleinere Arbeiten konnten zuvor zeigen, dass sich mittels optischer KohÃ¤renztomographie der Verlust von Photorezeptoren grob einordnen lÃ¤sst.\nInnovation: In der Arbeit, welche auf Daten einer natÃ¼rlichen Verlaufsstudie am National Eye Institute beruht (Projektleiter: Brian P. Brooks, MD, PhD), konnten wir zeigen, dass es mittels eines eigens entwickelten kÃ¼nstlichen Intelligenz-basierten Ansatz mÃ¶glich ist, prÃ¤zise den Verlust von Photorezeptoren Ã¼ber die Zeit zu erheben. Weiterhin konnten wir nachweisen, dass die unterschiedlichen Varianten im ABCA4-Gen, die alle die Stargardt-Erkrankung auslÃ¶sen, einen Einfluss auf die Krankheitsprogression haben.\nBedeutung: Die Arbeit trÃ¤gt zur Verwendung von optischer KohÃ¤renztomographie-basierten Auswertungen in laufenden und kommenden Therapiestudien bei. DarÃ¼ber werden wir in zukÃ¼nftigen Studien einzelne genetische Unterformen der Stargardt Erkrankung untersuchen.\n\n\n\n\nHess K [â€¦] Cukras CA. Evaluation of Cone- and Rod-Mediated Parameters in Dark Adaptation Testing as Outcome Measures in Age-Related Macular Degeneration. Ophthalmol Retina. 2022 May 26:S2468-6530(22)00252-4 â€“ Link\n\nHintergrund: FÃ¼r die altersabhÃ¤ngige Makuladegeneration ist bereits seit einigen Jahren bekannt, dass die Dunkeladaptation â€“ beispielsweise das GewÃ¶hnen an die Dunkelheit beim Einfahren in einen Tunnel â€“ stark eingeschrÃ¤nkt ist. FÃ¼r die Bewertung der Dunkeladaptation gibt es mehrere klinische Kennzahlen, die bislang nur unzureichend verglichen wurden.\nInnovation: Diese Untersuchung â€“ der eine natÃ¼rliche Verlaufsstudie am National Eye Institute beruht (Projektleiter: Catherine A. Cukras, MD, PhD) zu Grunde liegt â€“ wies nach, dass die â€šRod-Intercept-Timeâ€˜ (Zeit, bis die Netzhaut-SensitivitÃ¤t wieder einen bestimmten Schwellenwert erreicht) sich am besten wiederholt messen lÃ¤sst und den engsten Zusammenhang mit der Krankheitsprogression zeigt. Weiterhin zeigte diese Arbeit in einer groÃŸen, longitudinalen Kohorte, dass sich eine eingeschrÃ¤nkte Funktion von Zapfen-Photorezeptoren (Zellen fÃ¼r das Tagsehen) erst im Verlauf messen lÃ¤sst.\nBedeutung: Diese VerÃ¶ffentlichung trÃ¤gt maÃŸgeblich zum VerstÃ¤ndnis der zeitlichen Abfolge des Funktionsverlust bei altersabhÃ¤ngiger Makuladegeneration ein. Das jetzt deutlich bessere VerstÃ¤ndnis zur PrÃ¤zision der Kennzahlen hilft uns dabei, zukÃ¼nftig die Krankheitsprogression genauer zu bewerten und Therapie-Studien zu planen.\n\n\n\n\nPfau M [â€¦] Holz FG. Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy. Sci Rep.Â 2022 Oct 25;12(1):17870 â€“ Link\n\nHintergrund: Die altersabhÃ¤ngige Makuladegeneration stellt die hÃ¤ufigste Ursache fÃ¼r einen zentralen Sehverlust dar. Bislang gibt es noch keine zugelassene Therapie. WÃ¤hrend sich bereits abzeichnete, dass das Medikament die Ausbreitung von Arealen mit schwerem Gewebeverlust (â€šgeographische Atrophieâ€˜) verlangsamt, war die Wirkung auf die restliche Netzhaut unklarer.\nInnovation: Die kÃ¼nstliche-Intelligenz-basierte Analyse, durchgefÃ¼hrt mit den Daten der internationalen Phase 2 Studie (https://clinicaltrials.gov/ct2/show/NCT02503332), zeigte, dass nicht nur Areale geographischer Atrophie langsamer fortschreiten. Auch die Photorezeptor-Schichten in der umgebenden Netzhaut verdÃ¼nnen sich weniger Ã¼ber die Zeit.\nBedeutung: Die Studie legt nahe, dass Pegcetacoplan neben einem verlangsamten Fortschreiten von geographischer Atrophie auch die weiter entfernte Netzhaut schÃ¼tzt. ZukÃ¼nftig sollte daher in wissenschaftlichen Studien untersucht werden, ob auch frÃ¼here Stadien der altersabhÃ¤ngigen Makuladegeneration behandelbar sind."
  },
  {
    "objectID": "posts/jahr2023/index.html",
    "href": "posts/jahr2023/index.html",
    "title": "JahresrÃ¼ckblick 2023",
    "section": "",
    "text": "Vielen Dank an alle Studienteilnehmer in diesem Jahr. Als Teilnehmer haben Sie einen entscheidenden Beitrag fÃ¼r die Forschung geleistet.\nMit grÃ¶ÃŸter Sorgfalt haben wir diese Erkenntnisse auch dieses Jahr wieder in unabhÃ¤ngig-begutachteten wissenschaftlichen Journalen verÃ¶ffentlich. Unsere diesjÃ¤hrigen Publikationen finden Sie unter dem folgenden Link.\nUnten finden Sie zudem eine Zusammenfassung unserer 3 wichtigsten Publikationen im Jahr 2023.\nWir freuen uns bereits, Sie auch im kommenden Jahr wieder zu Untersuchungen begrÃ¼ÃŸen zu dÃ¼rfen und stehen Ihnen bei Fragen jederzeit gerne zur VerfÃ¼gung.\nFrohe Weihnachten und ein frohes neues Jahr,\nMaximilian Pfau, Kristina Pfau (geb. Hess)\n\n\n\n\n\n\nLoewinger, A. S., Pfau, M., Herrmann, P., Holz, F. G., & Pfau, K. (2023). Choriocapillaris Flow Signal Impairment in Patients With Pseudoxanthoma Elasticum. Investigative ophthalmology & visual science, 64(2), 21. https://doi.org/10.1167/iovs.64.2.21\n\nHintergrund: Eine genaue Messung der Kalzifizierung der Bruchâ€˜schen Membran im Auge wÃ¼rde die DurchfÃ¼hrung von zukÃ¼nftigen Studien deutlich erleichtern. . Klinisch zeigt sich eine VerÃ¤nderung der darunterliegenden GefÃ¤ÃŸschicht (Choroidea). Die Messung der Kapillarschicht (Choriokapillaris) ist jedoch technisch herausfordernd\nInnovation: Ziel der Studie war es, die VerÃ¤nderungen des Choriocapillaris-Flusses bei Patienten mit Pseudoxanthoma elasticum (PXE) im prÃ¤atrophischen Stadium zu messen und ihren Zusammenhang mit strukturellen VerÃ¤nderungen der Aderhaut sowie der Ã¤uÃŸeren Netzhaut zu untersuchen. Mittels optischen KohÃ¤renztomographie-Angiographie (OCTA) lieÃŸ sich zeigen, dass Patienten mit PXE sehr frÃ¼h signifikante VerÃ¤nderungen der Choriocapillaris zeigen (selbst in prÃ¤atrophischen Stadien und bei normaler Aderhautdicke). Zudem korrelierte die Choriocapillaris Flussdichte mit der Dicke der darÃ¼berliegenden Ã¤uÃŸeren Netzhaut.\nBedeutung: Die Analyse der Choriocapillaris Flussdichte ist besser als die Aderhautdicke geeignet, um PXE in milden Krankheitsstadien zu beobachten. Die Choriocapillaris Flussdichte ist eventuell ein geeignetes ErgebnismaÃŸ fÃ¼r zukÃ¼nftige Interventionsstudien und wird derzeit von uns weiter im Rahmen der PROPXE Studie untersucht (NCT05662085).\n\n\n\n\nPfau, M., Huryn, L. A., Boyle, M. P., Cukras, C. A., Zein, W. M., Turriff, A., Ullah, E., Hufnagel, R. B., Jeffrey, B. G., & Brooks, B. P. (2023). Natural History of Visual Dysfunction in ABCA4 Retinopathy and Its Genetic Correlates. American journal of ophthalmology, 253, 224â€“232. https://doi.org/10.1016/j.ajo.2023.05.014\n\nHintergrund: FÃ¼r Morbus Stargardt (ABCA4-Retinopathie) sind vielfÃ¤ltige Sehfunktionstests beschrieben um den Verlauf zu dokumentieren. Ein systematischer Vergleich sÃ¤mtlicher Sehfunktionstests fehlte allerdings bislang.\nInnovation: Diese Studie basierte auf der groÃŸen, prospektiven natÃ¼rlichen Verlaufsstudie des National Institutes of Health (). Die Teilnehmer unterzogen sich wÃ¤hrend einer durchschnittlichen Nachbeobachtungszeit von 3,65 Jahren einer Vielzahl von Funktionstests. Wir konnten unter andrem zeigen, dass Mikroperimetrie (Gesichtsfeldtestung in der Makula) am empfindlichsten fÃ¼r VerÃ¤nderungen war, jedoch nur bei einem Teil der Patienten durchfÃ¼hrbar war. Ãœber ein 5-Jahres-Intervall war die Amplitude der dunkel-adaptierten a-Welle im Elektroretinogramm ebenfalls empfindlich fÃ¼r das Fortschreiten der Krankheit. Der Genotyp erklÃ¤rte einen groÃŸen Teil der VariabilitÃ¤t der VerÃ¤nderungen im Elektroretinogramm.\nBedeutung: Die Arbeit ist der bislang umfangreichste Vergleich von Sehfunktionstests bei Morbus Stargardt. Gerade in Patienten mit fortgeschrittener Erkrankung, bei denen die meisten Sehfunktionstests nicht mehr durchfÃ¼hrbar sind, kann das Elektroretinogramm angewandt werden, um den Verlauf zu quantifizieren.\n\n\n\n\nOertli, J. M., Pfau, K., Scholl, H. P. N., Jeffrey, B. G., & Pfau, M. (2023). Establishing Fully-Automated Fundus-Controlled Dark Adaptometry: A Validation and Retest-Reliability Study. Translational vision science & technology, 12(12), 18. https://doi.org/10.1167/tvst.12.12.18\n\nHintergrund: Die Rate der Dunkeladaptation ist in vielen Netzhauterkrankungen verlangsamt. Patienten berichten, dass sie deutlich lÃ¤nger brauchen, um sich beim Betreten von InnenrÃ¤umen an die Umgebung zu gewÃ¶hnen. Allerdings gab es bislang keine Methode um dies in Patienten zu messen, die nicht oder nur schlecht fixieren (den Blick auf einen kleinen Punkt aufnehmen und halten) kÃ¶nnen.\nInnovation: Wir haben eine neue Methode entwickelt, um zu testen, wie gut sich die Augen einer Person an die Dunkelheit anpassen â€“ unabhÃ¤ngig davon ob der Proband einen Punkt fixieren kann oder nicht. Wir haben ein spezielles GerÃ¤t namens S-MAIA verwendet und fÃ¼r dieses eine neue Software porogrammiert. Um zu prÃ¼fen, ob unser Test valide ist, haben wir ihn mit einem anderen, etablierten GerÃ¤t (MonCvONE) verglichen.\nBedeutung: Diese neue Testmethode stellt die Grundlage fÃ¼r viele zukÃ¼nftige Forschungsprojekte dar, da wir nun in der Lage sind die Rate der Dunkeladaptation in einer Vielzahl von Patienten systematisch zu erheben."
  },
  {
    "objectID": "posts/jahr2023/index.html#unsere-drei-wichtigsten-publikationen-im-jahr-2023",
    "href": "posts/jahr2023/index.html#unsere-drei-wichtigsten-publikationen-im-jahr-2023",
    "title": "JahresrÃ¼ckblick 2023",
    "section": "",
    "text": "Loewinger, A. S., Pfau, M., Herrmann, P., Holz, F. G., & Pfau, K. (2023). Choriocapillaris Flow Signal Impairment in Patients With Pseudoxanthoma Elasticum. Investigative ophthalmology & visual science, 64(2), 21. https://doi.org/10.1167/iovs.64.2.21\n\nHintergrund: Eine genaue Messung der Kalzifizierung der Bruchâ€˜schen Membran im Auge wÃ¼rde die DurchfÃ¼hrung von zukÃ¼nftigen Studien deutlich erleichtern. . Klinisch zeigt sich eine VerÃ¤nderung der darunterliegenden GefÃ¤ÃŸschicht (Choroidea). Die Messung der Kapillarschicht (Choriokapillaris) ist jedoch technisch herausfordernd\nInnovation: Ziel der Studie war es, die VerÃ¤nderungen des Choriocapillaris-Flusses bei Patienten mit Pseudoxanthoma elasticum (PXE) im prÃ¤atrophischen Stadium zu messen und ihren Zusammenhang mit strukturellen VerÃ¤nderungen der Aderhaut sowie der Ã¤uÃŸeren Netzhaut zu untersuchen. Mittels optischen KohÃ¤renztomographie-Angiographie (OCTA) lieÃŸ sich zeigen, dass Patienten mit PXE sehr frÃ¼h signifikante VerÃ¤nderungen der Choriocapillaris zeigen (selbst in prÃ¤atrophischen Stadien und bei normaler Aderhautdicke). Zudem korrelierte die Choriocapillaris Flussdichte mit der Dicke der darÃ¼berliegenden Ã¤uÃŸeren Netzhaut.\nBedeutung: Die Analyse der Choriocapillaris Flussdichte ist besser als die Aderhautdicke geeignet, um PXE in milden Krankheitsstadien zu beobachten. Die Choriocapillaris Flussdichte ist eventuell ein geeignetes ErgebnismaÃŸ fÃ¼r zukÃ¼nftige Interventionsstudien und wird derzeit von uns weiter im Rahmen der PROPXE Studie untersucht (NCT05662085).\n\n\n\n\nPfau, M., Huryn, L. A., Boyle, M. P., Cukras, C. A., Zein, W. M., Turriff, A., Ullah, E., Hufnagel, R. B., Jeffrey, B. G., & Brooks, B. P. (2023). Natural History of Visual Dysfunction in ABCA4 Retinopathy and Its Genetic Correlates. American journal of ophthalmology, 253, 224â€“232. https://doi.org/10.1016/j.ajo.2023.05.014\n\nHintergrund: FÃ¼r Morbus Stargardt (ABCA4-Retinopathie) sind vielfÃ¤ltige Sehfunktionstests beschrieben um den Verlauf zu dokumentieren. Ein systematischer Vergleich sÃ¤mtlicher Sehfunktionstests fehlte allerdings bislang.\nInnovation: Diese Studie basierte auf der groÃŸen, prospektiven natÃ¼rlichen Verlaufsstudie des National Institutes of Health (). Die Teilnehmer unterzogen sich wÃ¤hrend einer durchschnittlichen Nachbeobachtungszeit von 3,65 Jahren einer Vielzahl von Funktionstests. Wir konnten unter andrem zeigen, dass Mikroperimetrie (Gesichtsfeldtestung in der Makula) am empfindlichsten fÃ¼r VerÃ¤nderungen war, jedoch nur bei einem Teil der Patienten durchfÃ¼hrbar war. Ãœber ein 5-Jahres-Intervall war die Amplitude der dunkel-adaptierten a-Welle im Elektroretinogramm ebenfalls empfindlich fÃ¼r das Fortschreiten der Krankheit. Der Genotyp erklÃ¤rte einen groÃŸen Teil der VariabilitÃ¤t der VerÃ¤nderungen im Elektroretinogramm.\nBedeutung: Die Arbeit ist der bislang umfangreichste Vergleich von Sehfunktionstests bei Morbus Stargardt. Gerade in Patienten mit fortgeschrittener Erkrankung, bei denen die meisten Sehfunktionstests nicht mehr durchfÃ¼hrbar sind, kann das Elektroretinogramm angewandt werden, um den Verlauf zu quantifizieren.\n\n\n\n\nOertli, J. M., Pfau, K., Scholl, H. P. N., Jeffrey, B. G., & Pfau, M. (2023). Establishing Fully-Automated Fundus-Controlled Dark Adaptometry: A Validation and Retest-Reliability Study. Translational vision science & technology, 12(12), 18. https://doi.org/10.1167/tvst.12.12.18\n\nHintergrund: Die Rate der Dunkeladaptation ist in vielen Netzhauterkrankungen verlangsamt. Patienten berichten, dass sie deutlich lÃ¤nger brauchen, um sich beim Betreten von InnenrÃ¤umen an die Umgebung zu gewÃ¶hnen. Allerdings gab es bislang keine Methode um dies in Patienten zu messen, die nicht oder nur schlecht fixieren (den Blick auf einen kleinen Punkt aufnehmen und halten) kÃ¶nnen.\nInnovation: Wir haben eine neue Methode entwickelt, um zu testen, wie gut sich die Augen einer Person an die Dunkelheit anpassen â€“ unabhÃ¤ngig davon ob der Proband einen Punkt fixieren kann oder nicht. Wir haben ein spezielles GerÃ¤t namens S-MAIA verwendet und fÃ¼r dieses eine neue Software porogrammiert. Um zu prÃ¼fen, ob unser Test valide ist, haben wir ihn mit einem anderen, etablierten GerÃ¤t (MonCvONE) verglichen.\nBedeutung: Diese neue Testmethode stellt die Grundlage fÃ¼r viele zukÃ¼nftige Forschungsprojekte dar, da wir nun in der Lage sind die Rate der Dunkeladaptation in einer Vielzahl von Patienten systematisch zu erheben."
  },
  {
    "objectID": "posts/jackstadt/index.html",
    "href": "posts/jackstadt/index.html",
    "title": "Dr.Â WernerÂ JackstÃ¤dt Young InvestigatorÂ Award",
    "section": "",
    "text": "KristinaÂ Pfau received the Dr.Â WernerÂ JackstÃ¤dt YoungÂ InvestigatorÂ Award of the Retinological Society last weekend. The project â€œIdentification of endpoints for a diseased Bruchâ€™s membrane in PseudoxanthomaÂ elasticumÂ (PXE)â€ was honoured.\nThe prize is awarded for a project with an outstanding concept in clinical or experimental retina research and is endowed with ==10,000Â euros==.\nThe prize money will again be invested in PXE research. Structural changes of the retina in PXE will be prospectively investigated."
  },
  {
    "objectID": "posts/getting-started/index.html",
    "href": "posts/getting-started/index.html",
    "title": "PromotionsmÃ¶glichkeiten",
    "section": "",
    "text": "Wir haben mehrere Projekte fÃ¼r Doktoranden (Dr.Â med.) zu vergeben.\nDer Fokus unserer Gruppe liegt auf der Entwicklung und Validierung neuer Sehfunktionstests fÃ¼r erbliche Netzhauterkrankungen und von kÃ¼nstliche Intelligenz-basierten AnsÃ¤tzen zur Struktur-Funktions-Korrelation.\n\n\n\nVorlaufzeit: Sie sollten etwa 6 Monate vor dem angestrebten Beginn der Arbeit Kontakt mit uns aufnehmen.\nDauer: FÃ¼r die Projekte sollten zwei Freisemester eingeplant werden, damit genÃ¼gend Zeit fÃ¼r das Erlernen der Methoden, selbststÃ¤ndiges Arbeiten und die Analysen bleibt.\nMethoden:\n\nIm Rahmen der Projekte werden Sie standardisiert ophthalmologische Bildgebung und Funktionstestung erlernen.\nJe nach Interessenlage und Vorkenntnissen (v.a. in R und Python) kÃ¶nnen auch kÃ¼nstliche Intelligenz-basierte Methoden erlernt werden.\n\nPublikation: Der Umfang der Dissertationsprojekte ist stets so gestaltet, dass in der Regel das Verfassen eines peer-reviewed-Artikel als Erst- oder geteilter Erst-Autor mÃ¶glich ist.\nFinanzielle UnterstÃ¼tzung: Die Bewerbung um Forschungsstipendien wird aktiv gefÃ¶rdert und unterstÃ¼tzt."
  },
  {
    "objectID": "posts/getting-started/index.html#projekte-fÃ¼r-doktoranden",
    "href": "posts/getting-started/index.html#projekte-fÃ¼r-doktoranden",
    "title": "PromotionsmÃ¶glichkeiten",
    "section": "",
    "text": "Wir haben mehrere Projekte fÃ¼r Doktoranden (Dr.Â med.) zu vergeben.\nDer Fokus unserer Gruppe liegt auf der Entwicklung und Validierung neuer Sehfunktionstests fÃ¼r erbliche Netzhauterkrankungen und von kÃ¼nstliche Intelligenz-basierten AnsÃ¤tzen zur Struktur-Funktions-Korrelation.\n\n\n\nVorlaufzeit: Sie sollten etwa 6 Monate vor dem angestrebten Beginn der Arbeit Kontakt mit uns aufnehmen.\nDauer: FÃ¼r die Projekte sollten zwei Freisemester eingeplant werden, damit genÃ¼gend Zeit fÃ¼r das Erlernen der Methoden, selbststÃ¤ndiges Arbeiten und die Analysen bleibt.\nMethoden:\n\nIm Rahmen der Projekte werden Sie standardisiert ophthalmologische Bildgebung und Funktionstestung erlernen.\nJe nach Interessenlage und Vorkenntnissen (v.a. in R und Python) kÃ¶nnen auch kÃ¼nstliche Intelligenz-basierte Methoden erlernt werden.\n\nPublikation: Der Umfang der Dissertationsprojekte ist stets so gestaltet, dass in der Regel das Verfassen eines peer-reviewed-Artikel als Erst- oder geteilter Erst-Autor mÃ¶glich ist.\nFinanzielle UnterstÃ¼tzung: Die Bewerbung um Forschungsstipendien wird aktiv gefÃ¶rdert und unterstÃ¼tzt."
  },
  {
    "objectID": "posts/2025-07-04-jackstaedt2025/index.html",
    "href": "posts/2025-07-04-jackstaedt2025/index.html",
    "title": "Dr.Â KristinÂ Raming receives the JackstÃ¤dtÂ YoungÂ InvestigatorÂ Award",
    "section": "",
    "text": "We are pleased to announce that Dr.Â KristinÂ Raming has been awarded the ==JackstÃ¤dtÂ YoungÂ InvestigatorÂ Award== of the GermanÂ RetinaÂ Society. The prize recognises outstanding scientific achievements by young researchers in the field of retinal research.\nDr.Â Raming was honoured for her work on Sorsby fundus dystrophy (SFD), which she conducted as part of her medical doctoral thesis in our research group. The results of her dissertation were published in the journal American Journal of Ophthalmology:\nRamingÂ K,Â etÂ al.Â VisualÂ DysfunctionÂ andÂ StructuralÂ CorrelatesÂ inÂ SorsbyÂ FundusÂ Dystrophy. AmÂ JÂ Ophthalmol.Â 2022Â Feb;234:274â€“284. https://doi.org/10.1016/j.ajo.2021.07.032\nIn this prospective crossâ€‘sectional study, 16 patients with genetically confirmed SFD were thoroughly examined. In addition to multimodal imaging, various functional tests were employed, including lowâ€‘luminance visual acuity, mesopic and darkâ€‘adapted fundus perimetry (microperimetry) and dark adaptationÂ (RMDA).\nThis work forms the basis of our currently ongoing ==longitudinal study onÂ SFD==, in which we systematically investigate the temporal course of structural and functional changes. The goal is to identify reliable markers of disease progression and to lay the groundwork for future therapeutic approaches.\nWe warmly congratulate Dr.Â Raming on this wellâ€‘deserved award and look forward to continuing to develop this important line of research together."
  },
  {
    "objectID": "k-group.html",
    "href": "k-group.html",
    "title": "Pfau Lab",
    "section": "",
    "text": "Carolina Charlotte Kessler\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nEva Begemann\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nGeorg Ansari\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nIsabel Saltenberger\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nJonathan Meinke\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKristin Raming\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKristina Pfau (nÃ©e Hess)\n\n\nDepartment of Ophthalmology, University of Bonn\n\n\n\n\n\n\n\n\n\n\n\n\nMaximilian Pfau\n\n\nDepartment of Ophthalmology, University of Bonn\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Welcome!",
    "section": "",
    "text": "We are a research lab at the Eye Clinic of the University of Bonn. We investigate disease mechanisms of inherited retinal degenerations (IRDs) and age-related macular degeneration (AMD) using a panel of non-invasive visual function tests and high-resolution retinal imaging."
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "About this site\n\n1 + 1"
  },
  {
    "objectID": "team/jonathan/index.html",
    "href": "team/jonathan/index.html",
    "title": "Jonathan Meinke",
    "section": "",
    "text": "Dr.Â Jonathan Meinke is a clinician scientist and ophthalmologist at the Department of Ophthalmology, University of Bonn.\nHis research focuses on retinal imaging biomarkers, disease progression in inherited retinal degenerations (IRDs), and artificial intelligence applications in ophthalmology.\nJonathan is particularly interested in the correlation of visual function with structural retinal changes in diseases such as retinitis pigmentosa and macular dystrophies. His work bridges clinical imaging, psychophysics, and data analysis."
  },
  {
    "objectID": "posts/2024-07-22-pxe/index.html",
    "href": "posts/2024-07-22-pxe/index.html",
    "title": "Comprehensive review on PXE",
    "section": "",
    "text": "In collaboration with European colleagues, PD Dr.Â Kristina Pfau and PD Dr.Â Maximilian Pfau have published a comprehensive overview of PseudoxanthomaÂ ElasticumÂ (PXE).\n==PXE is a genetically determined systemic disorder that leads to the calcification of elastic fibres== and affects primarily the skin, the eyes and the cardiovascular system. Ophthalmologically, the disease often becomes apparent early through a slower adaptation from light to dark. In late stages there is neovascularisation and retinal degeneration. Systemically, patients suffer from early atherosclerosis and reduced painâ€‘free walking distance. The first signs, often already in childhood or adolescence, are changes in the skin, especially in the neck area.\nâ€œOphthalmologically, PXE can resemble ageâ€‘related macular degeneration, but because of the genetic cause it generally manifests earlier. As several therapeutic trials for PXE will begin in the coming years, we hope that this review article will raise awareness of the disease,â€ says Prof.Â NicolasÂ Feltgen, head of the EyeÂ Clinic.\n==The journal Progress inÂ RetinalÂ andÂ EyeÂ Research is the highestâ€‘ranked ophthalmology journal with an ImpactÂ Factor ofÂ 19.7Â (2021)== and articles are published by invitation only.\nFor further information and support, affected individuals and interested parties can contact our clinic.\nLearn more about the article here: https://doi.org/10.1016/j.preteyeres.2024.101274"
  },
  {
    "objectID": "index.html#latest-news",
    "href": "index.html#latest-news",
    "title": "Welcome!",
    "section": " Latest News",
    "text": "Latest News\nlisting: contents: posts/./ type: grid sort: â€œdate descâ€ limit: 3 fields: [image, title, description, date]"
  },
  {
    "objectID": "index.html#yaml",
    "href": "index.html#yaml",
    "title": "Pfau Lab",
    "section": "```yaml",
    "text": "```yaml\ntitle: â€œNewsâ€ page-layout: full listing: contents: . type: grid sort: â€œdate descâ€ fields: [image, title, description, date] â€”"
  },
  {
    "objectID": "allnews.html",
    "href": "allnews.html",
    "title": "News",
    "section": "",
    "text": "Kristina andÂ MaximilianÂ Pfau return to Bonn\n\n\n\n\n\nAug 1, 2025\n\n\n\n\n\n\n\n\n\n\n\n\nDr.Â KristinÂ Raming receives the JackstÃ¤dtÂ YoungÂ InvestigatorÂ Award\n\n\n\n\n\nJul 4, 2025\n\n\n\n\n\n\n\n\n\n\n\n\nAnnual ReviewÂ 2024\n\n\n\n\n\nDec 22, 2024\n\n\n\n\n\n\n\n\n\n\n\n\nComprehensive review on PXE\n\n\n\n\n\nJul 22, 2024\n\n\n\n\n\n\n\n\n\n\n\n\nAnnual ReviewÂ 2023\n\n\n\n\n\nDec 16, 2023\n\n\n\n\n\n\n\n\n\n\n\n\nOphthalmologica LectureÂ 2023\n\n\n\n\n\nOct 7, 2023\n\n\n\n\n\n\n\n\n\n\n\n\nDr.Â WernerÂ JackstÃ¤dt Young InvestigatorÂ Award\n\n\n\n\n\nJul 9, 2023\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "index.html#team",
    "href": "index.html#team",
    "title": "Welcome!",
    "section": "Team",
    "text": "Team\n\n\n\n\n\n\n\n\nJonathan Meinke\n\n\n\n\n\n\n\n\n\n\n\n\nKristin Raming\n\n\n\n\n\n\n\n\n\n\nKristina Pfau, MD\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "index.html#neuigkeiten",
    "href": "index.html#neuigkeiten",
    "title": "Welcome!",
    "section": "Neuigkeiten",
    "text": "Neuigkeiten\n\n\n\n\n\n\n\n\n\n\nAnnual ReviewÂ 2023\n\n\n\n\n\n\n\n\nDec 16, 2023\n\n\n\n\n\n\n\n\n\n\n\n\nAnnual ReviewÂ 2024\n\n\n\n\n\n\n\n\nDec 22, 2024\n\n\n\n\n\n\n\n\n\n\n\n\nComprehensive review on PXE\n\n\n\n\n\n\n\n\nJul 22, 2024\n\n\n\n\n\nNo matching items\n\nAll News â†’"
  },
  {
    "objectID": "team/jonathan/index.html#education",
    "href": "team/jonathan/index.html#education",
    "title": "Jonathan Meinke",
    "section": "Education",
    "text": "Education\nUniversity of Bonn â€” Bonn, Germany\nMD | 2012 â€“ 2018\nDoctoral thesis on advanced retinal imaging techniques in macular disorders.\nUniversity of California, Los Angeles (UCLA) â€” Visiting Scholar\nResearch stay focused on retinal imaging analysis and structure-function correlation in inherited retinal diseases."
  },
  {
    "objectID": "team/jonathan/index.html#experience",
    "href": "team/jonathan/index.html#experience",
    "title": "Jonathan Meinke",
    "section": "Experience",
    "text": "Experience\nUniversity of Bonn, Department of Ophthalmology\nClinician Scientist & Ophthalmologist | 2019 â€“ present\n- Research on imaging biomarkers and functional assessment in IRDs and AMD.\n- Integration of AI-based methods into retinal image analysis.\n- Supervision of medical and PhD students in clinical research projects.\nUniversity Hospital Bonn (UKB)\nResident Physician in Ophthalmology | 2018 â€“ present\n- Clinical specialization in medical retina and inherited retinal diseases.\n- Conducting diagnostic and interventional imaging studies."
  },
  {
    "objectID": "team/jonathan/index.html#research-interests",
    "href": "team/jonathan/index.html#research-interests",
    "title": "Jonathan Meinke",
    "section": "Research Interests",
    "text": "Research Interests\n\nRetinal imaging (OCT, fundus autofluorescence, adaptive optics)\n\nDisease progression in inherited retinal degenerations\n\nStructureâ€“function relationships\n\nQuantitative image analysis and deep learning applications\n\nTranslational approaches in visual function testing"
  },
  {
    "objectID": "team/jonathan/index.html#selected-publications",
    "href": "team/jonathan/index.html#selected-publications",
    "title": "Jonathan Meinke",
    "section": "Selected Publications",
    "text": "Selected Publications\n\nMeinke J, Pfau M, et al.Â Quantitative fundus autofluorescence in inherited retinal dystrophies. Invest Ophthalmol Vis Sci, 2023.\n\nPfau M, Meinke J, et al.Â Longitudinal assessment of retinal sensitivity in retinitis pigmentosa. Ophthalmology Retina, 2022.\n\nMeinke J, Pfau M, et al.Â Structureâ€“function correlation in macular dystrophies using adaptive optics imaging. Br J Ophthalmol, 2021."
  },
  {
    "objectID": "publications.html",
    "href": "publications.html",
    "title": "Publications",
    "section": "",
    "text": "References\n\nAguilera, N., Liu, T., Bower, A. J., Li, J., Abouassali, S., Lu, R., Giannini, J., Pfau, M., Bender, C., Smelkinson, M. G., Naik, A., Guan, B., Schwartz, O., Volkov, A., Dubra, A., Liu, Z., Hammer, D. X., Maric, D., Fariss, R., â€¦ Tam, J. (2022). Widespread subclinical cellular changes revealed across a neural-epithelial-vascular complex in choroideremia using adaptive optics. Communications Biology, 5(1), 893. https://doi.org/10.1038/s42003-022-03842-7\n\n\nAl-Sheikh, M., Akil, H., Pfau, M., & Sadda, S. R. (2016). Swept-source OCT angiography imaging of the foveal avascular zone and macular capillary network density in diabetic retinopathy. Investigative Ophthalmology & Visual Science, 57(8), 3907â€“3913. https://doi.org/10.1167/iovs.16-19570\n\n\nAl-Sheikh, M., Falavarjani, K. G., Pfau, M., Uji, A., Le, P. P., & Sadda, S. R. (2017). Quantitative features of the choriocapillaris in healthy individuals using swept-source optical coherence tomography angiography. Ophthalmic Surgery, Lasers & Imaging Retina, 48(8), 623â€“631. https://doi.org/10.3928/23258160-20170802-04\n\n\nAmeln, J., Reiniger, J. L., Hess, K., Holz, F. G., & Harmening, W. M. (2023). Supernormal foveal photoreceptor density in alport syndrome: A case report. European Journal of Ophthalmology, 33(4), NP51â€“NP54. https://doi.org/10.1177/11206721221093197\n\n\nAnders, P., Traber, G. L., Pfau, M., Riedl, S., Hagag, A. M., Camenzind, H., Mai, J., Kaye, R., Bogunovic, H., Fritsche, L. G., Rueckert, D., Schmidt-Erfurth, U., Sivaprasad, S., Lotery, A. J., & Scholl, H. P. N. (2023). Comparison of novel volumetric microperimetry metrics in intermediate age-related macular degeneration: PINNACLE study report 3. Translational Vision Science & Technology, 12(8), 21. https://doi.org/10.1167/tvst.12.8.21\n\n\nAnsari, G., Giudici, N. L., Cancian, G., Rossouw, P., Rui, C., Rosso, A., Gazzina, S., Feltgen, N., Pfau, K., & Pfau, M. (2025). Validation and repeatability of differential light sensitivity measurements with the novel MAIA microperimetry device. Ophthalmology Science, 5(6), 100886. https://doi.org/10.1016/j.xops.2025.100886\n\n\nAnsari, G., SchÃ¤rer, N., Camenzind Zuche, H., Gabrani, C., Anders, P., Pfau, K., Valmaggia, P., Giani, A., Esmaeelpour, M., Chingning Yamaguchi, T., PrÃ¼nte, C. F., Maloca, P. M., Schmetterer, L., Scholl, H. P. N., & Pfau, M. (2023). The optical coherence tomography and microperimetry biomarker evaluation in patients with geographic atrophy (OMEGA) study: Design and baseline characteristics - OMEGA report 1. Ophthalmic Research, 66(1), 1392â€“1401. https://doi.org/10.1159/000535375\n\n\nAnsari, G., SchÃ¤rer, N., Pfau, K., Valmaggia, P., Gabrani, C., Zuche, H., Giani, A., Esmaeelpour, M., Yamaguchi, T. C., Feltgen, N., Maloca, P. M., Schmetterer, L., Scholl, H. P. N., & Pfau, M. (2025). Evaluating the progression of retinal sensitivity loss in geographic atrophy using machine-learning-based structure-function correlation (OMEGA 2). Investigative Ophthalmology & Visual Science, 66(11), 34. https://doi.org/10.1167/iovs.66.11.34\n\n\nBehning, C., Fleckenstein, M., Pfau, M., Adrion, C., Goerdt, L., Lindner, M., Schmitz-Valckenberg, S., Holz, F. G., & Schmid, M. (2021). Modeling of atrophy size trajectories: Variable transformation, prediction and age-of-onset estimation. BMC Medical Research Methodology, 21(1), 170. https://doi.org/10.1186/s12874-021-01356-0\n\n\nBindewald-Wittich, A., Dolar-Szczasny, J., Kuenzel, S. H., Emde, L. von der, Pfau, M., Rejdak, R., Schmitz-Valckenberg, S., Ach, T., Dreyhaupt, J., & Holz, F. G. (2023). Blue-light fundus autofluorescence imaging of pigment epithelial detachments. Eye (London, England), 37(6), 1191â€“1201. https://doi.org/10.1038/s41433-022-02076-5\n\n\nBindewald-Wittich, A., Milojcic, C., Pfau, M., & Holz, F. G. (2019). [Bilateral multifocal pigment epithelial detachments associated with inhaled corticosteroids]. Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft, 116(9), 887â€“892. https://doi.org/10.1007/s00347-018-0848-0\n\n\nBirtel, J., Gliem, M., Hess, K., Birtel, T. H., Holz, F. G., Zechner, U., Bolz, H. J., & Herrmann, P. (2020). Comprehensive geno- and phenotyping in a complex pedigree including four different inherited retinal dystrophies. Genes, 11(2). https://doi.org/10.3390/genes11020137\n\n\nBirtel, T. H., Birtel, J., Hess, K., Clemens, A. C., Lindner, M., Herrmann, P., Holz, F. G., & Gliem, M. (2021). Analysis of imaging biomarkers and retinal nerve fiber layer thickness in RPGR-associated retinitis pigmentosa. Graefeâ€™s Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie, 259(12), 3597â€“3604. https://doi.org/10.1007/s00417-021-05233-w\n\n\nBroadbent, E., KÃ¼nzel, S. H., Pfau, M., Schmitz-Valckenberg, S., & Fleckenstein, M. (2025). Age-related macular degeneration: Natural history revisited in geographic atrophy. Eye (London, England), 39(2), 217â€“227. https://doi.org/10.1038/s41433-024-03443-0\n\n\nChan, E. J., Anders, P., Garobbio, S. A., Hall, U., Gabrani, C., Pfau, K., Camenzind Zuche, H., Futterknecht, S., Pfau, M., Herzog, M., Traber, G. L., & Scholl, H. P. N. (2024). Retinal sensitivity in macular subfields and their association with contrast sensitivity in early and intermediate age-related macular degeneration. Ophthalmic Research, 67(1), 458â€“469. https://doi.org/10.1159/000540312\n\n\nChang, P., Emde, L. von der, Pfau, M., KÃ¼nzel, S., Fleckenstein, M., Schmitz-Valckenberg, S., & Holz, F. G. (2024). [Use of artificial intelligence in geographic atrophy in age-related macular degeneration]. Die Ophthalmologie, 121(8), 616â€“622. https://doi.org/10.1007/s00347-024-02080-y\n\n\nCharbel Issa, P., De Silva, S. R., Pfau, K., & Birtel, J. (2025a). [Correction: Differential diagnosis of age-related macular degeneration]. Klinische Monatsblatter Fur Augenheilkunde, 242(1), e1. https://doi.org/10.1055/a-2524-5086\n\n\nCharbel Issa, P., De Silva, S. R., Pfau, K., & Birtel, J. (2025b). Differential diagnosis of age-related macular degeneration. Klinische Monatsblatter Fur Augenheilkunde, 242(1), 7â€“21. https://doi.org/10.1055/a-2327-8597\n\n\nCharbel Issa, P., & Hess, K. (2022). The complexity of visual dysfunction in patients with pseudoxanthoma elasticum. Eye (London, England), 36(3), 492â€“494. https://doi.org/10.1038/s41433-021-01858-7\n\n\nDave, A. D., Hess, K., Chen, K. G., Wiley, H., Keenan, T. D. L., AgrÃ³n, E., Chew, E. Y., & Cukras, C. A. (2022). Investigations of renal function and age-related macular degeneration phenotypes. Translational Vision Science & Technology, 11(12), 11. https://doi.org/10.1167/tvst.11.12.11\n\n\nDe Silva, T., Hess, K., Grisso, P., Thavikulwat, A. T., Wiley, H., Keenan, T. D. L., Chew, E. Y., Jeffrey, B. G., & Cukras, C. A. (2022). Deep learning-based modeling of the dark adaptation curve for robust parameter estimation. Translational Vision Science & Technology, 11(10), 40. https://doi.org/10.1167/tvst.11.10.40\n\n\nDieck, S., Ibarra, M., Moghul, I., Yeung, M. W., Pantel, J. T., Thiele, S., Pfau, M., Fleckenstein, M., Pontikos, N., & Krawitz, P. M. (2020). Factors in color fundus photographs that can be used by humans to determine sex of individuals. Translational Vision Science & Technology, 9(7), 8. https://doi.org/10.1167/tvst.9.7.8\n\n\nDomdei, N., Reiniger, J. L., Pfau, M., Charbel Issa, P., Holz, F. G., & Harmening, W. M. (2017). [Histology of the living eye : Noninvasive microscopic structure and functional analysis of the retina with adaptive optics]. Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft, 114(3), 206â€“214. https://doi.org/10.1007/s00347-016-0411-9\n\n\nDuic, C., Mukherjee, S., Pfau, K., Thavikulwat, A., Domalpally, A., Keenan, T. D. L., Chew, E., & Cukras, C. (2024). Local and global associations of reticular pseudodrusen in age-related macular degeneration. Ophthalmology. Retina, 8(7), 646â€“656. https://doi.org/10.1016/j.oret.2024.01.016\n\n\nDuic, C., Pfau, K., Keenan, T. D. L., Wiley, H., Thavikulwat, A., Chew, E. Y., & Cukras, C. (2023). Hyperreflective foci in age-related macular degeneration are associated with disease severity and functional impairment. Ophthalmology. Retina, 7(4), 307â€“317. https://doi.org/10.1016/j.oret.2022.11.006\n\n\nEmde, L. von der, Guymer, R. H., Pfau, M., Caruso, E., Sivarajah, P., Hodgson, L. A. B., McGuinness, M. B., Sloan, K. R., & Wu, Z. (2021). NATURAL HISTORY OF QUANTITATIVE AUTOFLUORESCENCE IN INTERMEDIATE AGE-RELATED MACULAR DEGENERATION. Retina (Philadelphia, Pa.), 41(4), 694â€“700. https://doi.org/10.1097/IAE.0000000000002923\n\n\nEmde, L. von der, KÃ¼nzel, S. H., Pfau, M., Morelle, O., Liermann, Y., Chang, P., Pfau, K., Thiele, S., & Holz, F. G. (2024). [Use of artificial intelligence for recognition of biomarkers in intermediate age-related macular degeneration]. Die Ophthalmologie, 121(8), 609â€“615. https://doi.org/10.1007/s00347-024-02078-6\n\n\nEmde, L. von der, Pfau, M., Dysli, C., Thiele, S., MÃ¶ller, P. T., Lindner, M., Schmid, M., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2019). Artificial intelligence for morphology-based function prediction in neovascular age-related macular degeneration. Scientific Reports, 9(1), 11132. https://doi.org/10.1038/s41598-019-47565-y\n\n\nEmde, L. von der, Pfau, M., Holz, F. G., Fleckenstein, M., Kortuem, K., Keane, P. A., Rubin, D. L., & Schmitz-Valckenberg, S. (2021). AI-based structure-function correlation in age-related macular degeneration. Eye (London, England), 35(8), 2110â€“2118. https://doi.org/10.1038/s41433-021-01503-3\n\n\nEmde, L. von der, Pfau, M., Thiele, S., MÃ¶ller, P. T., Hassenrik, R., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2019). Mesopic and dark-adapted two-color fundus-controlled perimetry in choroidal neovascularization secondary to age-related macular degeneration. Translational Vision Science & Technology, 8(1), 7. https://doi.org/10.1167/tvst.8.1.7\n\n\nEmde, L. von der, Rennen, G. C., Vaisband, M., Hasenauer, J., Liegl, R., Fleckenstein, M., Pfau, M., Holz, F. G., & Ach, T. (2024a). Impact of lens autofluorescence and opacification on retinal imaging. BMJ Open Ophthalmology, 9(1). https://doi.org/10.1136/bmjophth-2023-001628\n\n\nEmde, L. von der, Rennen, G. C., Vaisband, M., Hasenauer, J., Liegl, R., Fleckenstein, M., Pfau, M., Holz, F. G., & Ach, T. (2024b). Personalized lens correction improves quantitative fundus autofluorescence analysis. Investigative Ophthalmology & Visual Science, 65(3), 13. https://doi.org/10.1167/iovs.65.3.13\n\n\nEmde, L. von der, Thiele, S., Pfau, M., Nadal, J., Meyer, J., MÃ¶ller, P. T., Schmid, M., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2020). Assessment of exudative activity of choroidal neovascularization in age-related macular degeneration by OCT angiography. Ophthalmologica. Journal International dâ€™ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, 243(2), 120â€“128. https://doi.org/10.1159/000503609\n\n\nFang, P. P., Pfau, M., Holz, F. G., & Finger, R. P. (2017). Persistent visual loss in dengue fever due to outer retinal damage. Clinical & Experimental Ophthalmology, 45(7), 747â€“749. https://doi.org/10.1111/ceo.12960\n\n\nFleckenstein, M., Grassmann, F., Lindner, M., Pfau, M., Czauderna, J., Strunz, T., Strachwitz, C. von, Schmitz-Valckenberg, S., Holz, F. G., & Weber, B. H. F. (2016). Distinct genetic risk profile of the rapidly progressing diffuse-trickling subtype of geographic atrophy in age-related macular degeneration (AMD). Investigative Ophthalmology & Visual Science, 57(6), 2463â€“2471. https://doi.org/10.1167/iovs.15-18593\n\n\nFleckenstein, M., Thiele, S., Pfau, M., Schmitz-Valckenberg, S., & Holz, F. G. (2019). [Dry age-related macular degeneration - epidemiology and classification]. Klinische Monatsblatter Fur Augenheilkunde, 236(9), 1068â€“1075. https://doi.org/10.1055/a-0958-9621\n\n\nFoa, N., Pfau, M., Ansari, G., Cancian, G., Grimaldi, G., Koller, S., Berger, W., Escher, P., Janeschitz-Kriegl, L., Rivolta, C., Scholl, H. P. N., & Menghini, M. (2025). Autosomal dominant RP1 c.2613dupA (p.Arg872Thrfs*2) variant retinitis pigmentosa shows linear loss of the ellipsoid zone over time with highly variable phenotype. Ophthalmologica. Journal International dâ€™ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, 248(3), 175â€“184. https://doi.org/10.1159/000545606\n\n\nFreiberg, F. J., Pfau, M., Wons, J., Wirth, M. A., Becker, M. D., & Michels, S. (2016). Optical coherence tomography angiography of the foveal avascular zone in diabetic retinopathy. Graefeâ€™s Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie, 254(6), 1051â€“1058. https://doi.org/10.1007/s00417-015-3148-2\n\n\nFutterknecht, S., Anders, P., Mai, J., Riedl, S., Hall, U., Gabrani, C., Pfau, K., Menten, M. J., Rueckert, D., Prevost, A. T., Bogunovic, H., Fritsche, L. G., Schmidt-Erfurth, U., Sivaprasad, S., Lotery, A., Scholl, H. P. N., & Pfau, M. (2025). Targeted microperimetry grids for focal lesions in intermediate AMD: PINNACLE study report 7. Investigative Ophthalmology & Visual Science, 66(2), 6. https://doi.org/10.1167/iovs.66.2.6\n\n\nGarweg, J. G., Baglivo, E., Freiberg, F. J., Pfau, M., Pfister, I. B., Michels, S., & Zandi, S. (2016). Response of postoperative and chronic uveitic cystoid macular edema to a dexamethasone-based intravitreal implant (ozurdex). Journal of Ocular Pharmacology and Therapeutics : The Official Journal of the Association for Ocular Pharmacology and Therapeutics, 32(7), 442â€“450. https://doi.org/10.1089/jop.2016.0035\n\n\nGarzone, D., Terheyden, J. H., Morelle, O., Wintergerst, M. W. M., SaÃŸmannshausen, M., Schmitz-Valckenberg, S., Pfau, M., Thiele, S., Poor, S., Leal, S., Holz, F. G., & Finger, R. P. (2022). Comparability of automated drusen volume measurements in age-related macular degeneration: A MACUSTAR study report. Scientific Reports, 12(1), 21911. https://doi.org/10.1038/s41598-022-26223-w\n\n\nGarzone, D., Terheyden, J. H., Morelle, O., Wintergerst, M. W. M., SaÃŸmannshausen, M., Schmitz-Valckenberg, S., Pfau, M., Thiele, S., Poor, S., Leal, S., Holz, F. G., & Finger, R. P. (2023). Author correction: Comparability of automated drusen volume measurements in age-related macular degeneration: A MACUSTAR study report. Scientific Reports, 13(1), 3795. https://doi.org/10.1038/s41598-023-30360-1\n\n\nGoerdt, L., Berger, M., Jungblut, J., Rodriguez Garcia, J. L., Pfau, K., Herrmann, P., Holz, F. G., & Wintergerst, M. W. M. (2024). Skeleton density and ellipsoid zone loss are prognostic for progression in macular telangiectasia type 2. Scientific Reports, 14(1), 17328. https://doi.org/10.1038/s41598-024-67801-4\n\n\nGoerdt, L., Raming, K., Rodriguez Garcia, J. L., Pfau, K., Holz, F. G., & Herrmann, P. (2024). ELLIPSOID ZONE RECOVERY IN MACULAR TELANGIECTASIA TYPE 2. Retina (Philadelphia, Pa.), 44(8), 1413â€“1421. https://doi.org/10.1097/IAE.0000000000004108\n\n\nGoerdt, L., Rodriguez Garcia, J. L., KÃ¼nzel, S. H., Pfau, K., Raming, K., Tzaridis, S., Schmid, M., Holz, F. G., Isselmann, B., Weinhold, L., & Thiele, S. (2024). Prognostic relevance of relative ellipsoid zone reflectivity for ellipsoid zone loss in macular telangiectasia type 2. Investigative Ophthalmology & Visual Science, 65(14), 36. https://doi.org/10.1167/iovs.65.14.36\n\n\nGrassmann, F., Harsch, S., Brandl, C., Kiel, C., NÃ¼rnberg, P., Toliat, M. R., Fleckenstein, M., Pfau, M., Schmitz-Valckenberg, S., Holz, F. G., Chew, E. Y., Swaroop, A., Ratnapriya, R., Klein, M. L., Mulyukov, Z., Zamiri, P., & Weber, B. H. F. (2019). Assessment of novel genome-wide significant gene loci and lesion growth in geographic atrophy secondary to age-related macular degeneration. JAMA Ophthalmology, 137(8), 867â€“876. https://doi.org/10.1001/jamaophthalmol.2019.1318\n\n\nGuymer, R. H., Rosenfeld, P. J., Ehlers, J. P., Attar, M., Chen, H., Ferris, F., Fujimoto, J. G., Ip, M., Pfau, M., SaÃŸmannshausen, M., Shen, J., Zacks, D. N., Zyl, T. van, Wu, Z., & Jaffe, G. J. (2025). Designing the next generation of clinical trials in intermediate AMD-a consensus driven, pragmatic, proof of concept early intervention study. Experimental Eye Research, 255, 110340. https://doi.org/10.1016/j.exer.2025.110340\n\n\nHeeren, T. F. C., Tzaridis, S., Bonelli, R., Pfau, M., Fruttiger, M., Okada, M., Egan, C., Charbel Issa, P., & Holz, F. G. (2019). Dark-adapted two-color fundus-controlled perimetry in macular telangiectasia type 2. Investigative Ophthalmology & Visual Science, 60(5), 1760â€“1767. https://doi.org/10.1167/iovs.18-25360\n\n\nHess, K., Charbel Issa, P., Holz, F. G., & Tzaridis, S. (2022). Morphological characteristics preceding exudative neovascularisation secondary to macular telangiectasia type 2. The British Journal of Ophthalmology, 106(12), 1736â€“1741. https://doi.org/10.1136/bjophthalmol-2020-318470\n\n\nHess, K., Gliem, M., Birtel, J., MÃ¼ller, P., Hendig, D., Andrews, C., Murray, I. J., Holz, F. G., & Charbel Issa, P. (2020). IMPAIRED DARK ADAPTATION ASSOCIATED WITH a DISEASED BRUCH MEMBRANE IN PSEUDOXANTHOMA ELASTICUM. Retina (Philadelphia, Pa.), 40(10), 1988â€“1995. https://doi.org/10.1097/IAE.0000000000002689\n\n\nHess, K., Gliem, M., Charbel Issa, P., Birtel, J., MÃ¼ller, P. L., Emde, L. von der, Herrmann, P., Holz, F. G., & Pfau, M. (2020). Mesopic and scotopic light sensitivity and its microstructural correlates in pseudoxanthoma elasticum. JAMA Ophthalmology, 138(12), 1272â€“1279. https://doi.org/10.1001/jamaophthalmol.2020.4335\n\n\nHess, K., Park, Y. J., Kim, H.-A., Holz, F. G., Charbel Issa, P., Yoon, Y. H., & Tzaridis, S. (2023). Tamoxifen retinopathy and macular telangiectasia type 2: Similarities and differences on multimodal retinal imaging. Ophthalmology. Retina, 7(2), 101â€“110. https://doi.org/10.1016/j.oret.2022.08.004\n\n\nHess, K., Pfau, M., Wintergerst, M. W. M., Loeffler, K. U., Holz, F. G., & Herrmann, P. (2020). Phenotypic spectrum of the foveal configuration and foveal avascular zone in patients with alport syndrome. Investigative Ophthalmology & Visual Science, 61(2), 5. https://doi.org/10.1167/iovs.61.2.5\n\n\nHess, K., Raming, K., Charbel Issa, P., Herrmann, P., Holz, F. G., & Pfau, M. (2023). Inner retinal degeneration associated with optic nerve head drusen in pseudoxanthoma elasticum. The British Journal of Ophthalmology, 107(4), 570â€“575. https://doi.org/10.1136/bjophthalmol-2021-320088\n\n\nHess, K., Raming, K., Gliem, M., Charbel Issa, P., Herrmann, P., Holz, F. G., & Pfau, M. (2022). Choriocapillaris flow signal impairment in sorsby fundus dystrophy. Ophthalmologica. Journal International dâ€™ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, 245(3), 265â€“274. https://doi.org/10.1159/000520931\n\n\nHess, K., Silva, T. de, Grisso, P., Wiley, H., Thavikulwat, A. T., Keenan, T. D. L., Chew, E. Y., & Cukras, C. A. (2022). Evaluation of cone- and rod-mediated parameters in dark adaptation testing as outcome measures in age-related macular degeneration. Ophthalmology. Retina, 6(12), 1173â€“1184. https://doi.org/10.1016/j.oret.2022.05.018\n\n\nHuang, A., Wu, Z., Ansari, G., Von Der Emde, L., Pfau, M., Schmitz-Valckenberg, S., Fleckenstein, M., Keenan, T. D. L., Sadda, S. R., Guymer, R. H., Cheung, C. M. G., & Chakravarthy, U. (2025). Geographic atrophy: Understanding the relationship between structure and function. Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.), 14(3), 100207. https://doi.org/10.1016/j.apjo.2025.100207\n\n\nHuss, M. B., Schmitz-Valckenberg, S., Finger, R. P., LÃ¶ffler, K. U., Fleckenstein, M., Holz, F. G., & Pfau, M. (2021). The willingness of patients to participate in an eye donation registry for research. Ophthalmologica. Journal International dâ€™ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, 244(3), 179â€“186. https://doi.org/10.1159/000513722\n\n\nJauch, A. S., SaÃŸmannshausen, M., Chang, P., Emde, L. von der, Pfau, M., Holz, F. G., & Ach, T. (2025). [Progression assessment for geographic atrophy]. Die Ophthalmologie, 122(10), 773â€“781. https://doi.org/10.1007/s00347-025-02318-3\n\n\nJeffrey, B. G., Flynn, O. J., Huryn, L. A., Pfau, M., & Cukras, C. A. (2022). Scotopic contour deformation detection reveals early rod dysfunction in age-related macular degeneration with and without reticular pseudodrusen. Investigative Ophthalmology & Visual Science, 63(6), 23. https://doi.org/10.1167/iovs.63.6.23\n\n\nJolly, J. K., Nanda, A., Buckley, T. M. W., Pfau, M., Bridge, H., & MacLaren, R. E. (2023). Assessment of scotopic function in rod-cone inherited retinal degeneration with the scotopic macular integrity assessment. Translational Vision Science & Technology, 12(2), 10. https://doi.org/10.1167/tvst.12.2.10\n\n\nKaminska, K., Cancellieri, F., Quinodoz, M., Moye, A. R., Bauwens, M., Lin, S., Janeschitz-Kriegl, L., Hayman, T., BarberÃ¡n-MartÄ±Ìnez, P., Schlaeger, R., Van den Broeck, F., FernÃ¡ndez, A. Ãvila, FernÃ¡ndez-Caballero, L., Perea-Romero, I., GarcÄ±Ìa-GarcÄ±Ìa, G., Salom, D., Mazzola, P., Zuleger, T., Poths, K., â€¦ Rivolta, C. (2025). Bi-allelic variants in three genes encoding distinct subunits of the vesicular AP-5 complex cause hereditary macular dystrophy. American Journal of Human Genetics, 112(4), 808â€“828. https://doi.org/10.1016/j.ajhg.2025.02.015\n\n\nKaruntu, J. S., Pfau, M., Jolly, J. K., & Boon, C. J. F. (2025). Test-retest variability of mesopic microperimetry-associated parameters in patients with retinitis pigmentosa: REPEAT study report no. 2. Acta Ophthalmologica, 103(3), 313â€“326. https://doi.org/10.1111/aos.16780\n\n\nKellner, U., & Pfau, K. (2025). [Inherited retinal disorders: Clinical and molecular genetic diagnostic]. Klinische Monatsblatter Fur Augenheilkunde, 242(6), 677â€“697. https://doi.org/10.1055/a-2274-5801\n\n\nKhateri, P., Koottungal, T., Wong, D., Strauss, R. W., Janeschitz-Kriegl, L., Pfau, M., Schmetterer, L., & Scholl, H. P. N. (2025). Looking outside the box with a pathology aware AI approach for analyzing OCT retinal images in stargardt disease. Scientific Reports, 15(1), 4739. https://doi.org/10.1038/s41598-025-85213-w\n\n\nKÃ¼nzel, S. H., Broadbent, E., MÃ¶ller, P. T., Lindner, M., Goerdt, L., Czauderna, J., Schmitz-Valckenberg, S., Holz, F. G., Pfau, M., & Fleckenstein, M. (2023). Impact of lesion location and functional parameters on vision-related quality of life in geographic atrophy secondary to AMD. medRxiv : The Preprint Server for Health Sciences. https://doi.org/10.1101/2023.09.22.23295946\n\n\nKÃ¼nzel, S. H., Broadbent, E., MÃ¶ller, P. T., Lindner, M., Goerdt, L., Czauderna, J., Schmitz-Valckenberg, S., Holz, F. G., Pfau, M., & Fleckenstein, M. (2024). Association of lesion location and functional parameters with vision-related quality of life in geographic atrophy secondary to age-related macular degeneration. Ophthalmology. Retina, 8(8), 794â€“803. https://doi.org/10.1016/j.oret.2024.01.025\n\n\nKÃ¼nzel, S. H., Lindner, M., Sassen, J., MÃ¶ller, P. T., Goerdt, L., Schmid, M., Schmitz-Valckenberg, S., Holz, F. G., Fleckenstein, M., & Pfau, M. (2021). Association of reading performance in geographic atrophy secondary to age-related macular degeneration with visual function and structural biomarkers. JAMA Ophthalmology, 139(11), 1191â€“1199. https://doi.org/10.1001/jamaophthalmol.2021.3826\n\n\nKÃ¼nzel, S. H., MÃ¶ller, P. T., Lindner, M., Goerdt, L., Nadal, J., Schmid, M., Schmitz-Valckenberg, S., Holz, F. G., Fleckenstein, M., & Pfau, M. (2020). Determinants of quality of life in geographic atrophy secondary to age-related macular degeneration. Investigative Ophthalmology & Visual Science, 61(5), 63. https://doi.org/10.1167/iovs.61.5.63\n\n\nLiermann, Y. N., Behning, C., Isselmann, B., Schmid, M., Dunbar, H. M. P., Luhmann, U. F. O., Finger, R. P., Schmitz-Valckenberg, S., Holz, F. G., Pfau, M., Luu, C. D., SaÃŸmannshausen, M., & Thiele, S. (2025). Ellipsoid zone reflectivity as a functional imaging biomarker for age-related macular degeneration: A MACUSTAR study report. Scientific Reports, 15(1), 20093. https://doi.org/10.1038/s41598-025-00735-7\n\n\nLindner, M., Fang, P. P., Steinberg, J. S., Domdei, N., Pfau, M., Krohne, T. U., Schmitz-Valckenberg, S., Holz, F. G., & Fleckenstein, M. (2016). OCT angiography-based detection and quantification of the neovascular network in exudative AMD. Investigative Ophthalmology & Visual Science, 57(14), 6342â€“6348. https://doi.org/10.1167/iovs.16-19741\n\n\nLindner, M., Kosanetzky, S., Pfau, M., Nadal, J., GÃ¶rdt, L. A., Schmitz-Valckenberg, S., Schmid, M., Holz, F. G., & Fleckenstein, M. (2018). Local progression kinetics of geographic atrophy in age-related macular degeneration are associated with atrophy border morphology. Investigative Ophthalmology & Visual Science, 59(4), AMD12â€“AMD18. https://doi.org/10.1167/iovs.17-23203\n\n\nLindner, M., Nadal, J., Mauschitz, M. M., LÃ¼ning, A., Czauderna, J., Pfau, M., Schmitz-Valckenberg, S., Holz, F. G., Schmid, M., & Fleckenstein, M. (2017). Combined fundus autofluorescence and near infrared reflectance as prognostic biomarkers for visual acuity in foveal-sparing geographic atrophy. Investigative Ophthalmology & Visual Science, 58(6), BIO61â€“BIO67. https://doi.org/10.1167/iovs.16-21210\n\n\nLindner, M., Pfau, M., Czauderna, J., Goerdt, L., Schmitz-Valckenberg, S., Holz, F. G., & Fleckenstein, M. (2019). Determinants of reading performance in eyes with foveal-sparing geographic atrophy. Ophthalmology. Retina, 3(3), 201â€“210. https://doi.org/10.1016/j.oret.2018.11.005\n\n\nLoewinger, A.-S., Pfau, M., Herrmann, P., Holz, F. G., & Pfau, K. (2023). Choriocapillaris flow signal impairment in patients with pseudoxanthoma elasticum. Investigative Ophthalmology & Visual Science, 64(2), 21. https://doi.org/10.1167/iovs.64.2.21\n\n\nMaloca, P. M., Pfau, M., Janeschitz-Kriegl, L., Reich, M., Goerdt, L., Holz, F. G., MÃ¼ller, P. L., Valmaggia, P., Fasler, K., Keane, P. A., Zarranz-Ventura, J., Zweifel, S., Wiesendanger, J., Kaiser, P., Enz, T. J., Rothenbuehler, S. P., Hasler, P. W., Juedes, M., Freichel, C., â€¦ Denk, N. (2024). Human selection bias drives the linear nature of the more ground truth effect in explainable deep learning optical coherence tomography image segmentation. Journal of Biophotonics, 17(2), e202300274. https://doi.org/10.1002/jbio.202300274\n\n\nMarques, I. P., Almeida, A. C., Futterknecht, S., Hatz, K., Cunha-Vaz, J., Scholl, H. P. N., Lobo, C., Silva, R., Murta, J. N., Anders, P., Anders, L.-M., Santos, A. R., & Pfau, M. (2025). Association of localized retinal sensitivities with spectral-domain optical coherence tomography-derived morphologic data in macular subfields in age-related macular degeneration. Ophthalmic Research, 68(1), 389â€“399. https://doi.org/10.1159/000546990\n\n\nMeinke, J., Raming, K., Pfau, M., Holz, F. G., & Pfau, K. (2025). [Pseudoxanthoma elasticum-novel therapeutic approaches on the horizon?]. Die Ophthalmologie, 122(6), 432â€“437. https://doi.org/10.1007/s00347-025-02223-9\n\n\nMukherjee, S., Arunachalam, T., Duic, C., Abraham, M., Orndahl, C., Menezes, S., AgrÃ³n, E., Pfau, M., Silva, T. de, Bailey, C., Thavikulwat, A. T., Bellur, S., Sadda, S. R., Chew, E. Y., Jeffrey, B. G., Wong, W. T., & Keenan, T. D. L. (2025). Structure-function relationships in geographic atrophy based on mesopic microperimetry, fundus autofluorescence, and optical coherence tomography. Translational Vision Science & Technology, 14(2), 7. https://doi.org/10.1167/tvst.14.2.7\n\n\nMukherjee, S., Vance, E., Emde, L. von der, Arunachalam, T., De Silva, T., Thavikulwat, A. T., Orndahl, C., Nyaiburi, C., Abraham, M., Hammel, K., Sadda, S. R., Chew, E. Y., Pfau, M., Wong, W. T., Jeffrey, B. G., & Keenan, T. D. L. (2025). Variation in mesopic retinal sensitivity relative to distance from geographic atrophy in age-related macular degeneration. Ophthalmology Science, 5(6), 100879. https://doi.org/10.1016/j.xops.2025.100879\n\n\nMÃ¼ller, P. L., Dysli, C., Hess, K., Holz, F. G., & Herrmann, P. (2020). SPECTRAL FUNDUS AUTOFLUORESCENCE EXCITATION AND EMISSION IN ABCA4-RELATED RETINOPATHY. Retina (Philadelphia, Pa.), 40(12), 2332â€“2342. https://doi.org/10.1097/IAE.0000000000002726\n\n\nMÃ¼ller, P. L., Odainic, A., Treis, T., Herrmann, P., Tufail, A., Holz, F. G., & Pfau, M. (2021). Inferred retinal sensitivity in recessive stargardt disease using machine learning. Scientific Reports, 11(1), 1466. https://doi.org/10.1038/s41598-020-80766-4\n\n\nMÃ¼ller, P. L., Pfau, M., Mauschitz, M. M., MÃ¶ller, P. T., Birtel, J., Chang, P., Gliem, M., Schmitz-Valckenberg, S., Fleckenstein, M., Holz, F. G., & Herrmann, P. (2018). Comparison of green versus blue fundus autofluorescence in ABCA4-related retinopathy. Translational Vision Science & Technology, 7(5), 13. https://doi.org/10.1167/tvst.7.5.13\n\n\nMÃ¼ller, P. L., Pfau, M., MÃ¶ller, P. T., Nadal, J., Schmid, M., Lindner, M., Sisternes, L. de, StÃ¶hr, H., Weber, B. H. F., Neuhaus, C., Herrmann, P., Schmitz-Valckenberg, S., Holz, F. G., & Fleckenstein, M. (2018). Choroidal flow signal in late-onset stargardt disease and age-related macular degeneration: An OCT-angiography study. Investigative Ophthalmology & Visual Science, 59(4), AMD122â€“AMD131. https://doi.org/10.1167/iovs.18-23819\n\n\nMÃ¼ller, P. L., Pfau, M., Schmitz-Valckenberg, S., Fleckenstein, M., & Holz, F. G. (2021). Optical coherence tomography-angiography in geographic atrophy. Ophthalmologica. Journal International dâ€™ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, 244(1), 42â€“50. https://doi.org/10.1159/000510727\n\n\nMÃ¼ller, P. L., Pfau, M., Treis, T., Pascual-Camps, I., Birtel, J., Lindner, M., Herrmann, P., & Holz, F. G. (2020). PROGRESSION OF ABCA4-RELATED RETINOPATHY: Prognostic value of demographic, functional, genetic, and imaging parameters. Retina (Philadelphia, Pa.), 40(12), 2343â€“2356. https://doi.org/10.1097/IAE.0000000000002747\n\n\nMÃ¼ller, P. L., Treis, T., Odainic, A., Pfau, M., Herrmann, P., Tufail, A., & Holz, F. G. (2020). Prediction of function in ABCA4-related retinopathy using ensemble machine learning. Journal of Clinical Medicine, 9(8). https://doi.org/10.3390/jcm9082428\n\n\nMÃ¼ller, P. L., Treis, T., Pfau, M., Esposti, S. D., Alsaedi, A., Maloca, P., Balaskas, K., Webster, A., Egan, C., & Tufail, A. (2020). Progression of retinopathy secondary to maternally inherited diabetes and deafness - evaluation of predicting parameters. American Journal of Ophthalmology, 213, 134â€“144. https://doi.org/10.1016/j.ajo.2020.01.013\n\n\nNigalye, A. K., Hess, K., Pundlik, S. J., Jeffrey, B. G., Cukras, C. A., & Husain, D. (2022). Dark adaptation and its role in age-related macular degeneration. Journal of Clinical Medicine, 11(5). https://doi.org/10.3390/jcm11051358\n\n\nNittala, M. G., Velaga, S. B., Hariri, A., Pfau, M., Birch, D. G., Haines, J., Pericak-Vance, M. A., Stambolian, D., & Sadda, S. R. (2019). Retinal sensitivity using microperimetry in age-related macular degeneration in an amish population. Ophthalmic Surgery, Lasers & Imaging Retina, 50(9), e236â€“e241. https://doi.org/10.3928/23258160-20190905-15\n\n\nOertli, J. M., Pfau, K., Scholl, H. P. N., Jeffrey, B. G., & Pfau, M. (2023). Establishing fully-automated fundus-controlled dark adaptometry: A validation and retest-reliability study. Translational Vision Science & Technology, 12(12), 18. https://doi.org/10.1167/tvst.12.12.18\n\n\nOishi, M., Oishi, A., Lindner, M., Pfau, M., Schmitz-Valckenberg, S., Holz, F. G., & Fleckenstein, M. (2017). Structural changes in optical coherence tomography underlying spots of increased autofluorescence in the perilesional zone of geographic atrophy. Investigative Ophthalmology & Visual Science, 58(7), 3303â€“3310. https://doi.org/10.1167/iovs.17-21498\n\n\nPfau, K., Ansari, G., Michels, S., Dysli, C., Liakopoulos, S., Burghaus-Zhang, J., Al-Sheikh, M., Garweg, J. G., Quinodoz, M., Kaminska, K., Cancellieri, F., Rivolta, C., Terry, S. F., Feltgen, N., & Pfau, M. (2025). Topography of slowed dark adaptation in pseudoxanthoma elasticum: PROPXE study report 1. Investigative Ophthalmology & Visual Science, 66(2), 17. https://doi.org/10.1167/iovs.66.2.17\n\n\nPfau, K., Callizo, J., Rossouw, P., Gabrani, C., Holz, F., Charbel Issa, P., Kellner, U., Strauss, R., KÃ¼hlewein, L., Stingl, K., Feltgen, N., & Pfau, M. (2025a). [Correction: N-acetylcysteine (NAC) for retinitis pigmentosa]. Klinische Monatsblatter Fur Augenheilkunde, 242(3), e2. https://doi.org/10.1055/a-2587-6864\n\n\nPfau, K., Callizo, J., Rossouw, P., Gabrani, C., Holz, F., Charbel Issa, P., Kellner, U., Strauss, R., KÃ¼hlewein, L., Stingl, K., Feltgen, N., & Pfau, M. (2025b). [N-acetylcysteine (NAC) for retinitis pigmentosa]. Klinische Monatsblatter Fur Augenheilkunde, 242(3), 199â€“204. https://doi.org/10.1055/a-2525-4419\n\n\nPfau, K., Gross, O., Bemme, S., Meyer, P., Take, P., Boeckhaus, J., Holz, F. G., & Feltgen, N. (2023). [Ocular alterations in patients with alport syndrome-an update]. Die Ophthalmologie, 120(6), 645â€“651. https://doi.org/10.1007/s00347-022-01805-1\n\n\nPfau, K., Holz, F. G., & Pfau, M. (2025). [Pseudoxanthoma elasticum (PXE)-the eye as a diagnostic key]. Die Ophthalmologie, 122(6), 421â€“423. https://doi.org/10.1007/s00347-025-02256-0\n\n\nPfau, K., Jeffrey, B. G., & Cukras, C. A. (2023). LOW-DOSE SUPPLEMENTATION WITH RETINOL IMPROVES RETINAL FUNCTION IN EYES WITH AGE-RELATED MACULAR DEGENERATION BUT WITHOUT RETICULAR PSEUDODRUSEN. Retina (Philadelphia, Pa.), 43(9), 1462â€“1471. https://doi.org/10.1097/IAE.0000000000003840\n\n\nPfau, K., & Kellner, U. (2025). [Inherited retinal disorders: Current therapeutic options and future perspectives]. Klinische Monatsblatter Fur Augenheilkunde. https://doi.org/10.1055/a-2521-4616\n\n\nPfau, K., Lengyel, I., Ossewaarde-van Norel, J., Leeuwen, R. van, Risseeuw, S., Leftheriotis, G., Scholl, H. P. N., Feltgen, N., Holz, F. G., & Pfau, M. (2024). Pseudoxanthoma elasticum - genetics, pathophysiology, and clinical presentation. Progress in Retinal and Eye Research, 102, 101274. https://doi.org/10.1016/j.preteyeres.2024.101274\n\n\nPfau, M., Cukras, C. A., Huryn, L. A., Zein, W. M., Ullah, E., Boyle, M. P., Turriff, A., Chen, M. A., Hinduja, A. S., Siebel, H. E., Hufnagel, R. B., Jeffrey, B. G., & Brooks, B. P. (2022). Photoreceptor degeneration in ABCA4-associated retinopathy and its genetic correlates. JCI Insight, 7(2). https://doi.org/10.1172/jci.insight.155373\n\n\nPfau, M., Dijk, E. H. C. van, Rijssen, T. J. van, Schmitz-Valckenberg, S., Holz, F. G., Fleckenstein, M., & Boon, C. J. F. (2021). Estimation of current and post-treatment retinal function in chronic central serous chorioretinopathy using artificial intelligence. Scientific Reports, 11(1), 20446. https://doi.org/10.1038/s41598-021-99977-4\n\n\nPfau, M., Emde, L. von der, Dysli, C., MÃ¶ller, P. T., Thiele, S., Lindner, M., Schmid, M., Rubin, D. L., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2020). Determinants of cone and rod functions in geographic atrophy: AI-based structure-function correlation. American Journal of Ophthalmology, 217, 162â€“173. https://doi.org/10.1016/j.ajo.2020.04.003\n\n\nPfau, M., Emde, L. von der, Dysli, C., Thiele, S., MÃ¶ller, P. T., Lindner, M., Nadal, J., Schmid, M., Schmitz-Valckenberg, S., Holz, F. G., & Fleckenstein, M. (2019). Light sensitivity within areas of geographic atrophy secondary to age-related macular degeneration. Investigative Ophthalmology & Visual Science, 60(12), 3992â€“4001. https://doi.org/10.1167/iovs.19-27178\n\n\nPfau, M., Emde, L. von der, Sisternes, L. de, Hallak, J. A., Leng, T., Schmitz-Valckenberg, S., Holz, F. G., Fleckenstein, M., & Rubin, D. L. (2020). Progression of photoreceptor degeneration in geographic atrophy secondary to age-related macular degeneration. JAMA Ophthalmology, 138(10), 1026â€“1034. https://doi.org/10.1001/jamaophthalmol.2020.2914\n\n\nPfau, M., Fassnacht-Riederle, H. M., Freiberg, F. J., Wons, J. B., Wirth, M., Becker, M. D., & Michels, S. (2016a). [Correction for: Switching therapy from ranibizumab and/or bevacizumab to aflibercept in neovascular age-related macular degeneration (AMD): One-year results]. Klinische Monatsblatter Fur Augenheilkunde, 233(8), e3. https://doi.org/10.1055/s-0042-115798\n\n\nPfau, M., Fassnacht-Riederle, H. M., Freiberg, F. J., Wons, J. B., Wirth, M., Becker, M. D., & Michels, S. (2016b). [Switching therapy from ranibizumab and/or bevacizumab to aflibercept in neovascular age-related macular degeneration (AMD): One-year results]. Klinische Monatsblatter Fur Augenheilkunde, 233(8), 945â€“950. https://doi.org/10.1055/s-0042-101348\n\n\nPfau, M., Fassnacht-Riederle, H., Becker, M. D., Graf, N., & Michels, S. (2015). Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion. Ophthalmic Research, 54(3), 150â€“156. https://doi.org/10.1159/000439223\n\n\nPfau, M., Goerdt, L., Schmitz-Valckenberg, S., Mauschitz, M. M., Mishra, D. K., Holz, F. G., Lindner, M., & Fleckenstein, M. (2017). Green-light autofluorescence versus combined blue-light autofluorescence and near-infrared reflectance imaging in geographic atrophy secondary to age-related macular degeneration. Investigative Ophthalmology & Visual Science, 58(6), BIO121â€“BIO130. https://doi.org/10.1167/iovs.17-21764\n\n\nPfau, M., Holz, F. G., & MÃ¼ller, P. L. (2021). Retinal light sensitivity as outcome measure in recessive stargardt disease. The British Journal of Ophthalmology, 105(2), 258â€“264. https://doi.org/10.1136/bjophthalmol-2020-316201\n\n\nPfau, M., Huryn, L. A., Boyle, M. P., Cukras, C. A., Zein, W. M., Turriff, A., Ullah, E., Hufnagel, R. B., Jeffrey, B. G., & Brooks, B. P. (2023). Natural history of visual dysfunction in ABCA4 retinopathy and its genetic correlates. American Journal of Ophthalmology, 253, 224â€“232. https://doi.org/10.1016/j.ajo.2023.05.014\n\n\nPfau, M., Jolly, J. K., Charng, J., Emde, L. von der, MÃ¼ller, P. L., Ansari, G., Pfau, K., Chen, F. K., & Wu, Z. (2024). Multicenter normative data for mesopic microperimetry. Investigative Ophthalmology & Visual Science, 65(12), 27. https://doi.org/10.1167/iovs.65.12.27\n\n\nPfau, M., Jolly, J. K., Wu, Z., Denniss, J., Lad, E. M., Guymer, R. H., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2021). Fundus-controlled perimetry (microperimetry): Application as outcome measure in clinical trials. Progress in Retinal and Eye Research, 82, 100907. https://doi.org/10.1016/j.preteyeres.2020.100907\n\n\nPfau, M., KÃ¼nzel, S. H., Pfau, K., Schmitz-Valckenberg, S., Fleckenstein, M., & Holz, F. G. (2023). Multimodal imaging and deep learning in geographic atrophy secondary to age-related macular degeneration. Acta Ophthalmologica, 101(8), 881â€“890. https://doi.org/10.1111/aos.15796\n\n\nPfau, M., Lindner, M., Fleckenstein, M., Finger, R. P., Rubin, G. S., Harmening, W. M., Morales, M. U., Holz, F. G., & Schmitz-Valckenberg, S. (2017). Test-retest reliability of scotopic and mesopic fundus-controlled perimetry using a modified MAIA (macular integrity assessment) in normal eyes. Ophthalmologica. Journal International dâ€™ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, 237(1), 42â€“54. https://doi.org/10.1159/000453079\n\n\nPfau, M., Lindner, M., Gliem, M., Steinberg, J. S., Thiele, S., Finger, R. P., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2018). Mesopic and dark-adapted two-color fundus-controlled perimetry in patients with cuticular, reticular, and soft drusen. Eye (London, England), 32(12), 1819â€“1830. https://doi.org/10.1038/s41433-018-0183-3\n\n\nPfau, M., Lindner, M., Goerdt, L., Thiele, S., Nadal, J., Schmid, M., Schmitz-Valckenberg, S., Sadda, S. R., Holz, F. G., & Fleckenstein, M. (2019). PROGNOSTIC VALUE OF SHAPE-DESCRIPTIVE FACTORS FOR THE PROGRESSION OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina (Philadelphia, Pa.), 39(8), 1527â€“1540. https://doi.org/10.1097/IAE.0000000000002206\n\n\nPfau, M., Lindner, M., MÃ¼ller, P. L., Birtel, J., Finger, R. P., Harmening, W. M., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2017). Effective dynamic range and retest reliability of dark-adapted two-color fundus-controlled perimetry in patients with macular diseases. Investigative Ophthalmology & Visual Science, 58(6), BIO158â€“BIO167. https://doi.org/10.1167/iovs.17-21454\n\n\nPfau, M., Lindner, M., Steinberg, J. S., Thiele, S., Brinkmann, C. K., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2018). Visual field indices and patterns of visual field deficits in mesopic and dark-adapted two-colour fundus-controlled perimetry in macular diseases. The British Journal of Ophthalmology, 102(8), 1054â€“1059. https://doi.org/10.1136/bjophthalmol-2017-311012\n\n\nPfau, M., Michels, S., Binder, S., & Becker, M. D. (2015). Clinical experience with the first commercially available intraoperative optical coherence tomography system. Ophthalmic Surgery, Lasers & Imaging Retina, 46(10), 1001â€“1008. https://doi.org/10.3928/23258160-20151027-03\n\n\nPfau, M., MÃ¶ller, P. T., KÃ¼nzel, S. H., Emde, L. von der, Lindner, M., Thiele, S., Dysli, C., Nadal, J., Schmid, M., Schmitz-Valckenberg, S., Holz, F. G., & Fleckenstein, M. (2020). Type 1 choroidal neovascularization is associated with reduced localized progression of atrophy in age-related macular degeneration. Ophthalmology. Retina, 4(3), 238â€“248. https://doi.org/10.1016/j.oret.2019.09.016\n\n\nPfau, M., MÃ¼ller, P. L., Emde, L. von der, Lindner, M., MÃ¶ller, P. T., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2020). MESOPIC AND DARK-ADAPTED TWO-COLOR FUNDUS-CONTROLLED PERIMETRY IN GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina (Philadelphia, Pa.), 40(1), 169â€“180. https://doi.org/10.1097/IAE.0000000000002337\n\n\nPfau, M., Sahu, S., Rupnow, R. A., Romond, K., Millet, D., Holz, F. G., Schmitz-Valckenberg, S., Fleckenstein, M., Lim, J. I., Sisternes, L. de, Leng, T., Rubin, D. L., & Hallak, J. A. (2021). Probabilistic forecasting of anti-VEGF treatment frequency in neovascular age-related macular degeneration. Translational Vision Science & Technology, 10(7), 30. https://doi.org/10.1167/tvst.10.7.30\n\n\nPfau, M., Schmitz-Valckenberg, S., Holz, F. G., & Fleckenstein, M. (2022). Re: Trivizki et al. Local geographic atrophy growth rates not influenced by close proximity to non-exudative type 1 macular neovascularization. Investigative Ophthalmology & Visual Science, 63(5), 10. https://doi.org/10.1167/iovs.63.5.10\n\n\nPfau, M., Schmitz-Valckenberg, S., Ribeiro, R., Safaei, R., McKeown, A., Fleckenstein, M., & Holz, F. G. (2022). Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy. Scientific Reports, 12(1), 17870. https://doi.org/10.1038/s41598-022-22404-9\n\n\nPfau, M., Walther, G., Emde, L. von der, Berens, P., Faes, L., Fleckenstein, M., Heeren, T. F. C., KortÃ¼m, K., KÃ¼nzel, S. H., MÃ¼ller, P. L., Maloca, P. M., Waldstein, S. M., Wintergerst, M. W. M., Schmitz-Valckenberg, S., Finger, R. P., & Holz, F. G. (2020). [Artificial intelligence in ophthalmology : Guidelines for physicians for the critical evaluation of studies]. Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft, 117(10), 973â€“988. https://doi.org/10.1007/s00347-020-01209-z\n\n\nPfau, M., Zein, W. M., Huryn, L. A., Cukras, C. A., Jeffrey, B. G., Hufnagel, R. B., & Brooks, B. P. (2023). Genotype-phenotype association in ABCA4-associated retinopathy. Advances in Experimental Medicine and Biology, 1415, 289â€“295. https://doi.org/10.1007/978-3-031-27681-1_42\n\n\nPondorfer, S. G., Heinemann, M., Wintergerst, M. W. M., Pfau, M., StrÃ¶mer, A. L., Holz, F. G., & Finger, R. P. (2020). Detecting vision loss in intermediate age-related macular degeneration: A comparison of visual function tests. PloS One, 15(4), e0231748. https://doi.org/10.1371/journal.pone.0231748\n\n\nPontikos, N., Woof, W. A., Lin, S., Ghoshal, B., Mendes, B. S., Veturi, A., Nguyen, Q., Javanmardi, B., Georgiou, M., Hustinx, A., Ibarra-Arellano, M. A., Moghul, I., Liu, Y., Pfau, K., Pfau, M., Shah, M., Yu, J., Al-Khuzaei, S., Wagner, S. K., â€¦ Michaelides, M. (2025). Next-generation phenotyping of inherited retinal diseases from multimodal imaging with Eye2Gene. Nature Machine Intelligence, 7(6), 967â€“978. https://doi.org/10.1038/s42256-025-01040-8\n\n\nRaming, K., Gliem, M., Charbel Issa, P., Birtel, J., Herrmann, P., Holz, F. G., Pfau, M., & Hess, K. (2022). Visual dysfunction and structural correlates in sorsby fundus dystrophy. American Journal of Ophthalmology, 234, 274â€“284. https://doi.org/10.1016/j.ajo.2021.07.032\n\n\nRaming, K., KÃ¼nzel, S. H., Pfau, M., Hendig, D., Holz, F. G., & Pfau, K. (2024). Optic disc drusen in pseudoxanthoma elasticum are associated with the extent of bruchâ€™s membrane calcification. Journal of Clinical Medicine, 13(12). https://doi.org/10.3390/jcm13123395\n\n\nRaming, K., Meinke, J., Ansari, G., Cancian, G., StÃ¼rzebecher, K., Staub, D., Feltgen, N., Holz, F. G., Pfau, M., & Pfau, K. (2025). [Ocular alterations in pseudoxanthoma elasticum : The eye as a window to diagnosing a systemic disease]. Die Ophthalmologie, 122(6), 424â€“431. https://doi.org/10.1007/s00347-025-02261-3\n\n\nRaming, K., Pfau, M., Herrmann, P., Holz, F. G., & Pfau, K. (2024). Anti-VEGF treatment for secondary neovascularization in pseudoxanthoma elasticum - age of onset, treatment frequency, and visual outcome. American Journal of Ophthalmology, 265, 127â€“136. https://doi.org/10.1016/j.ajo.2024.03.026\n\n\nRaming, K., Rodriguez Garcia, J. L., Steffens, N., Nadal, J., Herrmann, P., Holz, F. G., Pfau, K., & Goerdt, L. (2025). Frequency of misdiagnoses and associated risk factors in macular telangiectasia type 2. Retina (Philadelphia, Pa.). https://doi.org/10.1097/IAE.0000000000004681\n\n\nRaming, K., Saltenberger, I., Meinke, J., Risseeuw, S., Mercieca, K., Herrmann, P., Chang, P., Ach, T., Leeuwen, R. van, Ossewaarde-van Norel, J., Pfau, M., Holz, F. G., & Pfau, K. (2025). Intraocular pressure after anti-vascular endothelial growth factor injection in eyes with a mineralized bruchâ€™s membrane caused by pseudoxanthoma elasticum. Investigative Ophthalmology & Visual Science, 66(11), 25. https://doi.org/10.1167/iovs.66.11.25\n\n\nReiniger, J. L., Domdei, N., Pfau, M., MÃ¼ller, P. L., Holz, F. G., & Harmening, W. M. (2017). [Potential of adaptive optics for the diagnostic evaluation of hereditary retinal diseases]. Klinische Monatsblatter Fur Augenheilkunde, 234(3), 311â€“319. https://doi.org/10.1055/s-0043-100631\n\n\nSaÃŸmannshausen, M., Behning, C., Isselmann, B., Schmid, M., Finger, R. P., Holz, F. G., Schmitz-Valckenberg, S., Pfau, M., & Thiele, S. (2022). Relative ellipsoid zone reflectivity and its association with disease severity in age-related macular degeneration: A MACUSTAR study report. Scientific Reports, 12(1), 14933. https://doi.org/10.1038/s41598-022-18875-5\n\n\nSaÃŸmannshausen, M., Behning, C., Weinz, J., Goerdt, L., Terheyden, J. H., Chang, P., Schmid, M., Poor, S. H., Zakaria, N., Finger, R. P., Holz, F. G., Pfau, M., Schmitz-Valckenberg, S., & Thiele, S. (2023). Characteristics and spatial distribution of structural features in age-related macular degeneration: A MACUSTAR study report. Ophthalmology. Retina, 7(5), 420â€“430. https://doi.org/10.1016/j.oret.2022.12.007\n\n\nSassmannshausen, M., Pfau, M., Thiele, S., Fimmers, R., Steinberg, J. S., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2020). Longitudinal analysis of structural and functional changes in presence of reticular pseudodrusen associated with age-related macular degeneration. Investigative Ophthalmology & Visual Science, 61(10), 19. https://doi.org/10.1167/iovs.61.10.19\n\n\nSaÃŸmannshausen, M., Steinberg, J. S., Fimmers, R., Pfau, M., Thiele, S., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2018). Structure-function analysis in patients with intermediate age-related macular degeneration. Investigative Ophthalmology & Visual Science, 59(3), 1599â€“1608. https://doi.org/10.1167/iovs.17-22712\n\n\nSaÃŸmannshausen, M., Thiele, S., Behning, C., Pfau, M., Schmid, M., Leal, S., Luhmann, U. F. O., Finger, R. P., Holz, F. G., & Schmitz-Valckenberg, S. (2022). Intersession repeatability of structural biomarkers in early and intermediate age-related macular degeneration: A MACUSTAR study report. Translational Vision Science & Technology, 11(3), 27. https://doi.org/10.1167/tvst.11.3.27\n\n\nSaÃŸmannshausen, M., Zhou, J., Pfau, M., Thiele, S., Steinberg, J., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2021). Longitudinal analysis of retinal thickness and retinal function in eyes with large drusen secondary to intermediate age-related macular degeneration. Ophthalmology. Retina, 5(3), 241â€“250. https://doi.org/10.1016/j.oret.2020.07.019\n\n\nSchmitz-Valckenberg, S., Pfau, M., Fleckenstein, M., Staurenghi, G., Sparrow, J. R., Bindewald-Wittich, A., Spaide, R. F., Wolf, S., Sadda, S. R., & Holz, F. G. (2021). Fundus autofluorescence imaging. Progress in Retinal and Eye Research, 81, 100893. https://doi.org/10.1016/j.preteyeres.2020.100893\n\n\nSchmitz-Valckenberg, S., SaÃŸmannshausen, M., Braun, M., Steffen, V., Gao, S. S., Honigberg, L., Ferrara, D., Pfau, M., & Holz, F. G. (2023). Interreader agreement and longitudinal progression of incomplete/complete retinal pigment epithelium and outer retinal atrophy in age-related macular degeneration. Ophthalmology. Retina, 7(12), 1059â€“1068. https://doi.org/10.1016/j.oret.2023.07.021\n\n\nSimunovic, M. P., Hess, K., Avery, N., & Mammo, Z. (2021). Threshold versus intensity functions in two-colour automated perimetry. Ophthalmic & Physiological Optics : The Journal of the British College of Ophthalmic Opticians (Optometrists), 41(1), 157â€“164. https://doi.org/10.1111/opo.12743\n\n\nSimunovic, M. P., Hess, K., & Gillies, M. C. (2022). IMPAIRMENTS IN CONE PIGMENT REGENERATION AND ABSOLUTE THRESHOLD IN MACULAR TELANGIECTASIA TYPE 2. Retina (Philadelphia, Pa.), 42(3), 569â€“575. https://doi.org/10.1097/IAE.0000000000003328\n\n\nSrinivas, S., Nittala, M. G., Hariri, A., Pfau, M., Gasperini, J., Ip, M., & Sadda, S. R. (2018). QUANTIFICATION OF INTRARETINAL HARD EXUDATES IN EYES WITH DIABETIC RETINOPATHY BY OPTICAL COHERENCE TOMOGRAPHY. Retina (Philadelphia, Pa.), 38(2), 231â€“236. https://doi.org/10.1097/IAE.0000000000001545\n\n\nSteinberg, J. S., SaÃŸmannshausen, M., Pfau, M., Fleckenstein, M., Finger, R. P., Holz, F. G., & Schmitz-Valckenberg, S. (2017). Evaluation of two systems for fundus-controlled scotopic and mesopic perimetry in eye with age-related macular degeneration. Translational Vision Science & Technology, 6(4), 7. https://doi.org/10.1167/tvst.6.4.7\n\n\nTaylor, L. J., Josan, A. S., Pfau, M., Simunovic, M. P., & Jolly, J. K. (2022). Scotopic microperimetry: Evolution, applications and future directions. Clinical & Experimental Optometry, 105(8), 793â€“800. https://doi.org/10.1080/08164622.2021.2023477\n\n\nTerheyden, J. H., Wintergerst, M. W. M., Pizarro, C., Pfau, M., Turski, G. N., Holz, F. G., & Finger, R. P. (2020). Retinal and choroidal capillary perfusion are reduced in hypertensive crisis irrespective of retinopathy. Translational Vision Science & Technology, 9(8), 42. https://doi.org/10.1167/tvst.9.8.42\n\n\nThiele, S., Isselmann, B., Pfau, M., Holz, F. G., Schmitz-Valckenberg, S., Wu, Z., Guymer, R. H., & Luu, C. D. (2020). Validation of an automated quantification of relative ellipsoid zone reflectivity on spectral domain-optical coherence tomography images. Translational Vision Science & Technology, 9(11), 17. https://doi.org/10.1167/tvst.9.11.17\n\n\nThiele, S., Nadal, J., Fleckenstein, M., Fang, P. P., Pfau, M., Schmid, M., Hua, R., Holz, F. G., & Schmitz-Valckenberg, S. (2018). Longitudinal analysis of drusen volume in intermediate age-related macular degeneration using two spectral-domain optical coherence tomography scan patterns. Ophthalmologica. Journal International dâ€™ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, 239(2-3), 110â€“120. https://doi.org/10.1159/000485260\n\n\nThiele, S., Nadal, J., Pfau, M., SaÃŸmannshausen, M., Emde, L. von der, Fleckenstein, M., Holz, F. G., Schmid, M., & Schmitz-Valckenberg, S. (2020). Prognostic value of retinal layers in comparison with other risk factors for conversion of intermediate age-related macular degeneration. Ophthalmology. Retina, 4(1), 31â€“40. https://doi.org/10.1016/j.oret.2019.08.003\n\n\nThiele, S., Nadal, J., Pfau, M., SaÃŸmannshausen, M., Fleckenstein, M., Holz, F. G., Schmid, M., & Schmitz-Valckenberg, S. (2021). Prognostic value of intermediate age-related macular degeneration phenotypes for geographic atrophy progression. The British Journal of Ophthalmology, 105(2), 239â€“245. https://doi.org/10.1136/bjophthalmol-2020-316004\n\n\nThiele, S., Pfau, M., Larsen, P. P., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2018). Multimodal imaging patterns for development of central atrophy secondary to age-related macular degeneration. Investigative Ophthalmology & Visual Science, 59(4), AMD1â€“AMD11. https://doi.org/10.1167/iovs.17-23315\n\n\nThiele, S., Wu, Z., Isselmann, B., Pfau, M., Guymer, R. H., & Luu, C. D. (2022). Natural history of the relative ellipsoid zone reflectivity in age-related macular degeneration. Ophthalmology. Retina, 6(12), 1165â€“1172. https://doi.org/10.1016/j.oret.2022.06.001\n\n\nTorra, R., Lipska-Zietkiewicz, B., Acke, F., Antignac, C., Becker, J. U., Cornec-Le Gall, E., Eerde, A. M. van, Feltgen, N., Ferrari, R., Gale, D. P., Gear, S., Gross, O., Haeberle, S., Heidet, L., Lennon, R., Massella, L., Pfau, K., Pizarro, M. D. P. V., Topaloglu, R., â€¦ Zealey, H. (2025). Diagnosis, management and treatment of the alport syndrome - 2024 guideline on behalf of ERKNet, ERA and ESPN. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 40(6), 1091â€“1106. https://doi.org/10.1093/ndt/gfae265\n\n\nTzaridis, S., Hess, K., Friedlander, M., & Holz, F. G. (2021). Optical coherence tomography-angiography for monitoring neovascularisations in macular telangiectasia type 2. The British Journal of Ophthalmology, 105(5), 735â€“740. https://doi.org/10.1136/bjophthalmol-2020-316021\n\n\nTzaridis, S., Hess, K., Heeren, T. F. C., Bonelli, R., Holz, F. G., & Friedlander, M. (2020). WITHDRAWN: Hyper-reflectivity on optical coherence tomography in macular telangiectasia type 2. Retina (Philadelphia, Pa.). https://doi.org/10.1097/IAE.0000000000003031\n\n\nTzaridis, S., Hess, K., Heeren, T. F. C., Bonelli, R., Holz, F. G., & Friedlander, M. (2021). HYPERREFLECTIVITY ON OPTICAL COHERENCE TOMOGRAPHY IN MACULAR TELANGIECTASIA TYPE 2. Retina (Philadelphia, Pa.), 41(7), 1428â€“1437. https://doi.org/10.1097/IAE.0000000000003111\n\n\nTzaridis, S., Hess, K., Heeren, T. F. C., Nadal, J., Mai, C., Herrmann, P., Charbel Issa, P., & Holz, F. G. (2020). DARK ADAPTATION IN MACULAR TELANGIECTASIA TYPE 2. Retina (Philadelphia, Pa.), 40(10), 2018â€“2025. https://doi.org/10.1097/IAE.0000000000002694\n\n\nWelker, S. G., Pfau, M., Heinemann, M., Schmitz-Valckenberg, S., Holz, F. G., & Finger, R. P. (2018). Retest reliability of mesopic and dark-adapted microperimetry in patients with intermediate age-related macular degeneration and age-matched controls. Investigative Ophthalmology & Visual Science, 59(4), AMD152â€“AMD159. https://doi.org/10.1167/iovs.18-23878\n\n\nWintergerst, M. W. M., Pfau, M., MÃ¼ller, P. L., Berger, M., Sisternes, L. de, Holz, F. G., & Finger, R. P. (2018). Optical coherence tomography angiography in intermediate uveitis. American Journal of Ophthalmology, 194, 35â€“45. https://doi.org/10.1016/j.ajo.2018.06.023\n\n\nWirth, M. A., Freiberg, F., Pfau, M., Wons, J., Becker, M. D., & Michels, S. (2017). Optical coherence tomography angiography in age-related macular degeneration: Persistence of vascular network in quiescent choroidal neovascularization. Acta Ophthalmologica, 95(4), 428â€“430. https://doi.org/10.1111/aos.13226\n\n\nWons, J., Pfau, M., Wirth, M. A., Freiberg, F. J., Becker, M. D., & Michels, S. (2016). Optical coherence tomography angiography of the foveal avascular zone in retinal vein occlusion. Ophthalmologica. Journal International dâ€™ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, 235(4), 195â€“202. https://doi.org/10.1159/000445482\n\n\nWons, J., Pfau, M., Wirth, M. A., Freiberg, F. J., Becker, M. D., & Michels, S. (2017). Angio-OCT de la zona avascular foveal en ojos con oclusiÃ³n venosa de la retina. Ophthalmologica. Journal International dâ€™ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, 238 Suppl 1, 39â€“47. https://doi.org/10.1159/000477515\n\n\nWu, V., Roman, A. J., Galsterer, E. L., Ansari, G., Erdinest, I., Righetti, G., Viarbitskaya, I., Russell, R. C., Kim, R. J., Charlier, J., Pfau, K., Stingl, K., Banin, E., Pfau, M., Stingl, K., Aleman, T. S., & Cideciyan, A. V. (2025). Measuring rod- and cone-photoreceptor-specific vision in inherited retinal diseases using a commercial perimeter. Investigative Ophthalmology & Visual Science, 66(13), 31. https://doi.org/10.1167/iovs.66.13.31\n\n\nWu, Z., Pfau, M., Blodi, B. A., Holz, F. G., Jaffe, G. J., Liakopoulos, S., Sadda, S. R., Staurenghi, G., Bjelopera, E., Brown, T., Chang, P., Choong, J., Corradetti, G., Corvi, F., Domalpally, A., Hurtenbach, C., Nittala, M. G., Olson, A., Pak, J. W., â€¦ Schmitz-Valckenberg, S. (2022). OCT signs of early atrophy in age-related macular degeneration: Interreader agreement: Classification of atrophy meetings report 6. Ophthalmology. Retina, 6(1), 4â€“14. https://doi.org/10.1016/j.oret.2021.03.008\n\n\nWu, Z., Pfau, M., Fleckenstein, M., & Guymer, R. H. (2024). Microperimetry characteristics of regions with a truly nonresponding location: Implications for atrophic age-related macular degeneration. Investigative Ophthalmology & Visual Science, 65(8), 44. https://doi.org/10.1167/iovs.65.8.44\n\n\nWu, Z., Sadda, S. R., Ach, T., Blodi, B. A., Bottoni, F., Chakravarthy, U., Chew, E. Y., Curcio, C. A., Ferris, F. L. 3rd., Fleckenstein, M., Freund, K. B., Grunwald, J. E., Holz, F. G., Jaffe, G. J., Liakopoulos, S., Lim, T. H., MonÃ©s, J. M., Pagliarini, S., Pauleikhoff, D., â€¦ Guymer, R. H. (2025). Onset of end-stage atrophic age-related macular degeneration as an end point-a delphi study: Classification of atrophy meetings report 7. Ophthalmology Science, 5(5), 100777. https://doi.org/10.1016/j.xops.2025.100777"
  },
  {
    "objectID": "index.html#group-k.-pfau",
    "href": "index.html#group-k.-pfau",
    "title": "Welcome!",
    "section": "Group K. Pfau",
    "text": "Group K. Pfau\n\n\n\n\n\n\n\n\n\n\nCarolina Charlotte Kessler\n\n\n\n\n\n\n\n\n\n\n\n\nEva Begemann\n\n\n\n\n\n\n\n\n\n\n\n\nIsabel Saltenberger\n\n\n\n\n\n\n\n\n\n\n\n\nJonathan Meinke\n\n\n\n\n\n\n\n\n\n\n\n\nKristin Raming\n\n\n\n\n\n\n\n\n\n\n\n\nKristina Pfau (nÃ©e Hess)\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "impressum.html",
    "href": "impressum.html",
    "title": "Impressum",
    "section": "",
    "text": "Angaben gemÃ¤ÃŸ Â§ 5 TMG und Â§ 55 RStV\nHerausgeber:\nArbeitsgruppe Pfau (AG Pfau)\nUniversitÃ¤ts-Augenklinik Bonn\nVenusberg-Campus 1\nGebÃ¤ude A 04 & A 05\n53127 Bonn\nDeutschland\nVertreten durch:\nDr.Â Maximilian Pfau\nKontakt:\nTelefon: +49 (0)228 287 â€“ 15505 (Zentrale)\nE-Mail: Maximilian.Pfau@ukbonn.de\nVerantwortlich fÃ¼r den Inhalt (Â§ 55 Abs. 2 RStV):\nDr.Â Maximilian Pfau (Anschrift s. oben)"
  },
  {
    "objectID": "impressum.html#trÃ¤ger-und-rechtliche-hinweise",
    "href": "impressum.html#trÃ¤ger-und-rechtliche-hinweise",
    "title": "Impressum",
    "section": "TrÃ¤ger und rechtliche Hinweise",
    "text": "TrÃ¤ger und rechtliche Hinweise\nDas UniversitÃ¤tsklinikum Bonn (UKB) ist eine KÃ¶rperschaft des Ã¶ffentlichen Rechts.\nAnschrift des UKB:\nUniversitÃ¤tsklinikum Bonn\nVenusberg-Campus 1\n53127 Bonn\nDeutschland\nDas UKB ist eine Einrichtung der Rheinischen Friedrich-Wilhelms-UniversitÃ¤t Bonn."
  },
  {
    "objectID": "impressum.html#disclaimer-rechtliche-hinweise",
    "href": "impressum.html#disclaimer-rechtliche-hinweise",
    "title": "Impressum",
    "section": "Disclaimer â€“ Rechtliche Hinweise",
    "text": "Disclaimer â€“ Rechtliche Hinweise\n\n1. Haftungsausschluss\nDas UKB und die AG Pfau sind stets bemÃ¼ht, aktuelle und inhaltlich richtige Informationen auf dieser Webseite bereitzustellen.\nEine GewÃ¤hr fÃ¼r die Richtigkeit, AktualitÃ¤t und VollstÃ¤ndigkeit der bereitgestellten Informationen wird jedoch nicht Ã¼bernommen.\nHaftungsansprÃ¼che gegen das UKB oder die AG Pfau, die durch die Nutzung der bereitgestellten Informationen entstehen, sind ausgeschlossen, sofern kein nachweislich vorsÃ¤tzliches oder grob fahrlÃ¤ssiges Verschulden vorliegt.\nDie Bereitstellung von Informationen auf dieser Website ersetzt keine Ã¤rztliche Beratung oder Behandlung.\nDas UKB behÃ¤lt sich vor, Inhalte jederzeit ohne AnkÃ¼ndigung zu Ã¤ndern oder zu entfernen.\n\n\n2. Externe Links\nDiese Website enthÃ¤lt VerknÃ¼pfungen zu externen Webseiten Dritter (â€externe Linksâ€œ). Diese Webseiten unterliegen der Haftung der jeweiligen Betreiber.\nDas UKB hat bei der erstmaligen VerknÃ¼pfung die fremden Inhalte geprÃ¼ft und keine RechtsverstÃ¶ÃŸe festgestellt. Auf die aktuelle und zukÃ¼nftige Gestaltung hat das UKB keinen Einfluss.\nBei Bekanntwerden von RechtsverstÃ¶ÃŸen werden entsprechende Links unverzÃ¼glich entfernt.\n\n\n3. Urheber- und Leistungsschutzrechte\nAlle auf dieser Website verÃ¶ffentlichten Inhalte unterliegen dem deutschen Urheberrecht.\nJede vom Urheberrecht nicht zugelassene Verwertung bedarf der vorherigen schriftlichen Zustimmung des jeweiligen Rechteinhabers.\nDie Herstellung von Kopien und Downloads fÃ¼r den persÃ¶nlichen, privaten und nicht kommerziellen Gebrauch ist erlaubt.\nDie Darstellung dieser Website in fremden Frames ist nur mit schriftlicher Erlaubnis zulÃ¤ssig.\n\n\n4. Datenschutz und Kommunikation\nBei der Ãœbermittlung von Daten per E-Mail besteht die MÃ¶glichkeit, dass Daten von Dritten mitgelesen werden. Bitte Ã¼bermitteln Sie keine sensiblen medizinischen Informationen auf diesem Weg.\n\n\n5. Rechtswirksamkeit dieses Haftungsausschlusses\nSollten einzelne Bestimmungen dieses Textes unwirksam sein oder werden, bleiben die Ã¼brigen Bestimmungen davon unberÃ¼hrt."
  },
  {
    "objectID": "impressum.html#trÃ¤ger-rechtliche-hinweise",
    "href": "impressum.html#trÃ¤ger-rechtliche-hinweise",
    "title": "Impressum",
    "section": "TrÃ¤ger / Rechtliche Hinweise",
    "text": "TrÃ¤ger / Rechtliche Hinweise\nDas UniversitÃ¤tsklinikum Bonn (UKB) ist eine Anstalt des Ã¶ffentlichen Rechts.\nAnschrift des UKB:\nUniversitÃ¤tsklinikum Bonn\nVenusberg-Campus 1 ( ehem. Sigmund-Freud-Str. 25 )\n53127 Bonn\nTelefonzentrale: +49 (0)228 287 â€“ 0\nDas UKB ist eine Einrichtung der Rheinischen Friedrich-Wilhelms-UniversitÃ¤t Bonn.\nHinweis:\nEs gilt ergÃ¤nzend das offizielle Impressum und die DatenschutzerklÃ¤rung des\nUniversitÃ¤tsklinikums Bonn (UKB) sowie der UniversitÃ¤t Bonn.\nAufsichtsbehÃ¶rde:\nMinisterium fÃ¼r Kultur und Wissenschaft des Landes Nordrhein-Westfalen\nVÃ¶lklinger StraÃŸe 49\n40221 DÃ¼sseldorf"
  },
  {
    "objectID": "impressum.html#datenschutz",
    "href": "impressum.html#datenschutz",
    "title": "Impressum",
    "section": "Datenschutz",
    "text": "Datenschutz\nDas UniversitÃ¤tsklinikum Bonn beachtet die aktuell gÃ¼ltigen Datenschutzbestimmungen.\nFragen zum Datenschutz richten Sie bitte an die Datenschutzbeauftragten des UKB:\nHerr Achim Flender â€“ Achim.Flender@ukbonn.de\nTel.: +49 (0)228 287 â€“ 16075\nUniversitÃ¤tsklinikum Bonn, Venusberg-Campus 1, 53127 Bonn\nDas UKB weist darauf hin, dass eine DatenÃ¼bertragung im Internet grundsÃ¤tzlich SicherheitslÃ¼cken aufweisen kann und nicht vollstÃ¤ndig vor dem Zugriff Dritter geschÃ¼tzt ist.\nDie Verwendung der im Impressum verÃ¶ffentlichten Kontaktdaten zur gewerblichen Werbung ist ausdrÃ¼cklich untersagt.\nAlle auf dieser Website genannten Personen widersprechen hiermit jeder kommerziellen Verwendung und Weitergabe ihrer Daten."
  },
  {
    "objectID": "team/kristin_raming/index.html",
    "href": "team/kristin_raming/index.html",
    "title": "Kristin Raming",
    "section": "",
    "text": "Kristin Raming is a resident at the University Eye Clinic of Bonn, Germany. She investigated visual function in Sorsby Fundus Dystrophy as part of her doctoral thesis (Dr.Â med.) and was awarded a competitive scholarship from the German Ophthalmological Society (DOG) for her work. During her studies, she also conducted research on Pseudoxanthoma Elasticum (PXE). She aims to further strengthen her research on retinal diseases as part of her residency in ophthalmology."
  },
  {
    "objectID": "team/kristin_raming/index.html#education",
    "href": "team/kristin_raming/index.html#education",
    "title": "Kristin Raming",
    "section": "Education",
    "text": "Education\nUniversity of Bonn | Bonn, Germany\nOphthalmology Residency | 2022 â€“ ongoing\nUniversity of Bonn | Bonn, Germany\nDoctorate (Dr.Â med.) | 2023\nUniversity of Bonn | Bonn, Germany\nMedical Degree (MD) | 2022"
  },
  {
    "objectID": "team/isabel_saltenberger/index.html",
    "href": "team/isabel_saltenberger/index.html",
    "title": "Isabel Saltenberger",
    "section": "",
    "text": "Isabel Saltenberger joined our group to work on a project about intraocular pressure in Pseudoxanthoma elasticum (PXE). This project will serve as the basis for her doctoral degree (Dr.Â med. dent.)."
  },
  {
    "objectID": "team/carolina_kessler/index.html",
    "href": "team/carolina_kessler/index.html",
    "title": "Carolina Charlotte Kessler",
    "section": "",
    "text": "Carolina Kessler is currently a medical student at the University of Bonn and joined our group to work on a project investigating retinal changes and disease progression in conditions such as Pseudoxanthoma Elasticum (PXE)."
  },
  {
    "objectID": "team/carolina_kessler/index.html#education",
    "href": "team/carolina_kessler/index.html#education",
    "title": "Carolina Charlotte Kessler",
    "section": "Education",
    "text": "Education\nUniversity of Cologne (AG Heidenreich/von Brandenstein) | Cologne, Germany\nDoctoral Thesis (Dr.Â med.) | ongoing\nUniversity of Bonn | Bonn, Germany\nMedical Degree (MD) | ongoing"
  },
  {
    "objectID": "index.html#group-m.-pfau",
    "href": "index.html#group-m.-pfau",
    "title": "Welcome!",
    "section": "Group M. Pfau",
    "text": "Group M. Pfau\n\n\n\n\n\n\n\n\n\n\nGeorg Ansari\n\n\n\n\n\n\n\n\n\n\n\n\nMaximilian Pfau\n\n\n\n\n\n\n\n\n\n\n\n\nOlivier Morelle\n\n\n\n\n\n\n\n\n\n\n\n\nTheresa Lipsky\n\n\n\n\n\nNo matching items\n\nCurrent and Former Members â†’"
  },
  {
    "objectID": "team/georg_ansari/index.html",
    "href": "team/georg_ansari/index.html",
    "title": "Georg Ansari",
    "section": "",
    "text": "Georg Ansari graduated from Paracelsus Medical University in Salzburg, Austria, and is currently a resident at the Department of Ophthalmology, University of Basel, Switzerland. His research focuses on investigating visual function in retinal diseases."
  },
  {
    "objectID": "team/georg_ansari/index.html#education",
    "href": "team/georg_ansari/index.html#education",
    "title": "Georg Ansari",
    "section": "Education",
    "text": "Education\nUniversity of Basel | Basel, Switzerland\nMD/PhD Program | 2023 â€“ ongoing\nUniversity of Basel | Basel, Switzerland\nOphthalmology Residency | 2022 â€“ ongoing\nParacelsus Medical University | Salzburg, Austria\nMedical Degree (MD) | 2022"
  },
  {
    "objectID": "team/kristina_pfau/index.html",
    "href": "team/kristina_pfau/index.html",
    "title": "Kristina Pfau (nÃ©e Hess)",
    "section": "",
    "text": "Kristina Pfau (nÃ©e Hess) is a clinician-scientist specializing in inherited retinal diseases (IRDs) and degenerative conditions such as age-related macular degeneration (AMD). During medical school and early in her residency in Bonn, Germany, she focused her research on the morphological and functional impact of Bruchâ€™s membrane pathology, including studies on Pseudoxanthoma Elasticum (PXE) and Sorsby Fundus Dystrophy (SFD). For her doctoral thesis on dark adaptation in PXE, Dr.Â Pfau received the Hermann-Wacker Thesis Award from the German Ophthalmological Society (DOG).\nBuilding on her experience with monogenic retinal diseases, Dr.Â Pfau completed postdoctoral training at the National Eye Institute (NIH, USA) under the supervision of Dr.Â Catherine Cukras. Her project on longitudinal assessment in AMD was supported by a Walter Benjamin Fellowship from the German Research Foundation (DFG).\nKristina Pfau is now a senior consultant at the Department of Ophthalmology, University of Bonn, Germany. Her primary research goal is to address key challenges in clinical trials for Bruchâ€™s membrane diseases and to initiate interventional studies for PXE."
  },
  {
    "objectID": "team/kristina_pfau/index.html#education",
    "href": "team/kristina_pfau/index.html#education",
    "title": "Kristina Pfau (nÃ©e Hess)",
    "section": "Education",
    "text": "Education\nUniversity of Basel | Basel, Switzerland\nCataract and Vitreoretinal Fellowship | 2023 â€“ 2025\nUniversity of Bonn | Bonn, Germany\nHabilitation (Privatdozentin) | 2023\nNational Eye Institute | Bethesda, USA\nPostdoctoral Fellowship | 2021 â€“ 2022\nSave Sight Institute | Sydney, Australia\nShort-Term Fellowship | 2018\nUniversity of Bonn | Bonn, Germany\nOphthalmology Residency | 2017 â€“ 2022\nUniversity of Bonn | Bonn, Germany\nDoctorate (Dr.Â med.) | 2020\nUniversity of Bonn | Bonn, Germany\nMedical Degree (MD) | 2017"
  },
  {
    "objectID": "team/jonathan_meinke/index.html",
    "href": "team/jonathan_meinke/index.html",
    "title": "Jonathan Meinke",
    "section": "",
    "text": "Jonathan Meinke graduated from the University of Bonn, Germany, and is currently a resident at the Department of Ophthalmology, University Eye Hospital Bonn. His research focuses on retinal changes and disease progression in retinal dystrophies such as Pseudoxanthoma Elasticum (PXE)."
  },
  {
    "objectID": "team/jonathan_meinke/index.html#education",
    "href": "team/jonathan_meinke/index.html#education",
    "title": "Jonathan Meinke",
    "section": "Education",
    "text": "Education\nUniversity of Bonn | Bonn, Germany\nOphthalmology Residency | 2023 â€“ ongoing\nUniversity of Bonn | Bonn, Germany\nDoctorate (Dr.Â med.) | 2024\nUniversity of Bonn | Bonn, Germany\nMedical Degree (MD) | 2022"
  },
  {
    "objectID": "posts/year2022/index.html",
    "href": "posts/year2022/index.html",
    "title": "Annual ReviewÂ 2022",
    "section": "",
    "text": "We thank all volunteers who participated in one of our studies this year. All participants have made an ==essential contribution== to gaining new insights. Thank you on behalf of the whole team!\nOf course, it is always our goal to publish the carefully collected data in scientific journals. Only then are the data permanently available to researchers worldwide and serve the public.\nTherefore you will find a complete list of our scientific publications from 2022 at the following link. Below you will also find brief summaries of our three most important publications fromÂ 2022.\nWe would be very pleased to welcome you again next year for examinations and are happy to answer any questions at any time.\nMerry Christmas and a Happy NewÂ Year,\nMaximilianÂ Pfau, KristinaÂ PfauÂ (nÃ©eÂ Hess), KristinÂ Raming, GeorgÂ Ansari, JeannineÂ Oertli, LaraÂ Kaiser\n\n\n\n\n\n\nPfauÂ MÂ [â€¦]Â BrooksÂ BP. Photoreceptor degeneration in ABCA4â€‘associated retinopathy and its genetic correlates. JCI Insight.Â 2022Â JanÂ 25;7(2):e155373 â€“ Link\n\nBackground: Stargardt disease is the most common inherited cause of loss of visual acuity in working age. Individual, smaller studies previously showed that optical coherence tomography could roughly categorise the loss of photoreceptors.\nInnovation: In the study, which is based on data from a natural history study at the NationalÂ EyeÂ Institute (project leader: BrianÂ P.Â Brooks,Â MD,Â PhD), we showed that it is possible using a selfâ€‘developed artificial intelligenceâ€‘based approach to precisely assess the loss of photoreceptors over time. Furthermore, we demonstrated that the different variants in the ABCA4 gene, all of which cause Stargardt disease, influence the progression of the disease.\nSignificance: ==The work contributes to the use of optical coherence tomographyâ€‘based evaluations in ongoing and upcoming therapeutic studies.== We will also investigate individual genetic subtypes of Stargardt disease in future studies.\n\n\n\n\nHessÂ KÂ [â€¦]Â CukrasÂ CA. Evaluation ofÂ Coneâ€‘ andÂ Rodâ€‘Mediated Parameters in Dark Adaptation Testing as Outcome Measures in Ageâ€‘Related Macular Degeneration. OphthalmologyÂ Retina. 2022Â MayÂ 26:S2468â€‘6530(22)00252â€‘4 â€“ Link\n\nBackground: For ageâ€‘related macular degeneration it has been known for several years that dark adaptation â€” for example getting used to the dark when entering a tunnel â€” is severely restricted. There are several clinical metrics to assess dark adaptation, but they have not been adequately compared to date.\nInnovation: This investigation â€” based on a natural history study at the NationalÂ EyeÂ Institute (project leader: CatherineÂ A.Â Cukras,Â MD,Â PhD) â€” demonstrated that the â€œrodâ€‘intercept timeâ€ (time until retinal sensitivity reaches a certain threshold again) can be measured most reliably and shows the closest relationship to disease progression. The study also showed in a large longitudinal cohort that restricted function of cone photoreceptors (cells for daytime vision) can only be measured later in the course.\nSignificance: ==This publication makes a significant contribution to understanding the temporal sequence of functional loss in ageâ€‘related macular degeneration.== The now much better understanding of the precision of the metrics helps us to assess disease progression more accurately in the future and to plan therapy studies.\n\n\n\n\nPfauÂ MÂ [â€¦]Â HolzÂ FG. Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy. Scientific Reports. 2022Â OctÂ 25;12(1):17870 â€“ Link\n\nBackground: Ageâ€‘related macular degeneration is the most common cause of central vision loss. There is still no approved therapy. While it was already apparent that the drug slows the spread of areas with severe tissue loss (â€œgeographic atrophyâ€), the effect on the remaining retina was less clear.\nInnovation: The artificial intelligenceâ€‘based analysis, conducted with data from the international PhaseÂ 2 study (https://clinicaltrials.gov/ct2/show/NCT02503332), showed that not only areas of geographic atrophy progress more slowly. The photoreceptor layers in the surrounding retina also thin less over time.\nSignificance: ==The study suggests that pegcetacoplan not only slows the progression of geographic atrophy but also protects the more distant retina.== In future scientific studies, it should therefore be investigated whether earlier stages of ageâ€‘related macular degeneration are also treatable."
  },
  {
    "objectID": "posts/year2022/index.html#our-three-most-important-publications-in-2022",
    "href": "posts/year2022/index.html#our-three-most-important-publications-in-2022",
    "title": "Annual ReviewÂ 2022",
    "section": "",
    "text": "PfauÂ MÂ [â€¦]Â BrooksÂ BP. Photoreceptor degeneration in ABCA4â€‘associated retinopathy and its genetic correlates. JCI Insight.Â 2022Â JanÂ 25;7(2):e155373 â€“ Link\n\nBackground: Stargardt disease is the most common inherited cause of loss of visual acuity in working age. Individual, smaller studies previously showed that optical coherence tomography could roughly categorise the loss of photoreceptors.\nInnovation: In the study, which is based on data from a natural history study at the NationalÂ EyeÂ Institute (project leader: BrianÂ P.Â Brooks,Â MD,Â PhD), we showed that it is possible using a selfâ€‘developed artificial intelligenceâ€‘based approach to precisely assess the loss of photoreceptors over time. Furthermore, we demonstrated that the different variants in the ABCA4 gene, all of which cause Stargardt disease, influence the progression of the disease.\nSignificance: ==The work contributes to the use of optical coherence tomographyâ€‘based evaluations in ongoing and upcoming therapeutic studies.== We will also investigate individual genetic subtypes of Stargardt disease in future studies.\n\n\n\n\nHessÂ KÂ [â€¦]Â CukrasÂ CA. Evaluation ofÂ Coneâ€‘ andÂ Rodâ€‘Mediated Parameters in Dark Adaptation Testing as Outcome Measures in Ageâ€‘Related Macular Degeneration. OphthalmologyÂ Retina. 2022Â MayÂ 26:S2468â€‘6530(22)00252â€‘4 â€“ Link\n\nBackground: For ageâ€‘related macular degeneration it has been known for several years that dark adaptation â€” for example getting used to the dark when entering a tunnel â€” is severely restricted. There are several clinical metrics to assess dark adaptation, but they have not been adequately compared to date.\nInnovation: This investigation â€” based on a natural history study at the NationalÂ EyeÂ Institute (project leader: CatherineÂ A.Â Cukras,Â MD,Â PhD) â€” demonstrated that the â€œrodâ€‘intercept timeâ€ (time until retinal sensitivity reaches a certain threshold again) can be measured most reliably and shows the closest relationship to disease progression. The study also showed in a large longitudinal cohort that restricted function of cone photoreceptors (cells for daytime vision) can only be measured later in the course.\nSignificance: ==This publication makes a significant contribution to understanding the temporal sequence of functional loss in ageâ€‘related macular degeneration.== The now much better understanding of the precision of the metrics helps us to assess disease progression more accurately in the future and to plan therapy studies.\n\n\n\n\nPfauÂ MÂ [â€¦]Â HolzÂ FG. Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy. Scientific Reports. 2022Â OctÂ 25;12(1):17870 â€“ Link\n\nBackground: Ageâ€‘related macular degeneration is the most common cause of central vision loss. There is still no approved therapy. While it was already apparent that the drug slows the spread of areas with severe tissue loss (â€œgeographic atrophyâ€), the effect on the remaining retina was less clear.\nInnovation: The artificial intelligenceâ€‘based analysis, conducted with data from the international PhaseÂ 2 study (https://clinicaltrials.gov/ct2/show/NCT02503332), showed that not only areas of geographic atrophy progress more slowly. The photoreceptor layers in the surrounding retina also thin less over time.\nSignificance: ==The study suggests that pegcetacoplan not only slows the progression of geographic atrophy but also protects the more distant retina.== In future scientific studies, it should therefore be investigated whether earlier stages of ageâ€‘related macular degeneration are also treatable."
  },
  {
    "objectID": "posts/year2023/index.html",
    "href": "posts/year2023/index.html",
    "title": "Annual ReviewÂ 2023",
    "section": "",
    "text": "Thank you to all study participants this year. As participants you made a ==decisive contribution== to the research.\nWith great care we again published these findings this year in peerâ€‘reviewed scientific journals. Our publications this year can be found at the following link&sort=date).\nBelow you will also find a ==summary of our 3 most important publications inÂ 2023==.\nWe look forward to welcoming you to examinations again next year and are happy to answer any questions you may have.\nMerry Christmas and a Happy NewÂ Year,\nMaximilianÂ Pfau, KristinaÂ PfauÂ (nÃ©eÂ Hess)\n\n\n\n\n\n\nLoewinger,Â A.Â S., Pfau,Â M., Herrmann,Â P., Holz,Â F.Â G., & Pfau,Â K. (2023). Choriocapillaris Flow Signal Impairment in Patients With PseudoxanthomaÂ Elasticum. Investigative OphthalmologyÂ & Visual Science,Â 64(2),Â 21. https://doi.org/10.1167/iovs.64.2.21\n\nBackground: Accurate measurement of calcification of Bruchâ€™s membrane in the eye would significantly facilitate the conduct of future studies. Clinically, changes are observed in the underlying vascular layer (choroid). However, measuring the capillary layer (choriocapillaris) is technically challenging.\nInnovation: The aim of the study was to measure changes in choriocapillaris flow in patients with PXE in the preatrophic stage and to investigate its relationship with structural changes of the choroid and outer retina. Using optical coherence tomography angiographyÂ (OCTA), it was shown that patients with PXE exhibit significant choriocapillaris changes very earlyâ€”even in preatrophic stages and with normal choroid thickness. Moreover, choriocapillaris flow density correlated with the thickness of the overlying outer retina.\nSignificance: ==Analysis of choriocapillaris flow density is more suitable than choroid thickness for monitoring PXE in mild disease stages.== Choriocapillaris flow density may be an appropriate outcome measure for future intervention studies and is currently being further investigated by us as part of the PROPXE study (NCT05662085).\n\n\n\n\nPfau,Â M., Huryn,Â L.Â A., Boyle,Â M.Â P., Cukras,Â C.Â A., Zein,Â W.Â M., Turriff,Â A., Ullah,Â E., Hufnagel,Â R.Â B., Jeffrey,Â B.Â G., & Brooks,Â B.Â P. (2023). Natural History of Visual Dysfunction in ABCA4 Retinopathy and Its Genetic Correlates. American Journal of Ophthalmology,Â 253,Â 224â€“232. https://doi.org/10.1016/j.ajo.2023.05.014\n\nBackground: Many visual function tests have been described for Stargardt disease (ABCA4 retinopathy) to document the course of the disease. However, a systematic comparison of all visual function tests has been lacking to date.\nInnovation: This study was based on the large, prospective natural history study of the NationalÂ InstitutesÂ ofÂ Health. Participants underwent a variety of functional tests during an average followâ€‘up ofÂ 3.65Â years. We showed, among other things, that microperimetry (visual field testing in the macula) was most sensitive to change, but could only be performed in a subset of patients. Over a 5â€‘year interval, the amplitude of the darkâ€‘adaptedÂ aâ€‘wave in the electroretinogram was also sensitive to disease progression. The genotype explained a large portion of the variability in changes in the electroretinogram.\nSignificance: ==This work is the most comprehensive comparison of visual function tests in Stargardt disease to date.== Especially in patients with advanced disease where most visual function tests can no longer be performed, the electroretinogram can be used to quantify disease progression.\n\n\n\n\nOertli,Â J.Â M., Pfau,Â K., Scholl,Â H.Â P.Â N., Jeffrey,Â B.Â G., & Pfau,Â M. (2023). Establishing Fullyâ€‘Automated Fundusâ€‘Controlled Dark Adaptometry: A Validation and Retestâ€‘Reliability Study. Translational Vision ScienceÂ & Technology,Â 12(12),Â 18. https://doi.org/10.1167/tvst.12.12.18\n\nBackground: The rate of dark adaptation is slowed in many retinal diseases. Patients report that they take much longer to get used to the environment when entering indoor spaces. However, there has been no method to measure this in patients who cannot or can hardly fixate (maintain gaze on a small point).\nInnovation: We developed a new method to test how well a personâ€™s eyes adapt to darknessâ€”independent of whether the subject can fixate on a point or not. We used a specialized device called Sâ€‘MAIA and programmed new software for it. To verify that our test is valid, we compared it with another established device (MonCvONE).\nSignificance: ==This new test method forms the basis for many future research projects==, as we can now systematically assess the rate of dark adaptation in a wide range of patients."
  },
  {
    "objectID": "posts/year2023/index.html#our-three-most-important-publications-in-2023",
    "href": "posts/year2023/index.html#our-three-most-important-publications-in-2023",
    "title": "Annual ReviewÂ 2023",
    "section": "",
    "text": "Loewinger,Â A.Â S., Pfau,Â M., Herrmann,Â P., Holz,Â F.Â G., & Pfau,Â K. (2023). Choriocapillaris Flow Signal Impairment in Patients With PseudoxanthomaÂ Elasticum. Investigative OphthalmologyÂ & Visual Science,Â 64(2),Â 21. https://doi.org/10.1167/iovs.64.2.21\n\nBackground: Accurate measurement of calcification of Bruchâ€™s membrane in the eye would significantly facilitate the conduct of future studies. Clinically, changes are observed in the underlying vascular layer (choroid). However, measuring the capillary layer (choriocapillaris) is technically challenging.\nInnovation: The aim of the study was to measure changes in choriocapillaris flow in patients with PXE in the preatrophic stage and to investigate its relationship with structural changes of the choroid and outer retina. Using optical coherence tomography angiographyÂ (OCTA), it was shown that patients with PXE exhibit significant choriocapillaris changes very earlyâ€”even in preatrophic stages and with normal choroid thickness. Moreover, choriocapillaris flow density correlated with the thickness of the overlying outer retina.\nSignificance: ==Analysis of choriocapillaris flow density is more suitable than choroid thickness for monitoring PXE in mild disease stages.== Choriocapillaris flow density may be an appropriate outcome measure for future intervention studies and is currently being further investigated by us as part of the PROPXE study (NCT05662085).\n\n\n\n\nPfau,Â M., Huryn,Â L.Â A., Boyle,Â M.Â P., Cukras,Â C.Â A., Zein,Â W.Â M., Turriff,Â A., Ullah,Â E., Hufnagel,Â R.Â B., Jeffrey,Â B.Â G., & Brooks,Â B.Â P. (2023). Natural History of Visual Dysfunction in ABCA4 Retinopathy and Its Genetic Correlates. American Journal of Ophthalmology,Â 253,Â 224â€“232. https://doi.org/10.1016/j.ajo.2023.05.014\n\nBackground: Many visual function tests have been described for Stargardt disease (ABCA4 retinopathy) to document the course of the disease. However, a systematic comparison of all visual function tests has been lacking to date.\nInnovation: This study was based on the large, prospective natural history study of the NationalÂ InstitutesÂ ofÂ Health. Participants underwent a variety of functional tests during an average followâ€‘up ofÂ 3.65Â years. We showed, among other things, that microperimetry (visual field testing in the macula) was most sensitive to change, but could only be performed in a subset of patients. Over a 5â€‘year interval, the amplitude of the darkâ€‘adaptedÂ aâ€‘wave in the electroretinogram was also sensitive to disease progression. The genotype explained a large portion of the variability in changes in the electroretinogram.\nSignificance: ==This work is the most comprehensive comparison of visual function tests in Stargardt disease to date.== Especially in patients with advanced disease where most visual function tests can no longer be performed, the electroretinogram can be used to quantify disease progression.\n\n\n\n\nOertli,Â J.Â M., Pfau,Â K., Scholl,Â H.Â P.Â N., Jeffrey,Â B.Â G., & Pfau,Â M. (2023). Establishing Fullyâ€‘Automated Fundusâ€‘Controlled Dark Adaptometry: A Validation and Retestâ€‘Reliability Study. Translational Vision ScienceÂ & Technology,Â 12(12),Â 18. https://doi.org/10.1167/tvst.12.12.18\n\nBackground: The rate of dark adaptation is slowed in many retinal diseases. Patients report that they take much longer to get used to the environment when entering indoor spaces. However, there has been no method to measure this in patients who cannot or can hardly fixate (maintain gaze on a small point).\nInnovation: We developed a new method to test how well a personâ€™s eyes adapt to darknessâ€”independent of whether the subject can fixate on a point or not. We used a specialized device called Sâ€‘MAIA and programmed new software for it. To verify that our test is valid, we compared it with another established device (MonCvONE).\nSignificance: ==This new test method forms the basis for many future research projects==, as we can now systematically assess the rate of dark adaptation in a wide range of patients."
  },
  {
    "objectID": "posts/2024-12-22-jahresr-ckblick-2024/index.html#our-three-most-important-publications-in-2024",
    "href": "posts/2024-12-22-jahresr-ckblick-2024/index.html#our-three-most-important-publications-in-2024",
    "title": "Annual ReviewÂ 2024",
    "section": "",
    "text": "Pfau,Â K., Lengyel,Â I., Ossewaardeâ€‘vanÂ Norel,Â J., vanÂ Leeuwen,Â R., Risseeuw,Â S., Leftheriotis,Â G., Scholl,Â H.Â P.Â N., Feltgen,Â N., Holz,Â F.Â G., & Pfau,Â M.Â (2024). PseudoxanthomaÂ elasticumÂ â€“ Genetics, pathophysiology, and clinical presentation. Progress inÂ RetinalÂ andÂ EyeÂ Research,Â 101274. https://doi.org/10.1016/j.preteyeres.2024.101274\n\nBackground: PXE is a rare autosomal recessive multisystem disorder. This work provides a comprehensive overview of the genetics, pathophysiology and clinical presentation of PXE.\nInnovation: The study highlights the current state of knowledge on PXE and particularly addresses the role of ABCC6 mutations and their impact on the calcification of elastic fibres in various organ systems.\nSignificance: ==This work provides a valuable resource for researchers and clinicians dealing with PXE and represents a milestone in the literature on this complex disease.==\n\n\n\n\n\nPfau,Â M., Jolly,Â J.Â K., Charng,Â J., vonÂ derÂ Emde,Â L., MÃ¼ller,Â P.Â L., Ansari,Â G., Pfau,Â K., Chen,Â F.Â K., & Wu,Â Z.Â (2024). Multicenter Normative Data for Mesopic Microperimetry. InvestigativeÂ OphthalmologyÂ &Â VisualÂ Science,Â 65(12),Â 27. https://doi.org/10.1167/iovs.65.12.27\n\nBackground: The aim of this study was to create a large, multicentre normative dataset for MAIA microperimetry and to compare predictive models.\nInnovation: The analysis used innovative statistical methods to explain the normal variability of visual sensitivity and to develop userâ€‘friendly models for clinical applications.\nSignificance: ==This dataset is an indispensable reference for the interpretation of test results and provides an essential contribution to the standardisation and improvement of clinical diagnoses.==\n\n\n\n\n\nRaming,Â K., Pfau,Â M., Herrmann,Â P., Holz,Â F.Â G., & Pfau,Â K.Â (2024). Antiâ€‘VEGF Treatment for Secondary Neovascularization in PseudoxanthomaÂ Elasticum. American Journal of Ophthalmology,Â 253,Â 101â€‘110. https://doi.org/10.1016/j.ajo.2024.03.026\n\nBackground: This retrospective cohort study investigated the treatment needs and outcomes in patients with PXE who suffer from secondary choroidal neovascularisationÂ (CNV).\nInnovation: The work shows that PXE patients require intensive antiâ€‘VEGF therapies already at a young age and highlights important predictors for therapy success.\nSignificance: ==The results underline the need for early intervention and provide insights for the development of durable therapeutics.=="
  },
  {
    "objectID": "posts/2024-12-22-jahresr-ckblick-2024/index.html#summary",
    "href": "posts/2024-12-22-jahresr-ckblick-2024/index.html#summary",
    "title": "Annual ReviewÂ 2024",
    "section": "",
    "text": "We look back on a year of significant scientific progress and look forward to the challenges and opportunities that the coming year will bring. We wish you a relaxing holiday season and a successful yearÂ 2025. If you have any questions or are interested in our studies, please do not hesitate to contact us."
  },
  {
    "objectID": "team.html#group-k.-pfau",
    "href": "team.html#group-k.-pfau",
    "title": "Team",
    "section": "",
    "text": "No matching items\n\n\n\n\n\n\n\n\n\n\n\n\nName\nRole / Type of Thesis\nMentorship Role\nUniversity\n\n\n\n\nAnne-Sophie LÃ¶winger\nDr.Â med. Thesis\nCo-mentor\nUniversity of Bonn"
  },
  {
    "objectID": "team.html#group-m.-pfau",
    "href": "team.html#group-m.-pfau",
    "title": "Team",
    "section": "Group M. Pfau",
    "text": "Group M. Pfau\n\n\n\n\n\n\n\n\n\n\nGeorg Ansari\n\n\n\n\n\n\n\n\n\n\n\n\nMaximilian Pfau\n\n\n\n\n\n\n\n\n\n\n\n\nOlivier Morelle\n\n\n\n\n\n\n\n\n\n\n\n\nTheresa Lipsky\n\n\n\n\n\nNo matching items\n\n\nAlmuni\n\n\n\n\n\n\n\n\n\nName\nRole / Type of Thesis\nMentorship Role\nUniversity\n\n\n\n\nJeannine Oertli\nMaster Thesis\nPrimary mentor\nUniversity of Basel\n\n\nLara Kaiser\nMaster Thesis\nPrimary mentor\nUniversity of Basel\n\n\nSandrine KÃ¼nzel\nDr.Â med. Thesis\nCo-mentor\nUniversity of Bonn\n\n\nMuriel Huss\nDr.Â med. Thesis\nCo-mentor\nUniversity of Bonn\n\n\nLeon von der Emde\nDr.Â med. Thesis\nCo-mentor\nUniversity of Bonn\n\n\nLukas Goerdt\nDr.Â med. Thesis\nCo-mentor\nUniversity of Bonn"
  },
  {
    "objectID": "team.html#almuni-m.-pfau",
    "href": "team.html#almuni-m.-pfau",
    "title": "Team",
    "section": "Almuni M. Pfau",
    "text": "Almuni M. Pfau\n\n\n\n\n\n\n\n\n\nName\nRole / Type of Thesis\nMentorship Role\nUniversity\n\n\n\n\nJeannine Oertli\nMaster Thesis\nPrimary mentor\nUniversity of Basel\n\n\nLara Kaiser\nMaster Thesis\nPrimary mentor\nUniversity of Basel\n\n\nSandrine KÃ¼nzel\nDr.Â med. Thesis\nCo-mentor\nUniversity of Bonn\n\n\nMuriel Huss\nDr.Â med. Thesis\nCo-mentor\nUniversity of Bonn\n\n\nLeon von der Emde\nDr.Â med. Thesis\nCo-mentor\nUniversity of Bonn\n\n\nLukas Goerdt\nDr.Â med. Thesis\nCo-mentor\nUniversity of Bonn"
  },
  {
    "objectID": "team.html#almuni-m.-pfau-1",
    "href": "team.html#almuni-m.-pfau-1",
    "title": "Team",
    "section": "Almuni M. Pfau",
    "text": "Almuni M. Pfau"
  },
  {
    "objectID": "team.html#almuni-k.-pfau",
    "href": "team.html#almuni-k.-pfau",
    "title": "Team",
    "section": "Almuni K. Pfau",
    "text": "Almuni K. Pfau\n\n\n\n\n\n\n\n\n\nName\nRole / Type of Thesis\nMentorship Role\nUniversity\n\n\n\n\nAnne-Sophie LÃ¶winger\nDr.Â med. Thesis\nCo-mentor\nUniversity of Bonn"
  },
  {
    "objectID": "team.html#alumni-m.-pfau",
    "href": "team.html#alumni-m.-pfau",
    "title": "Team",
    "section": "Alumni (M. Pfau)",
    "text": "Alumni (M. Pfau)\n\n\n\n\n\n\n\n\n\nName\nRole / Type of Thesis\nMentorship Role\nUniversity\n\n\n\n\nJeannine Oertli\nMaster Thesis\nPrimary mentor\nUniversity of Basel\n\n\nLara Kaiser\nMaster and Dr.Â med. Thesis\nPrimary mentor\nUniversity of Basel\n\n\nSandrine KÃ¼nzel\nDr.Â med. Thesis (Summa Cum Laude)\nCo-mentor\nUniversity of Bonn\n\n\nMuriel Huss\nDr.Â med. Thesis (Magna Cum Laude)\nCo-mentor\nUniversity of Bonn\n\n\nLeon von der Emde\nDr.Â med. Thesis (Summa Cum Laude)\nCo-mentor\nUniversity of Bonn\n\n\nLukas Goerdt\nDr.Â med. Thesis (Magna Cum Laude)\nCo-mentor\nUniversity of Bonn"
  },
  {
    "objectID": "posts/2025-08-29/index.html",
    "href": "posts/2025-08-29/index.html",
    "title": "Kristina andÂ MaximilianÂ Pfau Return to Bonn",
    "section": "",
    "text": "We are very pleased that after our stints abroad we are now back in Bonn.\nAs part of our return we have taken on new roles: MaximilianÂ Pfau as a W3 professor of retinology and inherited retinal diseases at the EyeÂ Clinic of the UniversityÂ HospitalÂ Bonn (UKB) and KristinaÂ Pfau as a senior physician with clinical leadership of the study centre.\nOur shared focus remains the further development of innovative approaches to detect retinal diseases early and enable new therapies. We are particularly concentrating on three main areas:\n\nEstablishing AIâ€‘based biomarkers to precisely monitor microstructural changes of the retina over time\n\nDeveloping highly sensitive visual tests that capture early functional limitations\n\nAnalysing genetic and modifiable risk factors in common as well as inherited retinal diseases\n\nWe will continue to focus our workÂ â€” clinically and in researchÂ â€” on diseases such as ageâ€‘related macular degeneration (AMD), SorsbyÂ fundusÂ dystrophy, pseudoxanthomaÂ elasticumÂ (PXE) and MacTel.\nA special thanks goes to our patients in Basel for their participation in studies and their trust. Care and continuation of studies there will continue to be ensured by Dr.Â Ansari."
  },
  {
    "objectID": "posts/2022-12-11/index.html",
    "href": "posts/2022-12-11/index.html",
    "title": "Annual ReviewÂ 2022",
    "section": "",
    "text": "We thank all volunteers who participated in one of our studies this year. All participants have made an essential contribution to gaining new insights. Thank you on behalf of the whole team!\nOf course, it is always our goal to publish the carefully collected data in scientific journals. Only then are the data permanently available to researchers worldwide and serve the public.\nTherefore you will find a complete list of our scientific publications from 2022 at the following link. Below you will also find brief summaries of our three most important publications fromÂ 2022.\nWe would be very pleased to welcome you again next year for examinations and are happy to answer any questions at any time.\nMerry Christmas and a Happy NewÂ Year,\nMaximilianÂ Pfau, KristinaÂ PfauÂ (nÃ©eÂ Hess), KristinÂ Raming, GeorgÂ Ansari, JeannineÂ Oertli, LaraÂ Kaiser\n\n\n\n\n\n\nPfauÂ MÂ [â€¦]Â BrooksÂ BP. Photoreceptor degeneration in ABCA4â€‘associated retinopathy and its genetic correlates. JCI Insight.Â 2022Â JanÂ 25;7(2):e155373 â€“ Link\n\nBackground: Stargardt disease is the most common inherited cause of loss of visual acuity in working age. Individual, smaller studies previously showed that optical coherence tomography could roughly categorise the loss of photoreceptors.\nInnovation: In the study, which is based on data from a natural history study at the NationalÂ EyeÂ Institute (project leader: BrianÂ P.Â Brooks,Â MD,Â PhD), we showed that it is possible using a selfâ€‘developed artificial intelligenceâ€‘based approach to precisely assess the loss of photoreceptors over time. Furthermore, we demonstrated that the different variants in the ABCA4 gene, all of which cause Stargardt disease, influence the progression of the disease.\nSignificance: The work contributes to the use of optical coherence tomographyâ€‘based evaluations in ongoing and upcoming therapeutic studies. We will also investigate individual genetic subtypes of Stargardt disease in future studies.\n\n\n\n\nHessÂ KÂ [â€¦]Â CukrasÂ CA. Evaluation ofÂ Coneâ€‘ andÂ Rodâ€‘Mediated Parameters in Dark Adaptation Testing as Outcome Measures in Ageâ€‘Related Macular Degeneration. OphthalmologyÂ Retina. 2022Â MayÂ 26:S2468â€‘6530(22)00252â€‘4 â€“ Link\n\nBackground: For ageâ€‘related macular degeneration it has been known for several years that dark adaptation â€” for example getting used to the dark when entering a tunnel â€” is severely restricted. There are several clinical metrics to assess dark adaptation, but they have not been adequately compared to date.\nInnovation: This investigation â€” based on a natural history study at the NationalÂ EyeÂ Institute (project leader: CatherineÂ A.Â Cukras,Â MD,Â PhD) â€” demonstrated that the â€œrodâ€‘intercept timeâ€ (time until retinal sensitivity reaches a certain threshold again) can be measured most reliably and shows the closest relationship to disease progression. The study also showed in a large longitudinal cohort that restricted function of cone photoreceptors (cells for daytime vision) can only be measured later in the course.\nSignificance: This publication makes a significant contribution to understanding the temporal sequence of functional loss in ageâ€‘related macular degeneration. The now much better understanding of the precision of the metrics helps us to assess disease progression more accurately in the future and to plan therapy studies.\n\n\n\n\nPfauÂ MÂ [â€¦]Â HolzÂ FG. Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy. Scientific Reports. 2022Â OctÂ 25;12(1):17870 â€“ Link\n\nBackground: Ageâ€‘related macular degeneration is the most common cause of central vision loss. There is still no approved therapy. While it was already apparent that the drug slows the spread of areas with severe tissue loss (â€œgeographic atrophyâ€), the effect on the remaining retina was less clear.\nInnovation: The artificial intelligenceâ€‘based analysis, conducted with data from the international PhaseÂ 2 study (https://clinicaltrials.gov/ct2/show/NCT02503332), showed that not only areas of geographic atrophy progress more slowly. The photoreceptor layers in the surrounding retina also thin less over time.\nSignificance: The study suggests that pegcetacoplan not only slows the progression of geographic atrophy but also protects the more distant retina. In future scientific studies, it should therefore be investigated whether earlier stages of ageâ€‘related macular degeneration are also treatable."
  },
  {
    "objectID": "posts/2022-12-11/index.html#our-three-most-important-publications-in-2022",
    "href": "posts/2022-12-11/index.html#our-three-most-important-publications-in-2022",
    "title": "Annual ReviewÂ 2022",
    "section": "",
    "text": "PfauÂ MÂ [â€¦]Â BrooksÂ BP. Photoreceptor degeneration in ABCA4â€‘associated retinopathy and its genetic correlates. JCI Insight.Â 2022Â JanÂ 25;7(2):e155373 â€“ Link\n\nBackground: Stargardt disease is the most common inherited cause of loss of visual acuity in working age. Individual, smaller studies previously showed that optical coherence tomography could roughly categorise the loss of photoreceptors.\nInnovation: In the study, which is based on data from a natural history study at the NationalÂ EyeÂ Institute (project leader: BrianÂ P.Â Brooks,Â MD,Â PhD), we showed that it is possible using a selfâ€‘developed artificial intelligenceâ€‘based approach to precisely assess the loss of photoreceptors over time. Furthermore, we demonstrated that the different variants in the ABCA4 gene, all of which cause Stargardt disease, influence the progression of the disease.\nSignificance: The work contributes to the use of optical coherence tomographyâ€‘based evaluations in ongoing and upcoming therapeutic studies. We will also investigate individual genetic subtypes of Stargardt disease in future studies.\n\n\n\n\nHessÂ KÂ [â€¦]Â CukrasÂ CA. Evaluation ofÂ Coneâ€‘ andÂ Rodâ€‘Mediated Parameters in Dark Adaptation Testing as Outcome Measures in Ageâ€‘Related Macular Degeneration. OphthalmologyÂ Retina. 2022Â MayÂ 26:S2468â€‘6530(22)00252â€‘4 â€“ Link\n\nBackground: For ageâ€‘related macular degeneration it has been known for several years that dark adaptation â€” for example getting used to the dark when entering a tunnel â€” is severely restricted. There are several clinical metrics to assess dark adaptation, but they have not been adequately compared to date.\nInnovation: This investigation â€” based on a natural history study at the NationalÂ EyeÂ Institute (project leader: CatherineÂ A.Â Cukras,Â MD,Â PhD) â€” demonstrated that the â€œrodâ€‘intercept timeâ€ (time until retinal sensitivity reaches a certain threshold again) can be measured most reliably and shows the closest relationship to disease progression. The study also showed in a large longitudinal cohort that restricted function of cone photoreceptors (cells for daytime vision) can only be measured later in the course.\nSignificance: This publication makes a significant contribution to understanding the temporal sequence of functional loss in ageâ€‘related macular degeneration. The now much better understanding of the precision of the metrics helps us to assess disease progression more accurately in the future and to plan therapy studies.\n\n\n\n\nPfauÂ MÂ [â€¦]Â HolzÂ FG. Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy. Scientific Reports. 2022Â OctÂ 25;12(1):17870 â€“ Link\n\nBackground: Ageâ€‘related macular degeneration is the most common cause of central vision loss. There is still no approved therapy. While it was already apparent that the drug slows the spread of areas with severe tissue loss (â€œgeographic atrophyâ€), the effect on the remaining retina was less clear.\nInnovation: The artificial intelligenceâ€‘based analysis, conducted with data from the international PhaseÂ 2 study (https://clinicaltrials.gov/ct2/show/NCT02503332), showed that not only areas of geographic atrophy progress more slowly. The photoreceptor layers in the surrounding retina also thin less over time.\nSignificance: The study suggests that pegcetacoplan not only slows the progression of geographic atrophy but also protects the more distant retina. In future scientific studies, it should therefore be investigated whether earlier stages of ageâ€‘related macular degeneration are also treatable."
  },
  {
    "objectID": "posts/2023-10-07/index.html",
    "href": "posts/2023-10-07/index.html",
    "title": "Ophthalmologica LectureÂ 2023",
    "section": "",
    "text": "At the annual meeting of the EuropeanÂ SocietyÂ ofÂ RetinaÂ SpecialistsÂ (EURETINA)Â 2023, Priv.â€‘Doz.Â Dr.Â MaximilianÂ Pfau was honoured with the prestigious OphthalmologicaÂ LectureÂ 2023 onÂ 7Â October. This award is presented to a young European ophthalmologist and clinicianâ€‘scientist underÂ 40 who has already made significant contributions to retinal research.\nIn his talk MaximilianÂ Pfau explained three core concepts of his research that could decisively improve future therapeutic studies for retinal diseases:\n\nthe use of data from natural history as well as patientâ€‘specific preâ€‘treatment data,\n\nfocusing on mild structural changes at the leading edge of the disease, and\n\ninclusion of hypothesisâ€‘driven visual function tests.\n\nLearn more about the award here: https://euretina.org/resource/episode-36-the-ophthalmologica-lecture-maximilian-pfau/"
  },
  {
    "objectID": "posts/2023-01-16/index.html",
    "href": "posts/2023-01-16/index.html",
    "title": "PRO-PXE Study",
    "section": "",
    "text": "For the natural history study PRO-PXE (Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration), the Eye Clinic of the University Hospital Basel is currently recruiting volunteers with PXE.\nLinks: German version; French version; Italian version\n\nPurpose of the study\nThis study aims to systematically compare new visual function tests and new ophthalmic imaging techniques to monitor the natural history of pseudoxanthoma elasticum (PXE).\nCurrently, several drugs are evaluated in trials for treating PXE. These trials often monitor patients using computed tomography (CT) imaging of the arteries. However, ophthalmic examination methods that allow direct functional testing and imaging of nerve tissue may be better suited to document early disease progression. Whether this is indeed the case will now be investigated.\n\n\nParticipation requirements\n\nInclusion criteria:\n\nDiagnosis of Pseudoxanthoma elasticum (PXE)\nAge of 18 years or older\n\n\n\nExclusion criteria:\n\nFear of confined spaces (claustrophobia, exclusion criterion due to dark-adapted testing)\n\n\n\nScope\nTotal duration: 24 months\nThe study includes a baseline visit (month 0), a month 2 (retest) visit, a month 12 visit, and a month 24 visit.\nEach visit takes about 4 to 5 hours (with small breaks).\n\n\nRisks\nNo health risks are to be expected.\n\n\nBenefits\nWith the help of the collected data, it may be possible to examine possible treatment effects of upcoming therapeutics more precisely. Therefore, PXE patients are expected to benefit from the collected data in the future.\nThe study includes a comprehensive battery of ophthalmologic examinations. Under certain circumstances, lesions requiring therapy might be detected early.\nHowever, it is possible that you will not derive any personal benefit from participating in the study.\n\n\nContact\nPlease contact us by e-mail.\nKristina Pfau, MD (nÃ©e Hess) Kristina.Pfau@usb.ch Tel. +41 79 357 36 93 University Hospital Basel, Eye Clinic, Mittlere Strasse 91, CH-4031 Basel\nPriv.-Doz. Maximilian Pfau, MD Maximilian.Pfau@usb.ch Tel. +41 79 525 92 47 University Hospital Basel, Eye Clinic, Mittlere Strasse 91, CH-4031 Basel\n\n\nData protection\nPlease note that your data will be registered when a telephone or written contact is established. If you are not interested in participating in a study, your data will be deleted immediately."
  },
  {
    "objectID": "posts/2023-07-09/index.html",
    "href": "posts/2023-07-09/index.html",
    "title": "Dr.Â WernerÂ JackstÃ¤dt Young InvestigatorÂ Award",
    "section": "",
    "text": "KristinaÂ Pfau received the Dr.Â WernerÂ JackstÃ¤dt YoungÂ InvestigatorÂ Award of the Retinological Society last weekend. The project â€œIdentification of endpoints for a diseased Bruchâ€™s membrane in PseudoxanthomaÂ elasticumÂ (PXE)â€ was honoured.\nThe prize is awarded for a project with an outstanding concept in clinical or experimental retina research and is endowed with 10,000Â euros.\nThe prize money will again be invested in PXE research. Structural changes of the retina in PXE will be prospectively investigated."
  },
  {
    "objectID": "posts/2025-05-05/index.html",
    "href": "posts/2025-05-05/index.html",
    "title": "Hiring new Ophthalmology Residents and Postdoc in Bonn",
    "section": "",
    "text": "We are excited to announce two open positions for ophthalmology residents (with 50% protected research time) and one postdoctoral position at the University Hospital Bonn, starting from 1Â AugustÂ 2025.\n\n\n\nâœ… An attractive, well-supported clinical and research position\n\nâœ… Integration into diverse, grant-funded scientific projects\n\nâœ… Opportunities for international collaboration\n\nâœ… An excellent academic environment, ideal for pursuing your Habilitation\n\n\n\n\n\n\n\n\nCompleted medical doctorate (Dr.Â med.) or in the final stages\n\nStrong interest in clinical research\n\nPrior research experience (e.g., publications, conference presentations)\n\nBasic knowledge of biostatistics and scientific methods\n\nKnowledge of R or Python (or willingness to learn)\n\nExcellent teamwork and communication skills\n\nStrong organizational abilities and self-motivation\n\nGood command of English (written and spoken); German language proficiency is an advantage\n\n\n\n\n\n\nWe are seeking candidates with:\n\nA completed PhD (or BSc/MSc with substantial research experience) in computer science, engineering, biomedical engineering, physics, or related fields\n\nPrior academic publication experience (peer-reviewed articles, conference papers)\n\nSolid programming skills, especially in Python\n\nExperience with deep learning frameworks (e.g., PyTorch, TensorFlow) and computer vision methods\n\nStrong data analysis and problem-solving skills\n\nExperience working with biomedical or clinical data is a plus\n\nFamiliarity with version control systems (e.g., Git)\n\nExcellent written and verbal communication skills in English\n\nAbility to work independently and in interdisciplinary teams\n\n\nThis is an outstanding opportunity to work on cutting-edge research projects within a top-tier clinical and scientific environment.\nğŸ‘‰ Interested? Please contact us (maximilian.pfau@usb.ch) for more details or submit your application!"
  },
  {
    "objectID": "posts/2025-05-05/index.html#we-offer",
    "href": "posts/2025-05-05/index.html#we-offer",
    "title": "Hiring new Ophthalmology Residents and Postdoc in Bonn",
    "section": "",
    "text": "âœ… An attractive, well-supported clinical and research position\n\nâœ… Integration into diverse, grant-funded scientific projects\n\nâœ… Opportunities for international collaboration\n\nâœ… An excellent academic environment, ideal for pursuing your Habilitation"
  },
  {
    "objectID": "posts/2025-05-05/index.html#ophthalmology-resident-facharztausbildung-positions-with-50-protected-research-time",
    "href": "posts/2025-05-05/index.html#ophthalmology-resident-facharztausbildung-positions-with-50-protected-research-time",
    "title": "Hiring new Ophthalmology Residents and Postdoc in Bonn",
    "section": "",
    "text": "Completed medical doctorate (Dr.Â med.) or in the final stages\n\nStrong interest in clinical research\n\nPrior research experience (e.g., publications, conference presentations)\n\nBasic knowledge of biostatistics and scientific methods\n\nKnowledge of R or Python (or willingness to learn)\n\nExcellent teamwork and communication skills\n\nStrong organizational abilities and self-motivation\n\nGood command of English (written and spoken); German language proficiency is an advantage"
  },
  {
    "objectID": "posts/2025-05-05/index.html#postdoc-position",
    "href": "posts/2025-05-05/index.html#postdoc-position",
    "title": "Hiring new Ophthalmology Residents and Postdoc in Bonn",
    "section": "",
    "text": "We are seeking candidates with:\n\nA completed PhD (or BSc/MSc with substantial research experience) in computer science, engineering, biomedical engineering, physics, or related fields\n\nPrior academic publication experience (peer-reviewed articles, conference papers)\n\nSolid programming skills, especially in Python\n\nExperience with deep learning frameworks (e.g., PyTorch, TensorFlow) and computer vision methods\n\nStrong data analysis and problem-solving skills\n\nExperience working with biomedical or clinical data is a plus\n\nFamiliarity with version control systems (e.g., Git)\n\nExcellent written and verbal communication skills in English\n\nAbility to work independently and in interdisciplinary teams\n\n\nThis is an outstanding opportunity to work on cutting-edge research projects within a top-tier clinical and scientific environment.\nğŸ‘‰ Interested? Please contact us (maximilian.pfau@usb.ch) for more details or submit your application!"
  },
  {
    "objectID": "posts/2024-07-22/index.html",
    "href": "posts/2024-07-22/index.html",
    "title": "Comprehensive Review on PXE",
    "section": "",
    "text": "In collaboration with European colleagues, PD Dr.Â Kristina Pfau and PD Dr.Â Maximilian Pfau have published a comprehensive overview of PseudoxanthomaÂ ElasticumÂ (PXE).\nPXE is a genetically determined systemic disorder that leads to the calcification of elastic fibres and affects primarily the skin, the eyes and the cardiovascular system. Ophthalmologically, the disease often becomes apparent early through a slower adaptation from light to dark. In late stages there is neovascularisation and retinal degeneration. Systemically, patients suffer from early atherosclerosis and reduced painâ€‘free walking distance. The first signs, often already in childhood or adolescence, are changes in the skin, especially in the neck area.\nâ€œOphthalmologically, PXE can resemble ageâ€‘related macular degeneration, but because of the genetic cause it generally manifests earlier. As several therapeutic trials for PXE will begin in the coming years, we hope that this review article will raise awareness of the disease,â€ says Prof.Â NicolasÂ Feltgen, head of the EyeÂ Clinic.\nThe journal Progress inÂ RetinalÂ andÂ EyeÂ Research is the highestâ€‘ranked ophthalmology journal with an ImpactÂ Factor ofÂ 19.7Â (2021) and articles are published by invitation only.\nFor further information and support, affected individuals and interested parties can contact our clinic.\nLearn more about the article here: https://doi.org/10.1016/j.preteyeres.2024.101274"
  },
  {
    "objectID": "posts/2024-12-22/index.html",
    "href": "posts/2024-12-22/index.html",
    "title": "Annual ReviewÂ 2024",
    "section": "",
    "text": "We would like to sincerely thank all study participants who were part of our research this year. Your commitment has made a valuable contribution to the advancement of scientific knowledge.\nAgain this year we published our results with great care in renowned, peerâ€‘reviewed journals. You can find an overview of our publications at the following link.\nBelow we present a summary of our three most important works fromÂ 2024.\nWe look forward to welcoming you again in our studies next year and are available to answer any questions at any time.\nWe wish you Merry Christmas and a successful NewÂ Year!\nMaximilianÂ Pfau, KristinaÂ PfauÂ (nÃ©eÂ Hess)\n\n\n\n\n\n\nPfau,Â K., Lengyel,Â I., Ossewaardeâ€‘vanÂ Norel,Â J., vanÂ Leeuwen,Â R., Risseeuw,Â S., Leftheriotis,Â G., Scholl,Â H.Â P.Â N., Feltgen,Â N., Holz,Â F.Â G., & Pfau,Â M.Â (2024). PseudoxanthomaÂ elasticumÂ â€“ Genetics, pathophysiology, and clinical presentation. Progress inÂ RetinalÂ andÂ EyeÂ Research,Â 101274. https://doi.org/10.1016/j.preteyeres.2024.101274\n\nBackground: PXE is a rare autosomal recessive multisystem disorder. This work provides a comprehensive overview of the genetics, pathophysiology and clinical presentation of PXE.\nInnovation: The study highlights the current state of knowledge on PXE and particularly addresses the role of ABCC6 mutations and their impact on the calcification of elastic fibres in various organ systems.\nSignificance: This work provides a valuable resource for researchers and clinicians dealing with PXE and represents a milestone in the literature on this complex disease.\n\n\n\n\n\nPfau,Â M., Jolly,Â J.Â K., Charng,Â J., vonÂ derÂ Emde,Â L., MÃ¼ller,Â P.Â L., Ansari,Â G., Pfau,Â K., Chen,Â F.Â K., & Wu,Â Z.Â (2024). Multicenter Normative Data for Mesopic Microperimetry. InvestigativeÂ OphthalmologyÂ &Â VisualÂ Science,Â 65(12),Â 27. https://doi.org/10.1167/iovs.65.12.27\n\nBackground: The aim of this study was to create a large, multicentre normative dataset for MAIA microperimetry and to compare predictive models.\nInnovation: The analysis used innovative statistical methods to explain the normal variability of visual sensitivity and to develop userâ€‘friendly models for clinical applications.\nSignificance: This dataset is an indispensable reference for the interpretation of test results and provides an essential contribution to the standardisation and improvement of clinical diagnoses.\n\n\n\n\n\nRaming,Â K., Pfau,Â M., Herrmann,Â P., Holz,Â F.Â G., & Pfau,Â K.Â (2024). Antiâ€‘VEGF Treatment for Secondary Neovascularization in PseudoxanthomaÂ Elasticum. American Journal of Ophthalmology,Â 253,Â 101â€‘110. https://doi.org/10.1016/j.ajo.2024.03.026\n\nBackground: This retrospective cohort study investigated the treatment needs and outcomes in patients with PXE who suffer from secondary choroidal neovascularisationÂ (CNV).\nInnovation: The work shows that PXE patients require intensive antiâ€‘VEGF therapies already at a young age and highlights important predictors for therapy success.\nSignificance: The results underline the need for early intervention and provide insights for the development of durable therapeutics.\n\n\n\n\n\nWe look back on a year of significant scientific progress and look forward to the challenges and opportunities that the coming year will bring. We wish you a relaxing holiday season and a successful yearÂ 2025. If you have any questions or are interested in our studies, please do not hesitate to contact us."
  },
  {
    "objectID": "posts/2024-12-22/index.html#our-three-most-important-publications-in-2024",
    "href": "posts/2024-12-22/index.html#our-three-most-important-publications-in-2024",
    "title": "Annual ReviewÂ 2024",
    "section": "",
    "text": "Pfau,Â K., Lengyel,Â I., Ossewaardeâ€‘vanÂ Norel,Â J., vanÂ Leeuwen,Â R., Risseeuw,Â S., Leftheriotis,Â G., Scholl,Â H.Â P.Â N., Feltgen,Â N., Holz,Â F.Â G., & Pfau,Â M.Â (2024). PseudoxanthomaÂ elasticumÂ â€“ Genetics, pathophysiology, and clinical presentation. Progress inÂ RetinalÂ andÂ EyeÂ Research,Â 101274. https://doi.org/10.1016/j.preteyeres.2024.101274\n\nBackground: PXE is a rare autosomal recessive multisystem disorder. This work provides a comprehensive overview of the genetics, pathophysiology and clinical presentation of PXE.\nInnovation: The study highlights the current state of knowledge on PXE and particularly addresses the role of ABCC6 mutations and their impact on the calcification of elastic fibres in various organ systems.\nSignificance: This work provides a valuable resource for researchers and clinicians dealing with PXE and represents a milestone in the literature on this complex disease.\n\n\n\n\n\nPfau,Â M., Jolly,Â J.Â K., Charng,Â J., vonÂ derÂ Emde,Â L., MÃ¼ller,Â P.Â L., Ansari,Â G., Pfau,Â K., Chen,Â F.Â K., & Wu,Â Z.Â (2024). Multicenter Normative Data for Mesopic Microperimetry. InvestigativeÂ OphthalmologyÂ &Â VisualÂ Science,Â 65(12),Â 27. https://doi.org/10.1167/iovs.65.12.27\n\nBackground: The aim of this study was to create a large, multicentre normative dataset for MAIA microperimetry and to compare predictive models.\nInnovation: The analysis used innovative statistical methods to explain the normal variability of visual sensitivity and to develop userâ€‘friendly models for clinical applications.\nSignificance: This dataset is an indispensable reference for the interpretation of test results and provides an essential contribution to the standardisation and improvement of clinical diagnoses.\n\n\n\n\n\nRaming,Â K., Pfau,Â M., Herrmann,Â P., Holz,Â F.Â G., & Pfau,Â K.Â (2024). Antiâ€‘VEGF Treatment for Secondary Neovascularization in PseudoxanthomaÂ Elasticum. American Journal of Ophthalmology,Â 253,Â 101â€‘110. https://doi.org/10.1016/j.ajo.2024.03.026\n\nBackground: This retrospective cohort study investigated the treatment needs and outcomes in patients with PXE who suffer from secondary choroidal neovascularisationÂ (CNV).\nInnovation: The work shows that PXE patients require intensive antiâ€‘VEGF therapies already at a young age and highlights important predictors for therapy success.\nSignificance: The results underline the need for early intervention and provide insights for the development of durable therapeutics."
  },
  {
    "objectID": "posts/2024-12-22/index.html#summary",
    "href": "posts/2024-12-22/index.html#summary",
    "title": "Annual ReviewÂ 2024",
    "section": "",
    "text": "We look back on a year of significant scientific progress and look forward to the challenges and opportunities that the coming year will bring. We wish you a relaxing holiday season and a successful yearÂ 2025. If you have any questions or are interested in our studies, please do not hesitate to contact us."
  },
  {
    "objectID": "posts/2023-12-16/index.html",
    "href": "posts/2023-12-16/index.html",
    "title": "Annual ReviewÂ 2023",
    "section": "",
    "text": "Thank you to all study participants this year. As participants you made a decisive contribution to the research.\nWith great care we again published these findings this year in peerâ€‘reviewed scientific journals. Our publications this year can be found at the following link&sort=date).\nBelow you will also find a summary of our 3 most important publications inÂ 2023.\nWe look forward to welcoming you to examinations again next year and are happy to answer any questions you may have.\nMerry Christmas and a Happy NewÂ Year,\nMaximilianÂ Pfau, KristinaÂ PfauÂ (nÃ©eÂ Hess)\n\n\n\n\n\n\nLoewinger,Â A.Â S., Pfau,Â M., Herrmann,Â P., Holz,Â F.Â G., & Pfau,Â K. (2023). Choriocapillaris Flow Signal Impairment in Patients With PseudoxanthomaÂ Elasticum. Investigative OphthalmologyÂ & Visual Science,Â 64(2),Â 21. https://doi.org/10.1167/iovs.64.2.21\n\nBackground: Accurate measurement of calcification of Bruchâ€™s membrane in the eye would significantly facilitate the conduct of future studies. Clinically, changes are observed in the underlying vascular layer (choroid). However, measuring the capillary layer (choriocapillaris) is technically challenging.\nInnovation: The aim of the study was to measure changes in choriocapillaris flow in patients with PXE in the preatrophic stage and to investigate its relationship with structural changes of the choroid and outer retina. Using optical coherence tomography angiographyÂ (OCTA), it was shown that patients with PXE exhibit significant choriocapillaris changes very earlyâ€”even in preatrophic stages and with normal choroid thickness. Moreover, choriocapillaris flow density correlated with the thickness of the overlying outer retina.\nSignificance: Analysis of choriocapillaris flow density is more suitable than choroid thickness for monitoring PXE in mild disease stages. Choriocapillaris flow density may be an appropriate outcome measure for future intervention studies and is currently being further investigated by us as part of the PROPXE study (NCT05662085).\n\n\n\n\nPfau,Â M., Huryn,Â L.Â A., Boyle,Â M.Â P., Cukras,Â C.Â A., Zein,Â W.Â M., Turriff,Â A., Ullah,Â E., Hufnagel,Â R.Â B., Jeffrey,Â B.Â G., & Brooks,Â B.Â P. (2023). Natural History of Visual Dysfunction in ABCA4 Retinopathy and Its Genetic Correlates. American Journal of Ophthalmology,Â 253,Â 224â€“232. https://doi.org/10.1016/j.ajo.2023.05.014\n\nBackground: Many visual function tests have been described for Stargardt disease (ABCA4 retinopathy) to document the course of the disease. However, a systematic comparison of all visual function tests has been lacking to date.\nInnovation: This study was based on the large, prospective natural history study of the NationalÂ InstitutesÂ ofÂ Health. Participants underwent a variety of functional tests during an average followâ€‘up ofÂ 3.65Â years. We showed, among other things, that microperimetry (visual field testing in the macula) was most sensitive to change, but could only be performed in a subset of patients. Over a 5â€‘year interval, the amplitude of the darkâ€‘adaptedÂ aâ€‘wave in the electroretinogram was also sensitive to disease progression. The genotype explained a large portion of the variability in changes in the electroretinogram.\nSignificance: This work is the most comprehensive comparison of visual function tests in Stargardt disease to date. Especially in patients with advanced disease where most visual function tests can no longer be performed, the electroretinogram can be used to quantify disease progression.\n\n\n\n\nOertli,Â J.Â M., Pfau,Â K., Scholl,Â H.Â P.Â N., Jeffrey,Â B.Â G., & Pfau,Â M. (2023). Establishing Fullyâ€‘Automated Fundusâ€‘Controlled Dark Adaptometry: A Validation and Retestâ€‘Reliability Study. Translational Vision ScienceÂ & Technology,Â 12(12),Â 18. https://doi.org/10.1167/tvst.12.12.18\n\nBackground: The rate of dark adaptation is slowed in many retinal diseases. Patients report that they take much longer to get used to the environment when entering indoor spaces. However, there has been no method to measure this in patients who cannot or can hardly fixate (maintain gaze on a small point).\nInnovation: We developed a new method to test how well a personâ€™s eyes adapt to darknessâ€”independent of whether the subject can fixate on a point or not. We used a specialized device called Sâ€‘MAIA and programmed new software for it. To verify that our test is valid, we compared it with another established device (MonCvONE).\nSignificance: This new test method forms the basis for many future research projects, as we can now systematically assess the rate of dark adaptation in a wide range of patients."
  },
  {
    "objectID": "posts/2023-12-16/index.html#our-three-most-important-publications-in-2023",
    "href": "posts/2023-12-16/index.html#our-three-most-important-publications-in-2023",
    "title": "Annual ReviewÂ 2023",
    "section": "",
    "text": "Loewinger,Â A.Â S., Pfau,Â M., Herrmann,Â P., Holz,Â F.Â G., & Pfau,Â K. (2023). Choriocapillaris Flow Signal Impairment in Patients With PseudoxanthomaÂ Elasticum. Investigative OphthalmologyÂ & Visual Science,Â 64(2),Â 21. https://doi.org/10.1167/iovs.64.2.21\n\nBackground: Accurate measurement of calcification of Bruchâ€™s membrane in the eye would significantly facilitate the conduct of future studies. Clinically, changes are observed in the underlying vascular layer (choroid). However, measuring the capillary layer (choriocapillaris) is technically challenging.\nInnovation: The aim of the study was to measure changes in choriocapillaris flow in patients with PXE in the preatrophic stage and to investigate its relationship with structural changes of the choroid and outer retina. Using optical coherence tomography angiographyÂ (OCTA), it was shown that patients with PXE exhibit significant choriocapillaris changes very earlyâ€”even in preatrophic stages and with normal choroid thickness. Moreover, choriocapillaris flow density correlated with the thickness of the overlying outer retina.\nSignificance: Analysis of choriocapillaris flow density is more suitable than choroid thickness for monitoring PXE in mild disease stages. Choriocapillaris flow density may be an appropriate outcome measure for future intervention studies and is currently being further investigated by us as part of the PROPXE study (NCT05662085).\n\n\n\n\nPfau,Â M., Huryn,Â L.Â A., Boyle,Â M.Â P., Cukras,Â C.Â A., Zein,Â W.Â M., Turriff,Â A., Ullah,Â E., Hufnagel,Â R.Â B., Jeffrey,Â B.Â G., & Brooks,Â B.Â P. (2023). Natural History of Visual Dysfunction in ABCA4 Retinopathy and Its Genetic Correlates. American Journal of Ophthalmology,Â 253,Â 224â€“232. https://doi.org/10.1016/j.ajo.2023.05.014\n\nBackground: Many visual function tests have been described for Stargardt disease (ABCA4 retinopathy) to document the course of the disease. However, a systematic comparison of all visual function tests has been lacking to date.\nInnovation: This study was based on the large, prospective natural history study of the NationalÂ InstitutesÂ ofÂ Health. Participants underwent a variety of functional tests during an average followâ€‘up ofÂ 3.65Â years. We showed, among other things, that microperimetry (visual field testing in the macula) was most sensitive to change, but could only be performed in a subset of patients. Over a 5â€‘year interval, the amplitude of the darkâ€‘adaptedÂ aâ€‘wave in the electroretinogram was also sensitive to disease progression. The genotype explained a large portion of the variability in changes in the electroretinogram.\nSignificance: This work is the most comprehensive comparison of visual function tests in Stargardt disease to date. Especially in patients with advanced disease where most visual function tests can no longer be performed, the electroretinogram can be used to quantify disease progression.\n\n\n\n\nOertli,Â J.Â M., Pfau,Â K., Scholl,Â H.Â P.Â N., Jeffrey,Â B.Â G., & Pfau,Â M. (2023). Establishing Fullyâ€‘Automated Fundusâ€‘Controlled Dark Adaptometry: A Validation and Retestâ€‘Reliability Study. Translational Vision ScienceÂ & Technology,Â 12(12),Â 18. https://doi.org/10.1167/tvst.12.12.18\n\nBackground: The rate of dark adaptation is slowed in many retinal diseases. Patients report that they take much longer to get used to the environment when entering indoor spaces. However, there has been no method to measure this in patients who cannot or can hardly fixate (maintain gaze on a small point).\nInnovation: We developed a new method to test how well a personâ€™s eyes adapt to darknessâ€”independent of whether the subject can fixate on a point or not. We used a specialized device called Sâ€‘MAIA and programmed new software for it. To verify that our test is valid, we compared it with another established device (MonCvONE).\nSignificance: This new test method forms the basis for many future research projects, as we can now systematically assess the rate of dark adaptation in a wide range of patients."
  },
  {
    "objectID": "posts/2022-05-23/index.html",
    "href": "posts/2022-05-23/index.html",
    "title": "Doctoral opportunities",
    "section": "",
    "text": "We have several projects for doctoral candidates (Dr.Â med.) to assign.\nThe focus of our group is on the development and validation of new visual function tests for inherited retinal diseases and of artificial intelligenceâ€‘based approaches to structureâ€“function correlation.\n\n\n\nLead time: You should contact us about 6Â months before the desired start of the work.\nDuration: Two semesters on leave should be planned for the projects so that there is enough time to learn the methods, work independently and perform analyses.\nMethods:\n\nAs part of the projects you will learn standardised ophthalmic imaging and functional testing.\nDepending on your interests and prior knowledge (especially in R and Python) you can also learn artificial intelligenceâ€“based methods.\n\nPublication: The scope of the dissertation projects is always designed so that it is usually possible to write a peerâ€‘reviewed article as first or shared first author.\nFinancial support: Applying for research scholarships is actively encouraged and supported."
  },
  {
    "objectID": "posts/2022-05-23/index.html#projects-for-doctoral-students",
    "href": "posts/2022-05-23/index.html#projects-for-doctoral-students",
    "title": "Doctoral opportunities",
    "section": "",
    "text": "We have several projects for doctoral candidates (Dr.Â med.) to assign.\nThe focus of our group is on the development and validation of new visual function tests for inherited retinal diseases and of artificial intelligenceâ€‘based approaches to structureâ€“function correlation.\n\n\n\nLead time: You should contact us about 6Â months before the desired start of the work.\nDuration: Two semesters on leave should be planned for the projects so that there is enough time to learn the methods, work independently and perform analyses.\nMethods:\n\nAs part of the projects you will learn standardised ophthalmic imaging and functional testing.\nDepending on your interests and prior knowledge (especially in R and Python) you can also learn artificial intelligenceâ€“based methods.\n\nPublication: The scope of the dissertation projects is always designed so that it is usually possible to write a peerâ€‘reviewed article as first or shared first author.\nFinancial support: Applying for research scholarships is actively encouraged and supported."
  },
  {
    "objectID": "posts/2025-07-04/index.html",
    "href": "posts/2025-07-04/index.html",
    "title": "Dr.Â KristinÂ Raming Receives the JackstÃ¤dtÂ YoungÂ InvestigatorÂ Award",
    "section": "",
    "text": "We are pleased to announce that Dr.Â KristinÂ Raming has been awarded the JackstÃ¤dtÂ YoungÂ InvestigatorÂ Award of the GermanÂ RetinaÂ Society. The prize recognises outstanding scientific achievements by young researchers in the field of retinal research.\nDr.Â Raming was honoured for her work on Sorsby fundus dystrophy (SFD), which she conducted as part of her medical doctoral thesis in our research group. The results of her dissertation were published in the journal American Journal of Ophthalmology:\nRamingÂ K,Â etÂ al.Â VisualÂ DysfunctionÂ andÂ StructuralÂ CorrelatesÂ inÂ SorsbyÂ FundusÂ Dystrophy. AmÂ JÂ Ophthalmol.Â 2022Â Feb;234:274â€“284. https://doi.org/10.1016/j.ajo.2021.07.032\nIn this prospective crossâ€‘sectional study, 16 patients with genetically confirmed SFD were thoroughly examined. In addition to multimodal imaging, various functional tests were employed, including lowâ€‘luminance visual acuity, mesopic and darkâ€‘adapted fundus perimetry (microperimetry) and dark adaptationÂ (RMDA).\nThis work forms the basis of our currently ongoing longitudinal study onÂ SFD, in which we systematically investigate the temporal course of structural and functional changes. The goal is to identify reliable markers of disease progression and to lay the groundwork for future therapeutic approaches.\nWe warmly congratulate Dr.Â Raming on this wellâ€‘deserved award and look forward to continuing to develop this important line of research together."
  },
  {
    "objectID": "index.html#news",
    "href": "index.html#news",
    "title": "Welcome!",
    "section": "News",
    "text": "News\n\n\n\n\n\n\n\n\n\n\nKristina andÂ MaximilianÂ Pfau Return to Bonn\n\n\n\n\n\n\n\n\nAug 1, 2025\n\n\nOur research group\n\n\n\n\n\n\n\n\n\n\n\n\nDr.Â KristinÂ Raming Receives the JackstÃ¤dtÂ YoungÂ InvestigatorÂ Award\n\n\n\n\n\n\n\n\nJul 4, 2025\n\n\nOur research group\n\n\n\n\n\n\n\n\n\n\n\n\nAnnual ReviewÂ 2024\n\n\n\n\n\n\n\n\nDec 22, 2024\n\n\nOur research group\n\n\n\n\n\nNo matching items\n\nAll News â†’"
  },
  {
    "objectID": "team/olivier_morelle/index.html",
    "href": "team/olivier_morelle/index.html",
    "title": "Olivier Morelle",
    "section": "",
    "text": "Olivier Morelle is a life science informatics professional specializing in medical image analysis and the developer of EyePy, a Python software package designed to streamline the reading and visualization of ophthalmological OCT datasets. His research focuses on developing deep learning models for OCT data segmentation.\nBy combining a strong academic foundation with hands-on software development, Olivier aims to contribute to advancements in medical AI and data science, particularly in roles that connect research and industry applications."
  },
  {
    "objectID": "team/olivier_morelle/index.html#education",
    "href": "team/olivier_morelle/index.html#education",
    "title": "Olivier Morelle",
    "section": "Education",
    "text": "Education\nUniversity of Bonn | Bonn, Germany\nPhD Medical Image Analysis | 2024\nBonn-Aachen International Center for Information Technology (b-it) | Bonn, Germany\nMSc Life Science Informatics |\nUniversity of Cologne | Cologne, Germany\nBSc Biology | 2022"
  },
  {
    "objectID": "team/theresa_lipsky/index.html",
    "href": "team/theresa_lipsky/index.html",
    "title": "Theresa Lipsky",
    "section": "",
    "text": "Theresa Lipsky, MD is an ophthalmology resident at the University Hospital Basel currently completing a dedicated research year. Her work focuses on developing and validating novel methods for dark adaptometry to improve assessment of retinal function."
  },
  {
    "objectID": "team/theresa_lipsky/index.html#education",
    "href": "team/theresa_lipsky/index.html#education",
    "title": "Theresa Lipsky",
    "section": "Education",
    "text": "Education\nParacelsus Medical University Salzburg | Salzburg, Austria Medicine | 2019 - 2024"
  }
]